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i Abstract 
 
This thesis shows the surface functionalisation of gold nanoparticles with surface active, luminescent 
Eu complexes and free light chain antibodies, to produce free light chain antibody functionalised gold 
nanoparticles which show characteristic, Eu luminescence. 
 
We show how these particles can be used in the development of a novel FRET based assay whereby 
the Eu luminescence is quenched on addition of free light chain specific antibody, labelled with a 
suitable organic FRET acceptor for Eu luminescence as measured by lifetime measurements. We show 
how these particles can be used to develop a competitive immunoassay to measure the concentration of 
free light chain antibodies. 
 
We also report the preparation of a novel functionalised dibenzoylmethane molecule with a thiol surface 
active group as to functionalise gold nanoparticles which can bind and sensitize Eu ions. 
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1 General Introduction 
1.1 Immunoassays 
Immunoassays are bioanalytical tests based on the highly specific antibody (Ab) – antigen (Ag) 
interaction and are among the most widely used biomedical diagnostic tools.1 An antigen is a foreign 
species present in the body which induces an immune response. An antibody is a large protein which is 
produced by the immune system to bind to and neutralize antigens. The binding between an antibody 
and an antigen to form an immunocomplex (Figure 1.1.1.) is incredibly specific and as such the binding 
between the two is analogous to a ‘lock and key’ whereby each lock is specific to a given key.  
 
 
Figure 1.1.1. 
The highly specific Ab – Ag interaction to form an immunocomplex.  
 
Red circle, Ag. 
 
In general, it is the concentration of antigen which is needed to be determined, although different 
biological analytes can also be determined via an immunoassay such as sugars, proteins or hormones.2,3,4 
The design of a biological detection system is different for each analyte, and several points must be 
considered when designing a successful and practical assay (Table 1.1.1.). 
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Table 1.1.1. 
Considerations for the design of an immunoassay system. 
Consideration Explanation 
 
Cost The cost of running the assay must be 
financially feasible. 
 
Required detection limits 
 
The upper and lower detection range of the 
assay must be within a clinically relevant 
range for the analyte(s). 
 
Readout time 
 
The readout time of the assay should be 
relatively quick. 
 
Complexity of performance 
 
The assay should be quick and easy to 
perform. 
 
Interference 
 
The assay is required to be sensitive to only 
the analyte(s) in question. 
 
 
These fundamental requirements should be balanced and considered for the design of the most 
appropriate assay for a given analyte. 
 
Generally, immunoassays can be classed as either homogenous (solution based) or heterogeneous 
(surface based).5 Heterogeneous assays have biomolecules attached to a surface whereupon a patient 
sample is added. The surface is washed, a detectable biomolecule is added, and the surface is washed 
again (Figure 1.1.2.). The signal from the detectable antibody is proportional to the concentration of 
analyte. 
 3 
 
 
Figure 1.1.2. 
General schematic of a heterogeneous immunoassay.  
 
O, detectable label. 
 
Several commercial heterogeneous assays are available on the marketplace, for example the DELFIA 
(dissociation enhanced lanthanide fluorescent assay) scheme (Figure 1.1.3.) which uses the optical 
properties of the lanthanides (Ln) for detection based on or the more widely known ELISA (enzyme-
linked immunoabsorbant assay) (Figure 1.1.4.) which uses enzymatic action upon a dye for detection, 
both of which are commercially available.6,7,8,9 
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Figure 1.1.3. 
General schematic of a DELFIA system. 
 
The DELFIA system uses the specific luminescence signal from a Eu(III) ion to detect the concentration 
of antigen. On addition of the enhancement solution the previously non emissive Eu(III) ions become 
bound to a sensitizing chelate forming an emissive complex. The concentration of antigen present is 
directly proportional to the emission intensity observed from the Eu(III) chelate. 
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Figure 1.1.4. 
General schematic of an ELISA system. 
 
The ELISA system uses an enzymatic activity on a substrate to give a measured colour change to 
quantify the amount of the antigen present in the sample. The amount of measured enzymatic activity 
is directly proportional to the concentration of the antigen. 
 
Homogenous assays have labelled antibodies in solution which come together to form an 
immunocomplex on specific binding to the particular antigen which results in a detectable signal. The 
concentration of the analyte is proportional to the signal which is measured (Figure 1.1.5.). These types 
of assays are discussed in much more detail in this thesis (Section 1.4.). 
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Figure 1.1.5. 
General schematic of a homogeneous immunoassay. 
O, detectable label; ●, detectable label. 
 
As discussed earlier, the design of an immunoassay is governed by balancing the working 
considerations of the device. Generally speaking, heterogeneous systems show lower detection limits, 
but suffer from drawbacks associated with their performance cost, complexity and long readout times. 
Homogeneous systems, in comparison, are considered experimentally simple and give quick readout 
times. Indeed, a reliable experimental result can be obtained within ninety seconds using this type of 
system, although homogeneous assays suffer from a lack of sensitivity with respect to the limit of 
detection (LOD) of the analyte.10  
 
Heterogeneous assay systems will always be limited by their experimental complexity, and whereby a 
large amount of work is done on these systems, which often involves the use of nanomaterials, the issue 
of complexity will always remain.11,12,13,14 Research into homogenous systems is based around 
improving their detection limits as such to rival that of the surface based systems. 
 
 
 
 
 
 
 
 
 7 
 
1.2 Förster resonance energy transfer 
Förster resonance energy transfer (FRET) is a photochemical process discovered by German chemist 
Theodore Förster in 1946.15 In its simplest definition, FRET is a coulombic distance dependant energy 
transfer between two chromophores, an energy donor in its excited state, and an energy acceptor (Figure 
1.2.1.). Competing pathways with FRET include radiative and non-radiative decay of the donor in its 
excited state.16  
 
 
  
 
 
  
   
 
 
 
Figure 1.2.1. 
Principle of a FRET system. 
 
D, Donor; A, Acceptor; hv, excitation wavelength; *, excited state; kr, knr, kFRET, radiative, non-radiative 
and FRET rates. 
D  + A D* +  A 
D  +  A 
D  +  A* 
D  +  A 
D  +  A D  +  A 
hν 
kR k
R 
kNR kNR 
kFRET 
Donor  Acceptor  
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For FRET to be active, the distance between the donor and the acceptor is usually required to be larger 
than 10 Å, to avoid short range interactions and shorter than 100 Å in space. kFRET is proportional to the 
inverse of the donor – acceptor distance (r) to its sixth power (Equation 1.2.1.).   
 
𝑘𝐹𝑅𝐸𝑇  ∝  
1
𝑟6
 
Equation 1.2.1. 
Distance dependence of FRET. 
 
kFRET, FRET rate; r, donor – acceptor distance. 
 
 
For FRET to occur, the emission spectrum of the energy donor must overlap with the absorption 
spectrum of the acceptor (Figure 1.2.2.). When these two spectra are overlaid, the region at which they 
overlap is known as the spectral overlap (J(λ)), and it is at this point where FRET is able to occur.   
 
Figure 1.2.2. 
Overlap of the donor emission spectrum and the acceptor absorption spectrum showing a spectral 
overlap. J(λ) where FRET can occur is indicated with the red lattice. 
 
Each FRET pair has an associated R0 value, defined as the distance between the two chromophores at 
which the energy transfer rate is 50% efficient. (Figure 1.2.3.). At this point kFRET is equal to the sum of 
all the competing processes from the excited state of the donor. 
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 Figure 1.2.3. 
Distance dependence of FRET with the R0 value shown. 
 
R0 differs between each FRET pair and is dependent on the emission quantum yield (Φ) of the donor, 
the dipole orientation factor between the pair and J(λ) of the pair. R0 can be worked out using these 
parameters mathematically (Equation 1.2.2.). Typical values for the R0 parameter for common organic 
FRET pairs from Thermofischer Scientific are included (Table 1.2.1.). 
 
𝑅0 =  [
9(𝑙𝑛10)𝜅2Φ𝐷
128𝜋5𝑁𝐴𝑛4
𝐽(𝜆)]
1
6
 
Equation 1.2.2. 
Mathematical representation of R0. 
 
κ, dipole orientation factor; ΦD, donor quantum yield; NA, Avogadro constant; n, refractive index of 
solvent; J(λ), spectral overlap. 
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Table 1.2.1. 
Typical R0 values of common organic dyes as provided by Thermofischer scientific.17 
Donor Acceptor R0 / Å 
Fluorescein (FITC) Tetramethylrhodamine 55 
IAEDANS FITC 46 
EDANS Dabcyl 33 
BODIPY FL BODIPY FL 57 
FITC QSY 7 and QSY 9 dyes 61 
 
 
J(λ) is dependent on the overlap of the donor emission and acceptor absorption spectra and the molar 
absorptivity (ε) of the acceptor, which can also be expressed mathematically (Equation 1.2.3.). 
 
𝐽(𝜆) =  ∫ 𝐼𝐷(𝜆)𝜀𝐴( 𝜆)   𝑑𝜆 
Equation 1.2.3. 
Mathematical representation of J(λ). 
 
ID, normalised donor emission spectrum; εA, acceptor molar absorptivity. 
 
FRET can be measured and monitored via steady state or time resolved (TR) emission spectroscopy 
measurements. It is more common in the literature to employ a method to quantify the quenching of 
the energy donor, although there are examples whereby a radiative energy acceptor is monitored for 
its steady state or time resolved emission spectra.18,19 
 
The quenching of the energy donor by a suitable acceptor causes a decrease in the excited state lifetime 
(τ) of the donor, a decrease in the Φ of the donor and a decrease in the emission intensity (I) of the 
donor. It is the lifetime which will be considered in this thesis hence this section will concentrate on 
how FRET is monitored via excited state lifetime measurements. 
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The comparison of the excited state lifetime of the donor with and without the presence of an applicable 
energy acceptor can be used to determine the donor – acceptor distance of the pair using R0 as a 
reference (Equation 1.2.4) and the energy transfer efficiency (ΦT) between the donor and acceptor 
(Equation 1.2.5.). These equations are analogous with measurements of I and Φ of the energy donor. 
 
𝑟 =  
𝑅0
(
𝜏𝐷
0
𝜏𝐷
− 1)
1
6
                                      Φ𝑇 = 1 −
𝜏𝐷
𝜏𝐷
0  
 
Equations 1.2.4. (Left) and 1.2.5. (Right) 
Determination of r and ΦT between a FRET pair. 
 
𝜏𝐷 , lifetime with quencher present; 𝜏𝐷
0 , lifetime without quencher present. 
 
The combination of FRET pairs reported in the literature is vast, whereby common donors have 
traditionally included luminescent Ln complexes and organic dyes. More current trends are focused on 
luminescent nanoparticles (NPs) as donors such as upconverting phosphors (UCPs) and quantum dots 
(QDs), all of which are discussed in detail at a later section of this thesis (Section 1.5.). FRET acceptors 
have traditionally been organic dyes with a broad absorption spectrum and have now been extended to 
include QDs, gold NPs (AuNPs) and very current work has included graphene as an energy acceptor, 
which again are discussed at a later section of this thesis (Section 1.5.).20 
 
Whilst the choice of energy donors and acceptors is broad, the fundamental requirements of the donor 
and the acceptor can be defined by common photophysical parameters (Tables 1.2.2. and 1.2.3.).  
 
There are extensive examples of the use of FRET in homogeneous immunoassay technology which is 
explored in large detail in a later section of this thesis (Sections 1.4 and 1.5).  
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Table 1.2.2. 
Photophysical considerations of a FRET donor. 
Consideration Explanation 
Excited state 
lifetime (τ) 
A long lived τ is advantageous for facile separation of the FRET signal from any 
background fluorescence signal which may be present. 
Φ A large emission quantum yield (Φ) is required so a larger amount of energy is 
available for the energy transfer process. 
ε A large molar absorptivity (ε) is required for the donor to have a large amount of 
initial energy absorbed. 
Stokes shift A large separation between the initial excitation wavelength (λexc) and emission 
wavelength (λem) leads to easier removal of background fluorescence. 
Emission 
spectrum 
A characteristic emission spectrum is easy to identify as the correct signal.  
A sharp emission signal can show a complete J(λ) with a broad energy acceptor 
in comparison to a broad emission spectrum which is difficult to get an acceptor 
to show a full J(λ) with. 
Photobleaching If a reusable device is proposed, the donor should not be susceptible to 
photobleaching. 
 
Table 1.2.3. 
Photophysical considerations of a FRET acceptor, assuming the acceptor is not required to show 
radiative emission.   
 
Consideration Explanation 
J(λ) The acceptor should show a large J(λ) with the emission spectrum of the donor. 
ε A large ε leads to the acceptor being able to accept a larger amount of energy 
during the energy transfer. 
λexc The acceptor should show no absorption at the initial λexc. 
Photobleaching If a reusable device is proposed, the donor should not be susceptible to 
photobleaching. 
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1.3 Lanthanide chemistry 
The Ln elements occupy the space on the periodic table between the 6s and 5d blocks. Research into 
this range of elements is extensive and ranges from taking advantage of their magnetic properties, such 
as the use of Gd(III) in magnetic resonance imaging (MRI) applications to their use in catalysis and 
small molecule activation.21,22,23,24 The optical properties of the Ln elements are unique and as such they 
have been used in a large variety of devices and have been used broadly in biomedical and sensing 
applications.25,26 Their optical properties are explored in detail in this work. 
 
The Ln elements exist almost exclusively in their 3+ oxidation state as a result of the stabilisation 
exerted by the 4f, 5d and 6s orbitals in this oxidation state, although other oxidation states of 4+ and 2+ 
have been reported, particularly of Eu and Sm.27,28,29 In this 3+ oxidation state, as the series is crossed 
the electronic structure of the Ln(III) ions can be denoted as [Xe]4fn (Table 1.3.1.) As the series is 
crossed a contraction in the ionic radii of the elements is observed because of the poor shielding ability 
of the f orbitals.     
 
Table 1.3.1. 
Ionic radii and electronic structure of the Ln(III) ions as measured using EXAFS data.30 
Element Ln(III) electronic structure Ln(III) ionic radius / Ǻ 
57 La [Xe] 1.250 
58 Ce [Xe]4f1 1.220 
59 Pr [Xe]4f2 1.200 
60 Nd [Xe]4f3 1.175 
61 Pm [Xe]4f4 Data not provided 
62 Sm [Xe]4f5 1.140 
63 Eu [Xe]4f6 1.120 
64 Gd [Xe]4f7 1.105 
65 Tb [Xe]4f8 1.090 
66 Dy [Xe]4f9 1.075 
67 Ho [Xe]4f10 1.055 
68 Er [Xe]4f11 1.040 
69 Tm [Xe]4f12 1.025 
70 Yb [Xe]4f13 1.010 
71 Lu [Xe]4f14 0.995 
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The radial distribution function of the Ln(III) ions show a general trend of the valence 4f electrons lying 
close to the nucleus in comparison to the shielding 6s and 5d orbitals and thus the 4f orbitals can be 
essentially considered as spherical and core like, with no significant orbital overlap with any ligand 
orbitals. As a consequence of this behaviour, the bonding of the Ln(III) elements is dominated by ionic 
interactions between the ligand and the metal ion and the design of Ln(III) complexes is based around 
ionic interactions between hard donor ligands and the central metal ion. The coordination number of 
the Ln ion is variable. The most common coordination numbers are eight or nine which varies as a result 
of the contraction of the Ln(III) series, although lower and higher numbers can be achieved of four and 
twelve with bulky or small ligand systems.31,32,33 Whilst the bonding of Ln(III) complexes is dominated 
by ionic interactions, crystal field effects cannot be completely overlooked and typical values for the 
ligand field stabilisation energy (LFSE) are in the order of the hundreds of cm-1, although for transition 
metal complexes this value is typically much larger with LFSEs of thousands to tens of thousands cm-
1.34,35 
 
Ln(III) ions, as before mentioned, display unique and useful optical properties and research into Ln(III) 
complexes as luminescent probes is prominent. The lack of orbital overlap between the Ln(III) ion and 
its surrounding environment results in the absorption and emission processes of the Ln series being due 
to the rearrangement of electrons within the 4f orbitals of the metal. Thus, formal absorption and 
emission processes are sharp and characteristic in nature, as a result of transitions between well-defined 
4f energy levels.  
 
The redistribution of electrons within 4f orbitals is a forbidden process, because of the Laporte and 
orbital angular momentum selection rules and some transitions are further forbidden by the spin 
selection rule. As a result of this, f–f absorption processes are incredibly weak for the naked Ln(III) ion 
and the molar absorptivity is typically less than 10 M-1 cm-1 and only occur due to weak vibronic 
coupling.36,37 This vibronic coupling can be increased as the symmetry of the 4f orbitals is decreased, 
although the transition is still considered weak as a consequence of the lack of 4f orbital overlap.  These 
selection rules also govern the release of energy within the Ln(III) series, hence a radiative emission 
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process from a Ln(III) ion is often a triply forbidden process. This leads to only a small chance of a 
radiative transition occurring and the excited state lifetime of the metal ion being extended into the 
micro and milliseconds range. These f–f emission bands are characteristically sharp and are termed as 
hypersensitive transitions. These hypersensitive transitions are sensitive to the coordination 
environment of the Ln(III) ion, such as the 5D0  7F2 transition within the Eu(III) ion which is 
particularly sensitive to the surroundings of the Eu(III) ion. 
 
The spectroscopic energy levels of the Ln(III) series can be described with use of Hund’s rules, which 
define the energy levels based on spin, orbital angular momentum and spin orbit coupling to give each 
Ln(III) ion a term symbol (Equation 1.3.1.) determined by the Russel-Saunders coupling scheme.38 
 
𝐿𝐽
(2𝑆+1)
 
Equation 1.3.1. 
General form of a spectroscopic term symbol. 
 
S, total spin angular momentum quantum number; L, total orbital angular momentum; J, total angular 
momentum quantum number. 
 
 
The observed emission bands of the Ln(III) ions are attributed to transitions between the lowest lying 
excited state and ground states of each Ln (Table 1.3.2.). 
 
Table 1.3.2. 
Main luminescent transitions of Ln(III) ions. ‘J’ indicates a range of transition levels. 
 
 
 
 
 
Ln(III) Emissive transitions 
Eu(III) 5D0  7FJ 
Tb(III) 5D4  7FJ 
Dy(III) 4F9/2  6HJ 
Sm(III) 4G5/2  6HJ 
Nd(III) 4F3/2  4IJ 
Yb(III) 2F5/2  2F7/2 
Er(III) 4S3/2  4IJ 
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For example, Eu(III) emission is a result of transitions from the 5D0 excited state to the 7FJ ground states 
of the Eu(III) ion, where J = 0 - 6 (Figure 1.3.1.). 
 
Figure 1.3.1. 
Emission bands observed in the Eu(III) ion. 
 
 
Of the Ln(III) ions, Eu(III), Tb(III), Dy(III) and Sm(III) all show luminescence in the visible region of 
the electromagnetic spectrum and Nd(III), Yb(III) and Er(III) are near infra-red (NIR) emitters. The 
photophysical properties of these ions have been extensively employed in a wide range of applications 
for their use as optical reporters in many biological and chemical systems.39,40,41,42 Their incredibly long 
excited state lifetime allows for time-gated measurements whereby background fluorescent readings 
can be easily separated from the optical signal produced from the Ln(III) ion with time resolved methods 
(Figure 1.3.2.), while the sharp nature of the transitions leads to very characteristic steady state emission 
spectrum which can be easily recognised.  
 
 
Figure 1.3.2. 
Example of time-gated emission process. 
 
Red curve, background fluorescence signal; blue curve, Ln(III) luminescent signal. 
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Despite these clear advantages associated with the use of the Ln(III) ions as optical probes, the series is 
not without its problems connected to their optical properties.  
 
The forbidden nature of the rearrangement of electrons in the 4f orbitals and the lack of LFSE effects 
leads to the absorption process within the metal ion to be inherently weak as previously discussed. This 
issue can be partially overcome with the careful design of organic chromophores which can indirectly 
transfer energy to the emissive state of a Ln(III) ion (Figure 1.3.3.). The organic chromophore is called 
a sensitizer and the process is known as sensitization. 
 
 
Figure 1.3.3. 
Lanthanide sensitization process for Eu(III) ion. 
 
S0, ground state; S1, first singlet excited state; hv, light; T1, first triplet excited state. 
 
Absorption of a photon to the first excited singlet state (S1) of the sensitizer is observed, followed by 
intersystem crossing to a lower energy first excited triplet state (T1) which can transfer energy to the 
Ln(III) ion. This process allows for population of the metal ion excited state, with an excitation 
wavelength in the UV (ultra-violet) region of the electromagnetic spectrum, showing the emission 
wavelength of the metal ion in the visible or NIR area of the spectrum. As such, the Stokes shift of this 
process can be incredibly large which is advantageous as, with careful sensitizer design, the optical 
signal from the Ln ion can be almost completely separated from the competing fluorescence and 
phosphorescence processes of the organic fluorophore.   
Sensitizer  Eu(III) ion  
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The design of efficient sensitizing units for emissive Ln(III) ions is a very well-known and understood 
area of a research and common sensitizers for Eu(III) are included (Table 1.3.3.). Indeed, these 
sensitizers can be functionalised with a Ln binding site to produce a luminescent Ln complex. 
 
Table 1.3.3. 
Common organic sensitizing units for Eu(III).43,44,45,46 
Name Structure Absorption max / nm ε / M
-1 cm-1 
Dibenzoylmethane  
 
342  25,000 
Bipyridine 
 
283 10,200 
Quinoline 
 
311 6,300 
Acridone 
 
399 7,600 
 
 
For efficient sensitization to be accomplised, the energy of the T1 state of the sensitizer relative to the 
energy of the Ln(III) excited state should be carefully considered. Indeed, the ideal senzitizing unit for 
Eu(III) and Tb(III) requires the T1 state of the sensitizer to be between 2500 – 3500 cm-1 higher in 
energy than the emisive state of the Ln(III) ion. If the T1 is close in energy to the metal ion, a back 
energy transfer transition can occur, reducing the energy avaliable for radiative tranitisions from the 
Ln(III) ion. If the T1 state is too high in energy, the state cannot populate the Ln(III) emissive state 
efficiently and can lead to radiative emission of the organic material or quenching from a ligand to 
metal charge transfer state from the metal. The ideal sensitizer allows long excitation wavelength of the 
chromafore to avoid simultaneous excitation of background biological molecules in a given system.  
 
A further issue connected to the luminescent properties of the Ln(III) series is their weak luminescence 
in aqueous environements. The emissive state of the metal ion is efficiently quenched by vibrational 
oscilations of the O-H bond. This is also observed for N-H and C-H bonds but to a much lesser extent. 
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This quenching in aqueous and alcoholic solvents leads to a decrease in the emission quantum yield and 
the excited state lifetime of the metal ion or complex being studied. Evidence of this observation is the 
change in the emission quantum yield and the excited state lifetime of Ln complexes in a D2O solvent 
when compared to a H2O solvent (Figure 1.3.4.).  
 
Figure 1.3.4. 
Quenching of 5D0 energy level of Eu(III) by O-H and O-D oscillators.  
OH, vibrational energy levels of OH oscillator; OD, vibrational energy levels of OD oscillator. 
 
This effect can be quantified with application of the Horrocks equation which compares the lifetime of 
the Ln(III) ion in deuterated solvent with non-deuterated solvent to give an estimate for the number of 
bound O-H oscillators (q) (Equation 1.3.2.).47 
𝑞 = 𝐴(𝑘𝑂𝐻 − 𝑘𝑂𝐷) 
Equation 1.3.2. 
Horrocks equation 
q, Number of bound OH oscillators; kOH, reciprocal lifetime in OH solvent; kOD, reciprocal lifetime in 
OD solvent; A, quenching constant. 
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The quenching constant applied to this equation differs between the Ln(III) series depending on the 
quenching contribution the metal ion, and the quenching contribution of the solvent, for example the 
quenching effect exerted from a methanol molecule is ca. half as strong as the quenching exerted from 
a water molecule. Values of the A parameter in ms for Tb(III) and Eu(III) in water and MeOH are 
included (Table 1.3.4.). 
 
Table 1.3.4. 
A parameters for Eu(III) and Tb(III) in MeOH and water.48,49 
Ln(III) Solvent A / ms 
Eu(III) Water 1.05 
Tb(III) Water 4.20 
Eu(III) MeOH 2.10 
Tb(III) MeOH 8.40 
 
The Horrocks equation fails to take into account quenching from outer sphere O-H oscillators. The 
Parker-Beeby equation has been proposed whereby the quenching constant is revised and a second 
quenching constant, B is included to account for the outer sphere oscillators (Equation 1.3.3.). Revised 
quenching constants for the Parker-Beeby equation are included (Table 1.3.5.). 
 
𝑞 = 𝐴′(𝑘𝑂𝐻 − 𝑘𝑂𝐷 −  𝐵) 
Equation 1.3.3. 
Parker - Beeby equation 
q, Number of bound OH oscillators; kOH, reciprocal lifetime in OH solvent; kOD, reciprocal lifetime in 
OH solvent; A’, revised quenching constant; B, outer sphere quenching constant. 
 
 
Table 1.3.5. 
A’ and B parameters for Eu(III) and Tb(III) in MeOH and water.50 
Ln(III) Solvent A’ / ms B / ms-1 
Eu(III) Water 1.20 0.25 
Tb(III) Water 5.00 0.06 
Eu(III) MeOH 2.40 0.25 
Tb(III) MeOH 10.00 0.06 
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Because of this quenching contribution, luminescent Ln(III) complexes are designed in a ‘cage like’ 
structure which physically hinders quenching O-H oscillators from deactivating the luminescent state 
of the metal ion. Common examples of these ‘cage like’ structures are shown, whereby the ligand can 
wrap around and protect a central Ln(III) cation (Figure 1.3.5.).  
 
                 
 
                     
 
 
 
 
 
 
 
 
Figure 1.3.5. 
Common ligands used to encapsulate and protect a Ln(III) ion.51,52 53,54 
 
Since the bonding between Ln ions and a ligand is mainly electrostatic in nature the building of hard 
donor groups into a Ln(III) ligand is crucial to achieve a high binding constant and to ensure the metal 
ion does not ‘leach’ out of the complex. Popular hard donor ligands to encapsulate Ln(III) ions are N 
and O groups and negative carboxylate groups are particularly useful for charge balance with the 
positive metal ion, which can lead to a neutral complex.55,56 
H4DOTA  
(tetraazacyclododecane-1,4,7,10-tetraacetic acid) 
 
H5DPTA 
(diethylenetriaminepentaacetic acid) 
Cryptate 
 
Hacac 
(acetylacetone) 
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The design of a luminescent Ln complex is based on the successful combination of a suitable sensitizing 
unit and a protected Ln(III) binding site, both of which should be located close in space for efficient 
energy transfer to the metal ion. As such there are countless combinations of binding site and sensitizer 
which have been reported and the design of novel Ln complexes is an area which is constantly being 
improved.57,58,59 
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1.4 Lanthanides in immunoassays 
The optical properties of luminescent Ln(III) chelates make for high quality donors in homogeneous 
FRET based immunoassay systems and in time resolved luminescence schemes. In the literature, there 
are plentiful examples of the use of both luminescent Ln(III) chelates and organic materials as FRET 
donors in immunoassay schemes.60,61 Whilst both have been commonly reported, the optical properties 
of luminescent Ln(III) complexes have preferential properties when compared to organic fluorescent 
materials, and these properties can be easily compared. Whilst organic fluorescent materials can show 
larger emission quantum yields and molar absorptivity’s, the luminescent properties of the Ln(III) series 
make for better FRET donors (Table 1.4.1.).  
 
Table 1.4.1. 
Comparison of organic fluorescence compared to Ln(III) luminescence as a FRET donor. 
Consideration Luminescent Ln(III) chelate Organic fluorescent material 
τ Long, ranging into milliseconds range Short, in the nanosecond range 
Stokes shift Large difference between sensitizer and 
Ln(III) emission 
Very small, often absorption and 
emission spectrum overlap 
Emission 
spectrum 
Sharp line, very characteristic and easy for 
large J(λ) with FRET acceptor 
Broad, difficult for a FRET 
acceptor to fully quench 
 
The earliest publication involving the use of the optical properties of Ln(III) ions in an immunoassay 
scheme was in 1983 by Siitari et al. showing the detection of hepatitis B surface antigen (HBsAg) 
employing a luminescent Eu(III) labelling agent.62 Anti HBsAg antibody was functionalised with the 
luminescent Eu(III) labelling agent and used in a sandwich assay format with anti HBsAg antigen 
immobilised on a surface (Figure 1.4.1.).  
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Figure 1.4.1. 
 
Eu(III) functionalised anti HBsAg antibody assay for the time resolved detection of HBsAg. 
 
Incubation of the functionalised antibodies and HBsAg led to formation of a surface immobilised 
immunocomplex which was detected via time resolved luminescence of the Eu(III) ion with excitation 
at 337 nm and emission at 613 nm. A 50 μs time delay between emission and excitation was used to 
eliminate any short-lived background fluorescence, ensuring the long-lived Eu(III) signal was the only 
optical signature being observed. A lower detection limit of 500 ng L-1 in terms of the concentration of 
analyte was achieved. 
 
This publication has since inspired a huge amount of work into the use of luminescent Ln(III) chelates 
as the detectable label in an immunoassay scheme. As such, similar schemes using the visible emitting 
Ln(III) ions have been vastly studied using Eu(III), Sm(III), Tb(III) and Dy(III) encapsulated by ligands 
incorporating β-diketone or aromatic sensitizing units. Eu(III) and Tb(III) have longer lived excited 
stated lifetime values than the other visible emitting Ln(III) ions and so are more commonly used for 
their luminescent signals at 545 nm (Tb) and 614 nm (Eu) respectively. Recent work has been expanded 
to explore the area of multiplexed assays for the detection of multiple analytes simultaneously as well 
as the use of luminescent Ln nanomaterials.63,64,65,66,67,68,69,70 
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The success of using Eu(III) in the first heterogeneous time resolved luminescence assay was followed 
up ten years later with the first report of a homogeneous FRET assay with Eu(III) as an energy donor 
by Mathis in the detection of prolactin. Eu(III) cryptate functionalised anti prolactin antibody was used 
as the donor and XL665 functionalised anti prolactin antibody as the acceptor. Excitation at 337 nm led 
to excitation of the Eu(III) cryptate which when bound to analyte and acceptor labelled antibody in a 
sandwich assay format leads to an XL665 emission at 665 nm with a detection limit of 300 ng L-1 in 
terms of the concentration of prolactin (Figure 1.4.2.).71 
 
 
Figure 1.4.2. 
 
First Eu(III) FRET assay developed by Mathis. 
 
The use of a luminescent Ln(III) complex as a FRET donor with an organic acceptor group is 
widespread in the literature and the work started by Mathis has been the inspiration of many more 
similar FRET schemes involving luminescent Ln complexes as FRET donors in immunoassay schemes 
(Table 1.4.2.).  
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Table 1.4.2. 
Selected examples of FRET assays whereby the donor is a single molecule luminescent Ln 
complex.72,73,74 
 
Analyte FRET scheme used LOD / ng L-1 
Urinary 
albumin 
Albumin-specific monoclonal antibody labelled with a stable 
fluorescent Eu chelate as donor and an albumin labelled with Cy5 as 
acceptor. 
5.5 x 106  
Interleukin-
13 
Anti-Interleukin-13 monoclonal antibody, Eu cryptate as donor and 
labelled different anti-Interleukin-13 monoclonal antibody labelled 
with XL665. 
0.6  
DNA 
Hybridisation 
Two DNA probes are used each being complementary to the two 
different consecutive regions of a target DNA. The donor strand is 
labelled with a Tb(III) chelate and the acceptor strand with Cy5. 
30 (pM) 
 
This technology is outdated and has such been expanded to incorporate the use of luminescent Ln NPs 
as FRET donors whereby much lower detection limits can be achieved, when compared to single 
molecule methods, pushing the limits of conventional homogenous assay systems. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27 
 
1.5 Nanoparticles in optical immunoassays 
A NP is defined as a material which is between 1 and 100 nm in one dimension. Whilst this term allows 
particles to be more than 100 nm in a given dimension to be defined as a NP, a majority of the literature 
is focused on spherical particles.  
 
The use of NPs in the literature is broad and a very widely studied area which has become enormous 
over the past twenty-five years. As such, the number of journals dedicated to publishing NP technology 
based research has risen from just one in 1990 to over 150 in 2012.75 Inorganic NPs have been employed 
in a vast number of applications which range from medicinal applications and sensing to energy 
conversion devices.76,77,78 
 
The reason for the vast amount of work dedicated to the applications of NPs is that it is possible to fine 
tune their properties for the application to which they are to be used. Indeed, NPs can be synthesised 
with very specific optical and electrochemical characteristics with variable surface to volume ratios.79,80 
Furthermore, the functionalisation of NPs is a very well-studied area hence molecules can be deposited 
on the surface of a particle which do not interfere with the core properties of the particles leading to a 
very specific set of properties for a given nanostructure.81,82 
 
The use of NPs in immunoassay technology is an area which has become increasingly popular over 
recent years. The ease of functionalisation and controllable properties of NPs provides significant 
opportunity within the field of medical diagnostics. Indeed, the use of NPs within this field can lead to 
lower detection limits for analytes when compared to single molecule methods for both homogeneous 
and heterogeneous systems. The NP can be used as a scaffold for the immobilisation of biomolecules, 
or more commonly, as the detectable label itself within the system. Where the NP is used as the 
detectable label within the system, the amount of literature available is vast and reports of 
immunoassays based on colorimetric, electrochemical, optical and mass sensitive detection methods 
are common.83,84,85,86,87,88 Indeed, it is the optical properties of NPs which are most widely studied, with 
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ca. 46% of all NP immunoassay publications being optical based between 2010 and 2013, and this is a 
continuing trend within the literature.89 Within the field of optical NP based immunoassays, a majority 
of the literature is focused on the use of QDs and luminescent Ln NPs as the luminescent agent 
employed for their optical signatures. 
 
1.5.1. Lanthanide doped nanoparticles in immunoassays 
Luminescent Ln NPs can incorporate many luminescent Ln chelates inside a NP host, usually comprised 
of a polymer or silica host material. This leads to a much larger concentration of detectable Ln unit per 
biomolecule when compared to single molecule methods as previously described. Consequently, a large 
signal amplification is observed leading to a more sensitive assay, pushing the lower limit of detection 
down.90 This type of technology started to trend in the literature in the early 2000’s. 
 
The first Ln based NPs developed were those whereby Ln(III) ions were encapsulated within a polymer 
host material with sensitising units. In 2001 Hӓrmӓ et al. used polystyrene based NPs (ca. 100 nm) 
encapsulated with >30,000 Eu(III) ions and β-diketone units, for Eu(III) sensitization and coated with 
streptavidin (SA) for the detection of biotinylated prostate specific antigen (PSA) in a model assay 
system.91 The PSA was detected via time resolved luminescence whereby the Eu(III) NP was excited 
at 340 nm to show emission at 615 nm, giving a lower detection limit of 0.4 ng L-1 of PSA. The same 
type of technology has more recently been employed for a polymer based assay with Eu(III) for cardiac 
troponin I (CTnI), whereby Eu(III) polystyrene NPs (ca. 100 nm) coated with anti CTnI antibodies were 
developed, showing a detection limit of 2 ng L-1 of CTnI via time resolved luminescence of the Eu(III) 
NP when bound to a surface via CTnI and surface immobilised anti CTnI antibodies (Figure 1.5.1.).92 
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Figure 1.5.1. 
 
Eu(III) doped polystyrene NP assay for the time resolved detection of CTnI. 
 
Further examples of time resolved luminescent assay systems whereby luminescent Ln ions are doped 
into a polymer based host are included (Table 1.5.1.) which show generally lower detection limits when 
compared to single molecule methods. 
 
Table 1.5.1. 
 
Further selected examples of polymer based Ln NPs developed.93,94,95,96,97 
 
Analyte NP and detection method used LOD / ng L-1 
α-fetoprotein 100 nm polystyrene NPs encapsulated with Eu(III) and β-
diketone units coupled to anti α-fetoprotein Abs detected 
via TR luminescence.  
0.04 
PSA 50 nm Eu(III) chelate embedded polystyrene NPs 
functionalised with anti PSA Abs with differing amounts of 
acrylic acid present detected via TR luminescence. 
1.6 (with 2.8% 
acrylic acid by 
mass) 
Thyroid-stimulating 
hormone (TSH) 
100 nm polystyrene NPs encapsulated with Eu(III) and β-
diketone units coupled to anti TSH Abs detected via TR 
luminescence. 
0.0012 (mIU I−1) 
PSA 100 nm polystyrene NPs encapsulated with Eu(III) and β-
diketone units functionalised with anti PSA Abs, detected 
via TR luminescence. 
0.21 
HBsAg  
 
100 nm polystyrene NPs encapsulated with Eu(III) and β-
diketone, functionalised with anti HBsAg Ab, detected via 
TR luminescence. 
28 
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Despite their advantages of high sensitivity, Ln doped polymer based NPs have drawbacks associated 
with their usage, due to issues with leakage of the luminescent material and a tendency to agglomerate 
can arise, which somewhat limits their potential.98 
 
As a solution to the problems associated with polymers as a host material, silica as the host material for 
luminescent Ln complexes for use in NP based immunoassays has been applied for their aqueous 
solubility without aggregation, surface biocompatibility and potential smaller particle size. 
 
Yuan et. al. in 2004 were able to utilise these properties to detect HBsAg employing Eu(III) chelate 
doped silica NPs of 40 nm in diameter, developed from polymerised tetraothoorthosilicate, along with 
Eu(III) sensitizer BHHT, and functionalised with anti HBsAg antibody.99 The HBsAg was detected 
with a lower detection limit of 74 ng L-1 via time resolved luminescence of the Eu(III) ion, exciting at 
340 nm and observing the Eu(III) emission signal at 615 nm. A 0.2 ms time delay was used to eliminate 
any short lived background fluorescence from the observed signal to ensure the long lived Eu(III) NP 
was exclusively being observed. Yuan et al. extended their work using Tb(III) chelate doped silica 
nanoparticles with BPTA sensitizer, and functionalised with anti PSA antibody for the detection of PSA 
which was achieved with a lower detection limit of 7 ng L-1 via time resolved luminescence of the 
Tb(III) after exciting at 320 nm and observing the Tb(III) emission signal at 545 nm with a 0.2 ms time 
delay.100 
 
Further examples of silica based Ln NPs are included (Table 1.5.2.). Whilst silica as a host material for 
Ln ions and their sensitizing units, is an improvement in comparison to the use of a polymer host 
material, the number of luminescent units encapsulated within the material is lower hence a slight loss 
in sensitivity can be observed when the two are compared. 
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Table 1.5.2. 
 
Further selected examples of silica based Ln NPs developed.101,102,103,104,105 
 
Analyte NP and detection method used LOD / ng L-1 
α-fetoprotein 45 nm silica NPs encapsulated with Tb(III) 
and BPTA, functionalised with anti α-
fetoprotein Ab, detected via TR luminescence. 
100 
HBsAg 
 
40 nm silica NPs encapsulated with BBCAP 
and Eu(III) / Tb(III) functionalised with anti 
HBsAg Ab, detected via TR luminescence. 
35 
CEA 
(Carcinoembryonic 
antigen) / HBsAg 
40 nm silica NPs encapsulated with Eu(III) 
and BHHCT functionalised with either anti 
CEA Ab or anti HBsAg, detected via TR 
luminescence. 
1.9 (for CEA) 
23 (for HBsAg) 
DNA 45 nm silica NPs encapsulated with Eu(III) 
quinolone complex and functionalised with 
complementary DNA strand, detected via TR 
luminescence.  
0.08 (nM) 
PSA 60 nm silica NPs encapsulated with Eu(III) / 
Tb(III) and PTTA, functionalised with anti 
PSA Ab, detected via TR luminescence. 
210 
 
 
Both polymer and silica doped Ln NPs can be used in FRET based assays whereby the Ln doped NPs 
are used as a detectable label with an appropriate FRET acceptor. The use of a polymer based Eu(III) 
chelate doped NP as a FRET donor was demonstrated by Valanne et al. in an assay for PSA. 100 nm 
polystyrene NPs containing Eu(III) with β-diketone and functionalised with anti PSA antibody were 
developed as a FRET donor. A 2 μm TransFluoSphere (TFS), containing multiple dyes with a spectral 
overlap with the Eu(III) emission signal, coated with anti PSA antibody was developed as the acceptor. 
As both the donor and the acceptor simultaneously bound PSA, FRET was observed between the Eu(III) 
NP and the TFS. Excitation of the Eu(III) NP at 340 nm led to emission from the TFS at 760 nm via 
FRET excitation of the TFS, showing a detection limit of 100 ng L-1 in terms of the concentration of 
PSA (Figure 1.5.2.).106  
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Figure 1.5.2. 
FRET system schematic with Eu(III) doped polymer NP as the donor and a TFS sphere as the acceptor. 
 
Indeed, further examples of Ln doped particles used in FRET assays from the literature show the 
potential from this type of system (Table 1.5.3.). 
 
Table 1.5.3. 
Selected examples of FRET assays whereby the donor is a luminescent Ln complex doped 
NP.107,108,109,110 
 
Analyte FRET scheme used LOD / ng L-1 
Estradiol 
(E2) 
100 nm polystyrene NPs encapsulated with Eu(III) and β-diketone 
units coupled to anti E2 Abs as the donor and anti E2 Abs 
functionalised with AlexaFluor (AF) 680 as the acceptor. 
50 (pM) 
BSA 
(Bovine 
serum 
Albumin) 
90 nm polystyrene NPs encapsulated with Eu(III) as the donor and 
CdSe / ZnS QDs functionalised with SA as the acceptor. BSA acts a 
blocking reagent between the NPs and the QDs. 
2.8 x 105 (In 
terms of conc. 
of QD) 
E2 90 nm polystyrene NPs encapsulated with Eu(III) and β-diketone 
units coupled to anti E2 Abs as the donor and anti E2 Abs 
functionalised with AF680 as the acceptor. 
70 (pM) 
Caspase 3 
inhibitors 
A dual FRET system with 50 nm polystyrene NPs encapsulated with 
Eu(III), functionalised with AF680 loaded substrate as the donor. 
Complementary substrate labelled with QD as the acceptor. 
N/A 
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1.5.2 Upconverting phosphors in immunoassays 
The excitation of an organic chromophore for the sensitization of Ln(III) ions is a fully understood area 
and as discussed widely used in assay systems. Excitation in the UV area of the electromagnetic 
spectrum leads to a large background fluorescent signal from biological samples which requires time 
gated methods to distinguish from the required Ln signal, at which point some of the signal can be lost. 
A huge body of literature in the field of medical diagnostics is focused on the use of Ln NPs which can 
be excited via a two – photon process. UCPs show anti-Stokes behaviour with the absorption of low 
energy infrared radiation and emission in the visible area of the electromagnetic spectrum via a two – 
photon process. This allows for no excitation of background biomolecules involved, and the use of a 
NIR excitation wavelength is much more safe and more penetrating than that of excitation in the UV 
area of the spectrum, whilst the unique emissive properties of the Ln ion involved are retained. 
 
UCPs are composed of Ln(III) ion pairs in crystals. Generally, Yb(III) ions which absorb light at 980 
nm via a two – photon process are used as sensitizers, which can transfer the energy to other Ln(III) 
ions such as Er(III) (Figure 1.5.3.), Tm(III), Ho(III) and Tb(III).111,112 113,114  
 
Figure 1.5.3. 
 
Energy level diagram of a 50 nm La2(MoO4)3 NP doped with Yb(III) and Er(III) with an λexc of 980 nm 
and emission at 519 nm, 541 nm, 653 nm. 
 
Solid lines, excitation and emission processes; dashed lines, non-radiative emissive processes; ET, 
energy transfer. 
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UCPs have been applied to biomedical applications as the absorption of the Yb(III) ion at 980 nm and 
sharp line emission in the visible region results in virtually zero background interference from biological 
samples.115 The first report of this type of luminescent reporter was in 1999 by Zijlmans et. al. where 
(Y.Yb.Er.)O2S and (Y.Yb.Tm.)O2S NPs between 0.2 and 0.4 µm were used in the detection of PSA and 
CD4 membrane antigen in tissue samples.116  
 
UCPs can be applied in FRET based applications whereby the UCP is excited via the two – photon 
process at 980 nm is used as a FRET donor. In 2007, Kuningas et. al. used La2O2S:Yb(III),Er(III) NPs 
of 390 nm in the detection of E2 in a competitive assay format. The UCPs were functionalised with anti 
E2 F(ab) which binds to unlabelled E2 and E2 labelled with small molecule acceptor (Figure 1.5.4.). 
The acceptor labelled E2 competes for binding with the analyte hence the FRET signal is inversely 
proportional to the concentration of E2 in the patient sample. Excitation at 980 nm led to emission at 
665 nm from the Er(III) ion and 740 nm from the acceptor with a lower detection limit of 60 ng L-1.117 
 
 
Figure 1.5.4. 
Schematic of a competitive FRET immunoassay utilising a UCP donor. 
 
=, Fab fragment; O, acceptor label; red circle, analyte; blue circle, competing labelled analyte. 
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Indeed FRET based UCPs have also been used with a variety of acceptors where NaYF4:Yb,Er type 
particles as the UCP are among the most popular (Table 1.5.4.). The use of these types of nanocrystals 
are currently the most extensively used Ln FRET donors available in the literature and research into the 
usage and improvement of these materials is extensive.  
 
Table 1.5.4. 
Selected examples of FRET assays whereby the donor is a UCP.118,119,120,121,122,123,124,125 126 
 
Analyte FRET scheme used LOD / ng L-1 
Avadin Na(Y1.5Na0.5)F6:Yb,Er and Na(Y1.5Na0.5)F6:Yb,Tm of 50 nm, 
functionalised with biotin were used as FRET donors and 7 nm 
AuNPs functionalised with biotin were used as FRET acceptors. 
0.5 (nM) 
DNA NaYF4:Yb,Er functionalised with complementary DNA strand as 
the donor and TAMRA labelled with complementary DNA 
strand as the acceptor. 
1.3 (nM) 
E2 La2O2S:Yb(III),Er(III) functionalised with anti E2 Fab Ab as the 
FRET donor and E2 labelled with Oyster 556 as the acceptor. 
0.4 (nM) 
Goat IgG 50 nm NaYF4:Yb,Er functionalised with anti goat IgG Ab as the 
donor and 20 nm AuNP functionalised with human IgG as the 
acceptor. 
880 
Biotin 22 x 24 x 32 nm NaYF4:Yb,Er particles functionalised with SA 
as the acceptor and 16 nm CdTe based QD labelled with biotin 
as the acceptor. 
2 (nM) 
Glycated 
Haemoglobin 
50 nm NaYF4:Yb,Er functionalised with anti HbA1c Ab as the 
donor and HbA1c as the acceptor. 
N/A 
CEA 50 nm NaYF4:Yb,Tm functionalised with CEA aptamer as the 
donor and PdNPs as the acceptor. 
0.8 
ATP NaYF4:Yb,Er functionalised with DNA as the donor and 
graphene oxide as the acceptor. 
80 (nM) 
DNA 30 nm NaYF4:Yb,Er functionalised with complementary DNA 
strand as the donor and graphene oxide as the acceptor. 
5 (pM) 
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Although these types of particles show virtually no background signal, the main disadvantage in this 
field is the low luminescent efficiency for smaller NPs which are of a desirable size for an immunoassay 
application where a smaller particle size shows the best FRET quenching which is possible.127,128  
 
Whilst the use of Ln NPs as FRET donors is broad and has been applied to the detection of many 
analytes, with the inclusion of many luminescent chelates within a single nanostructure, a serious 
concern associated with the use of LnNPs as FRET donors, is the distance between the chromophores 
involved. The typical FRET range for a luminescent Ln complex to organic chromophore is <10 nm. 
Where LnNPs are used, particles of between 50 and 100 nm in diameter are often used, whereby Ln 
material deep within the large particle is outside the FRET range for an acceptor molecule bound to the 
surface, and this can be considered as lost signal which will not be quenched (Figure 1.5.5.).129 A non-
luminescent core would be advantageous to overcome this. 
 
Figure 1.5.5. 
Schematic showing the loss of signal from a doped Ln NP. 
 
O, acceptor label; dashed red line, area where Eu is within potential FRET range; dashed blue line, 
area where acceptor is within potential FRET range; green lattice, area where FRET is currently active. 
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1.5.3 Quantum dots in immunoassays 
As well as luminescent Ln NPs as FRET donors, another important class of NPs which can act as FRET 
donors are QDs. QDs are semiconductor NPs that have the capability to exhibit unique optical 
properties.130 The semiconductor cores most commonly consist of CdSe or CdTe materials and are 
surrounded by one or more shells such as ZnS and CdS with a higher band gap and are often surrounded 
by a polymer and surface ligands (Figure 1.5.6.).131,132,133,134  
 
 
Figure 1.5.6. 
Generic QD structure. 
 
The optical properties of QDs are highly tunable and depend on both the size and composition of the 
core and the surrounding shells. As such QDs can be designed to have an extremely high molar 
absorptivity (106 M-1 cm-1), exhibit sharp emission spectra and have a high emission quantum yield, 
with a large Stokes shift which makes them ideal candidates for labelling in immunodiagnostics, 
especially as their absorption properties can be tuned to avoid background excitation of biomolecules 
present.135,136 
 
The optical properties of QDs have made them ideal for use in FRET systems. Whilst QDs can be used 
as energy acceptors, using luminescent Lns as donors, a clear majority of the literature is focussed on 
QDs as energy donors.137,138  
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Wei et. al. were able to use the luminescent properties of QDs in a homogeneous FRET assay for 
estrogen receptor β (ER-β) in a sandwich assay format. QD 565 which has a core of CdSe and a ZnS 
shell were functionalised with anti ER-β antibody and used as a FRET donor whereby the FRET 
acceptor was anti ER-β antibody labelled with organic dye AF568 which shows a large spectral overlap 
with the emission spectrum of QD 565. As the immunocomplex formed, excitation at 476 nm led to 
emission from the dye at between 590 and 720 nm via fluorescence microscopy, leading to a lower 
detection limit of 2.65 ng L-1 based on the concentration of ER-β present.139 
 
The use of QDs as FRET donors in the literature is plentiful, whereby common energy acceptors have 
included organic dyes, AuNPs and black hole quenchers (Table 1.5.5.). QDs also have a large potential 
for simultaneous detection of analytes with the ability to excite many different QDs with the same 
excitation wavelength.140,141 
 
Table 1.5.5. 
Selected examples of FRET assays whereby the donor is a QD.142 143,144,145 
  
Analyte FRET scheme used LOD / ng L-1 
CEA CdTe based QDs immobilised on 100 nm SiO2 and functionalised 
with anti CEA Ab as the donor and AuNP functionalised with anti 
CEA Ab as the acceptor. 
300 
Glucose CdTe based QDs functionalised with concanavalin A as the donor and 
13 nm AuNP functionalised with β-cyclodextrin as the acceptor. 
50 (nM) 
Thrombin QD 565 functionalised with a DNA aptamer beacon is the donor and 
DNA intercalating dye BOBO-3 is the acceptor. 
1 (nM) 
Renin SA functionalised QD as the donor and biotin functionalised peptide 
conjugated to Cy5, which is cleaved up action from analyte, as the 
acceptor.  
25 (pM) 
 
 
 
 39 
 
Despite their advantages, QDs suffer from drawbacks. Namely the blinking effect which is common 
with the use of QDs whereby the emission has “on or off” states which can somewhat limit their use as 
the optical signal is not constant.146 The excited state lifetime of the QD is short in the nanosecond range 
which can cause issues associated with eliminating the optical signal from background fluorescence, 
although the tunable nature of the excitation wavelength can help avoid the use of dangerous excitation 
wavelengths in the experimental setup. Also, similarly to Ln NPs, often a large size of the QD can lead 
to a large distance between the donor and the acceptor leading to a poor FRET signal as the coatings 
required to tune the properties of the material can often be relatively thick leading to a poor 
chromophore separation. Also, the toxicity of QDs is a downfall to these materials, when safer 
alternatives, such as Ln NPs, can be used.147,148 
 
1.5.4 Nanoparticles as FRET acceptors 
Whilst much of the literature in the area of NPs in FRET assays is dominated by the use of the NP as a 
FRET donor from their tunable and exciting emissive properties, there have been reports of 
nanoparticles as FRET acceptors. As afore mentioned, QDs have found application as FRET acceptors, 
although this is uncommon. AuNPs have been widely reported at FRET donors due to their high 
fluorescence quenching capability because of their surface plasmon resonance (SPR) absorption band 
which is both highly absorbing and broad, meaning a broad range of emission wavelengths can be 
quenched. Indeed, the spherical nature of the AuNP means that the FRET signal is no longer limited by 
the dipole orientation factor as the AuNP has no defined dipole.149 Where the AuNP is used as a FRET 
acceptor, common donors are organic dyes and QDs, both of which have a short lived excited state 
lifetime.  
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The high quenching capability of AuNPs was demonstrated by Chen et. al. in a competitive FRET assay 
for IgM molecules. Anti IgM antibodies were conjugated to AuNPs of 13 nm in diameter and IgM 
molecules were conjugated to FITC molecules, the emission which shows a large spectral overlap with 
the SPR band of 13 nm AuNPs. As the FITC labelled IgM were incubated with varying concentrations 
of anti IgM antibody labelled AuNP, upon excitation at 490 nm, the emission intensity of the FITC was 
decreased as the concentration of anti IgM antibody labelled AuNP was increased by monitoring the 
emission siganl of the FITC at 520 nm, as a result of FRET quenching from the SPR band of the AuNP. 
This was able be taken forward to develop a competitive FRET based assay for IgM molecules to show 
a lower detection limit for IgM of 42 nM (Figure 1.5.7.).150 
 
 
Figure 1.5.7. 
Schematic of a competitive FRET immunoassay utilising AuNP acceptor.  
 
O, FITC label; red circle, IgM; blue circle, competing labelled IgM. 
 
Indeed, the use of the SPR band of AuNPs as a FRET quencher is common and have been applied to 
many assay systems in the literature (Table 1.5.6.).  
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Table 1.5.6. 
Selected examples of FRET assays whereby the acceptor is an AuNP.151,152 153,154  
 
Analyte FRET scheme used LOD / ng L-1 
CTnI Anti CTnI Abs functionalised with Cy3 dye as the 
donor and 20 nm AuNP functionalised with anti CTnI 
Abs as the acceptor. 
700 
DNA methylation FITC labelled DNA as the donor and gold nanorods of 
10 x 10 x 30 nm as the acceptor. 
0.25 (U mL-1) 
CEA DNA modified fluorescent polymer NP of 50 nm 
functionalised with DNA as the donor and AuNP of 13 
nm functionalised with DNA as the acceptor. 
100 
DNA 
hybridisation 
Silica particles of 50 nm doped with FITC 
functionalised with complementary DNA strand as the 
donor and 13 nm AuNPs functionalised with a 
complementary DNA strand as the acceptor. 
3 (pM) 
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1.6 Free light chain assays 
Immunoglobin G (IgG) type antibodies are comprised of four individual units to make up a whole 
antibody, which is typically a ‘Y’ shape with two antigen binding sites. These units are made of heavy 
chains (HCs) and light chains (LCs). Each IgG antibody has two HCs and two LCs (Figure 1.6.1.).155 
 
Figure 1.6.1. 
IgG structure with HC and LC regions shown. 
F(ab), Ag binding fragment region; Fc, crystallisable region. 
 
Whilst IgG is the most common antibody in humans providing most resistance against invading 
antigens, other structures can be found. These are IgD and IgE which also have a ‘Y’ shape as well as 
dimer IgA and pentamer IgM (Figure 1.6.2.). Similarly, all of these contain HC and LC units. 
 
 
Figure 1.6.2. 
Schematic of IgM (left) and IgA (right) Abs. 
Each IgG is comprised of two antigen binding fragment (F(ab)) units and one crystallisable fragment 
(Fc). The LC antibodies are located on the (F(ab)) and are connected to the HC with disulphide bonds 
(Figure 1.6.3.). An IgG molecule is ca. 150 kDa in size. 
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Figure 1.6.3. 
General F(ab) structure with LC highlighted in yellow and HC highlighted in blue. 
Vr, variable region; Cr constant region. 
 
There are two types of LC in mammalian species, so called Kappa (κ) and Lambda (λ) chains. Each LC 
is comprised of ca. 210 – 220 amino acids, is ca. 25 kDa in size and is made up of a variable region 
(Vr) which sits at the antigen binding site of the antibody, and a constant region (Cr) which is bound to 
a HC in an antibody molecule.156,157 Each type of LC chain antibody has an identical Cr amino acid 
sequence and the amino acid sequence of the Vr differs. As such many LC antibodies have been 
sequenced and reported.158,159,160 
  
Antibodies are made and developed in bone marrow cells and are released into the serum for use. During 
this production process LC antibodies are produced in a small excess to HC antibodies. LC and HC 
units become joined to form whole Ig units which leaves a small concentration of LC antibody which 
is also released in the serum (Figure 1.6.4.). The unbound LCs are called free light chains (FLCs) and 
known as Bence Jones (BJ) proteins if they are present in the urine.161 
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Figure 1.6.4. 
Graph of HC production against LC production in an apparently healthy individual. Not to scale. 
 
In an apparently healthy individual the concentration of κ and λ FLC in the blood is 3.3 – 19.4 mg L-1 
(κ) and 5.7 – 26.3 mg L-1 (λ) and a κ : λ ratio of between 0.26 : 1.65.162 The quantification of the 
concentration of both κ and λ FLC in the serum or urine is crucial in the diagnosis of multiple myeloma 
and can be used in the aid of other BJ related disorders including multiple sclerosis, systemic lupus 
erythematosus and others.163,164,165 
 
Currently there is no known cure for myeloma. Many patients die within months of diagnosis of this 
condition, with symptoms such as bone pain, tiredness and renal failure, and the patient will also become 
much more susceptible to infection.166 The five year survival rate of myeloma in the UK is currently 
47.0% after the initial diagnosis and the ten year survival rate is 32.5%.167 As such, early diagnosis of 
this condition is crucial to delivering the care and treatment to patients in aid of them surviving the 
disease as long and as comfortably as possible. 
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Myeloma is a cancer of the bone marrow which leads to a large excess of cancerous bone marrow to be 
produced. These clonal bone marrow cells are also involved in the production of antibodies and as a 
result a large overproduction of antibodies is observed, and a large FLC concentration is present in the 
serum (Figure 1.6.5.). This FLC concentration varies depending on the time course of the disease from 
the normal concentrations to of 30 – 40 times larger than the normal serum concentration. A patient 
diagnosed with myeloma will see an increase in the concentration of only one type of LC, hence the     
κ : λ ratio is an important measurement to make a successful diagnosis of either a κ or a λ myeloma.  
 
Figure 1.6.5. 
Graph of HC production against LC production in an apparently healthy individual against a myeloma 
patient. Not to Scale. 
 
Until the 1970s diagnosis of myeloma was particularly challenging as researchers were looking at 
quantifying the concentration of BJ protein in the urine.168 This led to a barrier to this research as the 
kidneys play a role in keeping proteins within the body and not letting them seep into the urine and it is 
not until the FLC concentration is large in the serum that experimentalists were detecting these proteins 
within the urine, as the kidneys reabsorption mechanisms are overcome.169,170 Because of this issue, it 
is serum FLC assays that are now generally used, although the first commercial serum FLC assays were 
based around electrophoresis and radioimmunoassay methods which were experimentally difficult and 
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lacked the sensitivity to give an early myeloma diagnosis. Indeed, the detection ranges of 
electrophoresis type assays were typically between 500 and 2000 mg L-1 which are well above normal 
serum levels of FLC.171,172,173 
 
In 2001, a breakthrough in the area of serum FLC assays was published by Bradwell et. al. whereby the 
concentration of κ and λ FLCs were measured separately via a turbidimetric immunoassay and this is 
currently the only US food and drug administration approved method of FLC concentration 
determination used today.174 The assay is able to determine the concentration of FLC in the serum 
between 3.6 – 172 mg L-1 for κFLC and 5.6 – 268 mg L-1 for λFLC, both of which are lower than the 
normal serum concentrations of FLC concentration, showing an increase in the sensitivity of ca. 500 
times in comparison to electrophoresis methods previously used. 
 
A large research effort is made towards the quantification of the concentration of both of κ and λ FLCs, 
and several new assays have been developed and commercialised, often using methods to quantify the 
concentration of both κ and λ FLCs.175,176 In 2013 a multiplex Luminex assay was developed by 
Campbell et. al. whereby Luminex beads coated with anti FLC antibody were developed which show 
competitive binding between FLC in a patient sample and FLC functionalised with biotin. SA 
functionalised with organic dye phycoerythrin was used for detection showing detection ranges of 5.3 
– 413.9 mg L-1 for κFLC and 2.5 – 406.5 mg L-1 for λFLC, both of which are within the normal serum 
concentrations of FLC.177 This is rivalled with the development of Seralite which uses a dipstick method 
to quantify the concentration of κ and λ FLCs simultaneously using anti FLC antibody functionalised 
AuNPs to bind FLCs as a patient sample flows over the NPs in a portable device, showing detection 
ranges of between 7.9 – 790 mg L-1 for κFLC and 7.8 – 780 mg L-1 for λFLC again within the normal 
serum concentrations of FLC.178,179 
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1.7 Thesis aims and objectives 
The aim of this thesis is to develop a novel, homogeneous FRET based assay for the quantification of 
FLCs using nanoparticles in a cheap and easy to run assay format, which in turn can be used to diagnose 
LC related disorders, such as multiple myeloma and others.  
 
Our approach is to develop a system whereby the FRET donor is a luminescent Eu(III) complex which 
has advantages over organic FRET donors with its large Stokes shift, sharp line emission spectrum and 
long lived τ. This complex is to be attached to the surface of a AuNP, along with LC material which 
can show competitive binding with FLC in a patient sample with anti FLC antibody. The anti FLC 
antibody is tagged with an organic dye which acts as a FRET acceptor, developing a system whereby 
the FRET is ‘on’ if no competitive binding occurs and ‘off’ if competitive binding occurs, as measured 
via quenching of the Eu(III) complex (Figure 1.7.1.). 
               
 
Figure 1.7.1. 
FRET assay design as discussed in this thesis. 
O, FRET acceptor; ●, FRET donor;           ,, LC either in sample or bound to AuNP.        
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The use of Ln NPs in assay technology is a popular area of research whereby lower detection limits can 
be reached for both surface and solution based assays. This homogeneous system is designed to be 
facile for the experimentalist to perform with no lengthy washing procedures, whilst also being cheap 
to run whereby only a small amount of material is required to get an assay readout.  This system 
competes with current technology based on luminescent Ln NPs in homogeneous assay schemes as the 
luminescent Ln reporter is bound to the surface, and not buried deep within a large nanomaterial, which 
can be 100 nm, far out of the FRET range for a surface bound acceptor (Section 1.5). The advantage of 
the surface bound donor molecule in our system is the distance between the donor and the acceptor is 
reduced and so all within the range for FRET to occur and signal from unquenched Eu(III) reporters is 
no longer an issue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
 
1.8 Referenced material 
1 J. L. Bock, Am. J. Clin. Pathol., 2000, 113, 628 – 646. 
2 S. Song, N. Liu, Z. Zhao, E. N. Ediage, S. Wu, C. Sun, S. D. Saeger and A. Wu, Anal. Chem., 2014, 
86, 4995–5001. 
3 X. Sun, Y. Zhang, D. Zheng, S. Yue, C. Yang and Z. Xu, Biosens. Bioelectron., 2017, 92, 81 – 86. 
4 M. Tschöp, H. M. Behre, E. Nieschlag, R. A. Dressendörfer and C. J. Strasburger, Clin. Chem. Lab. 
Med., 1998, 36, 223 – 230.  
5 I. A. Darwish, Int. J. Biomed. Sci., 2006, 2, 217 – 235.  
6 PerkinElmer DELFIA kit information, http://www.perkinelmer.co.uk/lab-products-and-
services/application-support-knowledgebase/delfia/delfia-trf-assays.html, (Acsessed online April 
2017). 
7 N. Kim and S. Son, J. Fluoresc., 2016, 26, 1715 – 1721. 
8 Thermofisher ELISA kit information, https://www.thermofisher.com/uk/en/home/life-
science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-
protein-methods/overview-elisa.html, (Accessed online April 2017). 
9 C. C. Capule and J. Yang, Anal. Chem., 2012, 84, 1786 – 1791. 
10 T. Kreisig, R. Hoffmann and T. Zuchner, Anal. Chem., 2011, 83, 4281 – 4287.  
11 Y. Wu, W. Guo, W. Peng, Q. Zhao, J. Piao, B. Zhang, X. Wu, H. Wang, X. Gong and J. Chang, ACS 
Appl. Mater., Interfaces, 2017, 9, 9369 – 9377. 
12 X. Huang, R. Chen, W. Lai and Y. Xiong, Anal. Chem., 2016, 88, 1951 – 1958.  
13 S. Wang, Z. Chen, J. Choo and L. Chen, Anal. Bioanal. Chem., 2016, 408, 1015–1022. 
14 C. Hsu, H. Huang, W. Chen, W. Nishie, H. Ujiie, K. Natsuga, S. Fan, H. Wang, J. Y. Lee, W. 
Tsai, H. Shimizu and C. Cheng, Anal. Chem., 2014, 86, 4605 – 4610.  
15 T. Förster, Naturwissenschaften, 1946, 33, 166 – 175.   
16 B. Valeur, Molecular fluorescence: Principles and applications, Wiley-VCH, Weirheim, 1st edition, 
2001, ch. 9, 247 – 271.   
17 Thermofisher  information on common FRET pairs for organic dyes,  
https://www.thermofisher.com/uk/en/home/references/molecular-probes-the-handbook/technical-
notes-and-product-highlights/fluorescence-resonance-energy-transfer-fret.html, (Accessed online 
April 2017). 
18 A. R. Clapp, I. L. Medintz, J. M. Mauro, B. R. Fisher, M. G. Bawendi and H. Mattoussi, J. Am. 
Chem. Soc., 2004, 126, 301 – 310.  
19 K. Boeneman, J. B. Delehanty, J. B. Blanco-Canosa, K. Susumu, M. H. Stewart, E. Oh, A. L. Huston, 
G. Dawson, S. Ingale, R. Walters, M. Domowicz, J. R. Deschamps, W. R. Algar, S.DiMaggio, J. 
                                                          
 50 
 
                                                                                                                                                                                    
Manono, C. M. Spillmann, D. Thompson, T.  L. Jennings, P. E. Dawson and I. L. Medintz, ACS Nano., 
2013, 7, 3778 – 3796. 
20 J. Shi, F. Tian, J. Lyu and M. Yang, J. Mater. Chem. B, 2015, 3, 6989 – 7005.  
21 P. Verwilst, S. Park, B. Yoon and J. S. Kim, Chem. Soc. Rev., 2015, 44, 1791 – 1806.   
22 M. Bottrill, L. K. Wok and N. J. Long, Chem. Soc. Rev., 2006, 35, 557 – 571.   
23 K. R. D. Johnson and P. G. Hayes, Chem. Soc. Rev., 2013, 42, 1947 – 1960.  
24 F. T. Edelmann, Chem. Soc. Rev., 2013, 42, 7657 – 7672.  
25 R. D. Teo, J. Termini and H. B. Gray, J. Med. Chem., 2016, 59, 6012 – 2024.   
26 S. Comby, E. M. Surender, O. Kotova, L. K. Truman, J. K. Molloy and T. Gunnlaugsson, Inorg. 
Chem., 2014, 53, 1867 – 1879. 
27 N. Kaltsoyannis and P. Scott, The f elements, Oxford science publications, New York, 1st edition, 
1999, ch. 2 and ch. 3, 6 – 32. 
28 L. A. Ekanger, D. R. Mills, M. M. Ali, L. A. Polin, Y. Shen, E. M. Haacke and M. J. Allen, Inorg. 
Chem., 2016, 55, 9981 – 9988.  
29 M. Szostak, N. J. Fazakerley, D. Parmar and D. J. Procter, Chem. Rev. 2014, 55, 5959 – 6039. 
30 P. D’Angelo, A. Zitolo, V. Migliorati, G. Chillemi, M. Duvail, P. Vitorge, S. Abadie and R. Spezia 
Inorg. Chem., 2011, 50, 4572 – 4579. 
31 J. G. Bünzli, J. Coord. Chem., 2014, 67, 3706 – 3733. 
32 J. Jiang, W. Liu, K. Poon, D. Du, D. P Arnold and D. K. P. Ng, Eur, J. Inorg. Chem., 2000, 205 – 
209.  
33 T. A. Beineke and J. Delgaudio, Inorg. Chem., 1968, 7, 715 – 721.  
34 M. Zbiri, C. A. Daul and T. A. Wesolowski, J. Chem. Theory Comput., 2006, 2, 1106 – 1111. 
35 P. Atkins, T. Overton, J. Rourke, M. Weller and F. Armstrong, Shriver and Atkins Inorganic 
chemistry, Oxford university press, New York, 5th edition, 2010, ch. 20, 473 – 506.  
36  S. V. Eliseevaa and J. G. Bünzli, Chem. Soc. Rev., 2010, 39, 189 – 227. 
37 J. G. Bünzli, Coord. Chem. Rev., 2015, 293, 19 – 47. 
38 J. G. Bünzli, Chem. Rev., 2010, 110, 2729 – 2755.  
39 R. D. Teo, J. Termini and H. B. Gray, J. Med. Chem., 2016, 59, 6012−6024. 
40 J. G. Bünzli and C. Piguet, Chem. Soc. Rev., 2005, 34, 1048 – 1077.  
41 J. M. Zwier, H. Bazin, L. Lamarque and G. Mathis, Inorg. Chem,. 2014, 53, 1854 – 1866. 
42 A. J. Amoroso and S. J. A. Pope, Chem. Soc. Rev., 2015, 44, 4723 – 4742.  
43 J. Zawadiak and M. Mrzyczek, Spectrochimica Acta Part A, 2010, 75, 925 – 929.  
44 K. Nakamoto J. Phys. Chem., 1960, 64, 1420 – 1425. 
45 D. Sutherland and C. Compton, J. Org. Chem., 1952, 17, 1257 – 1261. 
46 U. Steiner, D. Woll and S. Walbert, WO 2003074542 A2, 2003. 
47 W. D. W. Horrocks and D. R. Sudnick,  J. Am. Chem. Soc., 1979, 101, 334 – 340. 
48 R. C. Holz, C. A. Chang and W. D. Horrocks, Inorg. Chem., 1991, 30, 3270 – 3275.   
 51 
 
                                                                                                                                                                                    
49 N. Sabbatini and M. Guardigli, Coord. Chem. Rev., 1993, 123, 210 – 228.  
50 A. Beeby, I. M. Clarkson, R. S. Dickins, S. Faulkner, D. Parker, L. Royle, A. S. de Sousa, J. A. G. 
Williams and M. Woods, J. Chem. Soc., Perkin Trans. 2, 1999, 493 – 503.  
51 N. Viola-Villegas and R. P. Doyle, Coord. Chem. Rev., 2009, 253, 1906 – 1925. 
52 K. L. Nash, D. Brigham, T. C. Shehee and A. Martin, Dalton Trans., 2012, 41, 14547 –  14556. 
53 T. Güden-Silber, C. Doffek, C. Platas-Iglesias and M. Seitz, Dalton Trans., 2014, 43, 4238 – 4241. 
54 A. N. Gusev, M. Hasegawa, T. Shimizu, T. Fukawa, S. Sakurai, G. A. Nishchymenko, Victor F. 
Shulgin, S. B. Meshkova and W. Linert, Inorg. Chim. Acta., 2013, 406, 279 – 284. 
55 J. Garcia and M. J. Allen, Eur. J. Inorg. Chem., 2012, 29, 4550 – 4563. 
56 P. D. Bernardoa, A. Melchiorb, M. Tolazzib and P. L. Zanonatoa, Coord. Chem. Rev., 2012, 256, 
328 – 351.  
57 L. Jiang, J. Zheng, W. Chen, J. Ye, L. Mo, Z. Li, L. Hu, C. Zhang and S. Dai, J. Phys. Chem. C, 
2017, 121, 5925 – 5930.  
58 D. M. Weekes, C. F. Ramogida, M. G. Jaraquemada-Peláez, B. O. Patrick, C. Apte, T. I. Kostelnik, 
J. F. Cawthray, L. Murphy and C. Orvig, Inorg. Chem., 2016, 55, 12544 – 12558.  
59 A. Mohamadi and L.W. Miller, Bioconjug. Chem., 2016, 27, 2540 – 2548. 
60 D. Geißler, S. Linden, K. Liermann, K. D. Wegner, L. J. Charbonnière and N. Hildebrandt, Inorg. 
Chem., 2014, 53, 1824 – 1838. 
61 R. Roy, S. Hohng and T. Ha, Nat. Methods. 2008, 5. 507 – 516. 
62 H. Siitari, I. Hemmila, E. Soini and T. Lovgren and V. Koistinen, Nature, 1983, 301, 258 – 260.   
63 J. Vuori, S. Rasi, T. Takala and K. Vaananen, Clin. Chem., 1991, 37, 2087 – 2092.   
64 R. Liang, Y, Yang, J. Zhou, T. Liu, X.  Xu, Q. Liang, Z. Chen, Z. Dong and Y. Wu, J. Fluoresc., 
2017, 27, 309 – 316. 
65 F. Wua and C. Zhang, Anal. Biochem., 2002, 311, 57 – 67.  
66 H. Kimura, M.  Mukaida, G. Wang, J. Yuan and K. Matsumoto, Forensic Sci. Int., 2000, 113, 345 – 
351. 
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2 Preparation of luminescent light chain 
functionalised gold nanoparticles for FRET 
assays 
2.1 Introduction 
The first uses of colloidal gold can be traced back to the middle ages with their use as red pigments in 
stained glass windows, although it was not until the 1950s that Turkevich et. al. reported the first 
synthesis of colloidal gold.1,2 Since then, the study into the properties and uses of AuNPs has been vast 
and as such AuNPs have been used in a plethora of applications due to their aqueous solubility, easy 
functionalisation and inert, non-toxic nature, whereby monodisperse particles with a tuneable diameter 
can be produced, whereby the optical properties of the particle are dependent on the size of the particle.3 
The uses of AuNPs is vast and ranges from medical diagnostics as previously discussed (Section 1.5), 
to energy conversion devices, intercellular imaging and many others.4,5,6  
 
2.1.1 Lanthanide functionalised AuNPs  
AuNPs offer a unique opportunity to incorporate multiple molecular scale luminophores into a single 
nanoscale architecture for signal detection without engaging in lengthy synthetic procedures for the 
incorporation of multiple labels. Indeed, it is possible to functionalise the surface of AuNPs with 
luminescent probes to retain the optical properties of the probe being used and this has been shown for 
transition metal and Ln based probes, both of which have found use in intercellular imaging 
applications.7,8 Indeed, as well as luminescent Ln functionalised AuNPs, researchers have explored the 
possibility of Gd(III) functionalised AuNPs for their application within the field of MRI imaging, by 
increasing the relaxation rate of water molecules.9,10,11 
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Luminescent Ln functionalised AuNPs were first reported in 2006 by Lewis et. al. who synthesised a 
luminescent Eu complex with a DTPA bis-amide backbone, with a dual phenylamide based sensitizer 
with terminal thiol groups. This complex was able to be deposited on the surface of 13 nm AuNPs via 
the strong Au – S bond (Figure 2.1.1).12 The luminescent Ln functionalised AuNPs were found to retain 
the characteristic sharp line emission spectrum of 5D0 to the ground states of 7FJ (J = 0 – 4) from the 
Eu(III) ion via excitation of the phenyl based sensitizer at 280 nm.  
 
 
Figure 2.1.1. 
Functionalisation of AuNP with surface active luminescent Eu(III) complex as developed by Davies. 
 
 
 
 
 
 
 
 
 
 
 
59 
 
Around the same time, Ipe et. al. were able to functionalise AuNPs with thiol modified dipyridyl units 
which bind and sensitize both Tb(III) and Eu(III) ions, similarly, showing strong f–f luminescence from 
both Ln(III) ions (Figure 2.1.2.).13  
 
 
Figure 2.1.2. 
Functionalisation of AuNP with surface active luminescent Eu(III) complex as developed by Ipe. 
 
Research into the use of luminescent Ln functionalised AuNPs has not been vast and few publications 
exist in this area, although their use as both imaging probes and within sensing applications has been 
reported. In 2012 Davies et. al. reported the use of a luminescent Ln probe functionalised AuNPs for 
imaging of human platelets. AuNPs were coated with both a luminescent Eu(III) quinoline based probe 
and a pH responsive peptide whereby at pH < 6.5 the peptide structure becomes altered and inserts itself 
across a cell membrane. The particles were imaged using an excitation wavelength of 340 nm, showing 
Eu(III) luminescence within the platelets.14 Gunnlaugsson et. al. have developed a range of AuNPs 
functionalised with Eu(III), Tb(III) and Yb(III) in DOTA complexes with terminal thiol groups for a 
range sensing applications including small molecules and BSA, as well as pH responsive AuNPs all of 
which are based on the sensitized luminescence of the Ln cation involved (Figure 2.1.3.).15,16,17  
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Figure 2.1.3. 
Functionalisation of AuNP with surface active Ln(III) complex as developed by Gunnlaugsson for 
sensing applications. 
 
Whilst the reports of Ln NPs as the luminescent agent in both surface and solution based luminescence 
bioassay schemes is a well understood area, the use of a Ln capped AuNP as the detectable label has 
yet to be explored in either type of system. Whilst Ln based NPs, are excellent candidates for FRET 
donors in solution based assays which can show lower detection limits than single molecule based 
methods, as previously discussed a large proportion of the luminescent reporter is buried deep within 
the particle, too deep for the reporter to experience a FRET quench from a surface bound acceptor 
(Section 1.5.). A surface bound luminescent reporter would effectively remove this large distance 
between the chromophores, hence bringing all of the FRET donor into usage.   
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In 2012 Pihlasalo et. al. developed a system whereby the determination of protein was achieved via 
FRET from the surface of a NP. Polystyrene NPs of 60 nm in diameter were prepared and γ-globulin 
proteins were functionalised with either luminescent Eu(III) complex or organic dye AF680, which 
shows a large ΔJ with the emission spectrum of the Eu(III) ion. The labelled proteins were adsorbed to 
the polystyrene NPs, whereby the emission of the Eu(III) was quenched via FRET by the AF680 using 
an excitation wavelength of 340 nm. On addition of competing proteins, the labelled γ-globulin proteins 
were displaced and the FRET turned ‘off’ as the donor and acceptor become separated (Figure 2.1.4.). 
A lower detection limit of 2.6 ng of protein was achieved and was also able to be applied to cell 
counting.18 This report highlights the possibility of using a surface bound luminescent Ln complex as a 
FRET donor.  
 
Figure 2.1.4. 
FRET assay for determination of protein concentration. 
red circle, analyte; blue circle, competing labelled analyte, O, AF680; ●, luminescent Eu complex. 
 
 
It was also shown in a recent report that FRET is active between organic fluorophores on the surface of 
a silica NP whereby FITC is used as an energy donor to a rhodamine B energy acceptor in a study 
evaluating the effect of the concentration the energy donor and energy acceptor on the observed FRET 
signal between the two.19 
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2.1.2 Antibody functionalised AuNPs in immunoassays 
AuNPs have been used extensively within immunoassay schemes. Indeed, as previously discussed, 
AuNPs have found use in homogeneous assay schemes as FRET acceptors (Section 1.5.), and the use 
of AuNPs as a scaffold upon which to immobilise biomolecules, such as antibodies, is common within 
immunoassay schemes. The use of antibody functionalised AuNPs within immunoassay schemes is 
common and can lead to lower detection limits in comparison to the use of single molecule methods. 
Mitchell et. al. were able to show how a surface based SPR assay for progesterone was able to be 
improved with the use of AuNP functionalised antibodies over single antibodies. It was found that the 
lower detection limit without the AuNP present was 20.1 pg mL-1 which was improved to 8.6 pg mL-1 
with the inclusion of the colloidal gold into the system.20 A similar effect was observed in an SPR assay 
for testosterone.21 Indeed, other NPs have also been used to scaffold antibodies in immunoassay 
schemes, although AuNPs are the most widely used for their properties as previously discussed such as 
silica.22,23 
 
As such, many methods have been developed for the conjugation of antibodies to AuNPs. These can be 
done by the experimentalist themselves, or several commercial sources are available which provide 
functionalised AuNPs to which the experimentalists antibodies can be simply added to develop antibody 
functionalised AuNPs.24,25 Where the experimentalist performs the conjugation themselves, AuNPs can 
be functionalised with antibodies in a variety of ways (Figure 2.1.6.). These include adsorption onto the 
AuNP surface, covalently linked via click chemistry or EDC coupling with lysine residues on the 
antibody, coupling to the sugar units on the on the Fc area of an IgG using boronic acid chemistry, or 
using AuNPs and antibodies functionalised with SA and biotin, taking advantage of their strong 
bond.26,27,28,29,30,31,32 
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Figure 2.1.6. 
Methodologies for functionalising AuNPs with antibodies. 
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2.2 Chapter outline 
This chapter shows the surface functionalisation of AuNPs with surface active, luminescent Eu 
complexes and LCs, to produce LC functionalised AuNPs which show characteristic Eu luminescence 
and are used a FRET donor. These particles are then incubated with anti FLC antibody modified with a 
suitable FRET acceptor for Eu(III) luminescence and it is demonstrated how FRET can be observed 
between the pair, measured by excited state lifetime measurements (Figure 2.2.1.). 
 
Figure 2.2.1. 
General schematic of FRET between the functionalised AuNPs with FLC and Eu complex and anti FLC 
Ab conjugated to FRET acceptor.  
 
O, acceptor label; •, Eu donor label; grey rectangle, FLC. 
 
 
This chapter reports the synthesis, of surface active Eu complexes, their photophysical properties and 
their functionalisation onto AuNPs. It is then reported how AuNPs can be dual functionalised with the 
surface active Eu complexes and FLCs whilst retaining their characteristic f-f luminescence and how 
these particles can be used in a homogenous FRET based assay. 
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2.3 Synthesis of surface active Eu complexes 
For the surface active luminescent europium complexes, EuQSH and EuQuinSAc (Figure 2.3.1.) were 
chosen.  
 
 
Figure 2.3.1. 
Left: Structure of EuQuinSAc; Right: Structure of EuQSH. 
 
EuQuinSAc incorporates a DTPA-bisamide backbone with a quinoline sensitizing unit, attached to a 
six carbon aliphatic linker which is terminated with thioester groups. The quinoline group is known to 
be an effective sensitizer for Eu(III) with a T1 state of ca. 22,000 cm-1 which can lead to an emission Φ 
of 4% in terms of Eu(III) luminescence.33 The DTPA-bisamide backbone gives thermodynamically 
stable Ln(III) complexes with hard donor atoms (N and O) and carboxylates with a binding constant of 
ca. 1015. On binding Eu(III) the arms become preorganised for binding to a surface which is achieved 
with the thioester surface active group. 
 
EuQSH is a similar design with the use of a DTPA-bisamide backbone with a quinoline sensitizer 
incorporated into the design and a terminal sulphur group for attachment to a gold surface.34,35 
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EuQuinSAc was synthesised via the following scheme for the ligand H3QuinSAc (Figure 2.3.2.) 
followed by the inclusion of Eu(III) into to form EuQuinSAc.  
 
Figure 2.3.2. 
 
Synthetic scheme for H3QuinSAc adopted. 
 
The synthesis of H3QuinSAc proceeded via an improvement of a synthesis previously achieved within 
the Pikramenou group which commenced by protection of the amine with a Boc protecting group on 
substituted quinoline 1 to generate N-Boc protected amine 2. The reaction was carried out at 0 0C to 
encourage formation of the N-Boc protected amine over the O-Boc protected compound. This is an 
improvement on previous attempts which were low yielding due to O-Boc formation. The protection 
step was followed by Williamson ether synthesis of 5, from the reaction of 2 with aliphatic carbon linker 
4, which was previously prepared via a radical reaction of 3 with thioacetic acid in the presence of 
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radical initiator ABCN. The N-Boc protected Williamson ether product, 5 was then treated with TFA 
in dry DCM to yield deprotected amine 6 which was used in the production of H3QuinSAc via dual 
acylation with DTPA-bisanhydride in dry pyridine. The synthesis was performed in an overall yield of 
11% based on the starting moles of 1. Characterisation data for compounds 2, 4, 5 and 6 and 
H3QuinSAc are found in the appendix.  
 
H3QuinSAc was characterised by 1H nuclear magnetic resonance (NMR) spectroscopy, 13C NMR 
spectroscopy, and mass spectrometry (MS) with signals confirming the product at m/z = 994.9 [M + 
H]+ and 498.0 [M + H]2+ where an electrospray ionisation technique was used.  
 
H3QSH was synthesised via dual acylation of DTPA-bisanhydride with 6-aminoquinoline and 4-
aminothiophenol which produced three acylation products (Figure 2.3.3.). The asymmetric product 
H3QSH was separated from the others (H3SH and H3Quin) via preparative high pressure liquid 
chromatography (HPLC) running a water / acetone gradient. Using this method H3Quin was found to 
elute first followed by H3QSH and the last to elute being H3SH, as seen via comparison of the HPLC 
traces at 210 nm and 336 nm and confirmed with MS where an electrospray ionisation technique was 
used.  
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Figure 2.3.3. 
 
Synthetic scheme for H3QSH adopted. 
 
 
H3QSH was characterised with 1H NMR data, 13C NMR data, and MS with peaks confirming the 
product at m/z = 627.3 [M + H]+ and 649.2 [M + Na]+. Characterisation data for H3QSH are found in 
the appendix. 
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The UV Vis spectra of H3QuinSAc and H3QSH were recorded (Figure 2.3.4.). 
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Figure 2.3.4. 
Left: UV Vis spectrum of H3QuinSAc (4 µM in THF : Water (1 : 1)), Right: UV Vis spectrum of H3QSH 
(8 µM in MeOH). 
 
The absorption spectrum of H3QuinSAc shows two distinct bands with λmax at 244 nm (ε = 67000 M-1 
cm -1) and 321 nm (ε = 9000 M-1 cm-1) arising from S0  S2 and S0  S1 transitions both π  π* in 
nature from the quinoline groups. That of H3QSH shows less distinct bands with λmax at 247 nm (ε = 
39000 M-1 cm -1) and 320 nm (ε = 3000 M-1 cm -1) both again arising from π  π* transitions from the 
quinoline group and the phenyl group will contribute to the band observed at 247 nm. 
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EuQuinSAc was prepared by the addition of EuCl3.6H2O into a solution of deprotonated H3QuinSAc 
in (1 : 1) by volume THF : water (Figure 2.3.5.). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.5. 
Preparation of EuQuinSAc from H3QuinSAc. 
 
EuQuinSAc was isolated after trituration with acetone with MS, using an electrospray ionisation, data 
showing peaks at m/z : 1144.4 [M + H]+ and 572.7 [M + H]2+ and 242 from residual [N(Bu)4]+ which 
was removed via trituration with MeCN, leaving the peaks arising from EuQuinSAc in the MS with 
the typical Eu(III) isotope pattern. The peaks arising from the MS of H3QuinSAc (m/z = 994.9 [M + 
H]+ and 498.0 [M + H]2+) were not observed. 
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EuQSH was prepared in a similar fashion by the addition of EuCl3.6H2O into a solution of deprotonated 
H3QSH in (1 : 1) by volume THF : water (Figure 2.3.6.). 
 
 
 
Figure 2.3.6. 
Preparation of EuQSH from H3QSH 
 
EuQSH was isolated after trituration with MeCN and characterised via MS data showing peaks at       
m/z : 797.1 [M + Na]+ with the typical Eu(III) isotope pattern. Similarly to the EuQuinSAc preparation, 
residual [N(Bu)4]+ was required to be removed via trituration with MeCN and peaks corresponding to 
the ligand (m/z : 627.3 [M + H]+ and 649.2 [M + Na]+) were not observed. 
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2.4 Photophysical properties of EuQSH and EuQuinSAc 
The photophysical properties of both EuQuinSAc and EuQSH were recorded using UV Vis 
spectroscopy and emission spectroscopy (Figures 2.4.1. and 2.4.2.). 
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Figure 2.4.1. 
Combined UV Vis (Black) and emission (Blue) spectra of EuQuinSAc (4 µM in MeOH, λexc = 320 nm) 
corrected for PMT response. 
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Figure 2.4.2. 
Combined UV Vis (Black) and emission (Blue) spectra of EuQSH (8 µM in MeOH, λexc = 315 nm), 
corrected for PMT response. 
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The emission spectra of both EuQSH and EuQuinSAc show the characteristic Eu(III) f-f luminescence 
from the 5D0 to the ground states of 7FJ (J = 0 – 5), whereby the J = 2 band at 614 nm is the most 
prominent in both cases. EuQuinSAc shows a small amount of ligand fluorescence from the quinoline 
π* groups at 440 nm which suggests the energy transfer process from the T1 state of the quinoline does 
not transfer all the energy from this state to the Eu(III) ion. The absorption profile of EuQuinSAc 
matches that of H3QuinSAc whereby two distinct bands at 243 nm (ε = 66000 M-1 cm-1) and 321 nm (ε 
= 9000 M-1 cm-1) arising from S0  S2 and S0  S1 transitions both π  π* in nature from the quinoline 
groups. Similarly, a small amount of ligand fluorescence is observed for EuQSH although this is less 
in comparison to EuQuinSAc, perhaps due to the presence of one quinoline group instead of two. The 
absorption spectrum of EuQSH shows two distinct bands at 246 nm (ε = 35000    M-1 cm-1) from a 
mixture of the thiophenyl and quinoline groups and 320 nm (ε = 3000 M-1 cm-1) from the quinoline 
group. Excitation spectra of both compounds monitoring the emission of the compounds at 614 nm 
(Figure 2.4.3.) confirms that sensitized luminescence from the quinoline groups is active in both cases. 
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Figure 2.4.3. 
Left: Excitation spectra of EuQuinSAc in MeOH, monitoring the emission at 614 nm; Right: Excitation 
spectra of EuQSH in MeOH monitoring the emission at 614 nm. 
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Lifetime data of EuQSH and EuQuinSAc in both H2O and D2O water and emission quantum yield 
data in MeOH as measured by integrating sphere were recorded (Table 2.4.1.). 
 
Table 2.4.1. 
Lifetime and Φ data for EuQSH (λexc = 315 nm) and EuQuinSAc (λexc = 320 nm). 
Sample τ (H2O) / μs τ (D2O) / μs τ (MeOH) / 
μs 
Φ (MeOH) / % 
EuQSH 580 (χ2 = 1.0) 1850 (χ2 = 1.1) 860 (χ2 = 1.3) 4.0 
EuQuinSAc 180 (42%), 450 (58%) 
(χ2 = 1.3) 
1090 (χ2 = 1.3) 540 (χ2 = 1.2) 1.0 
 
The emission quantum yield data for f-f emission for both EuQSH and EuQuinSAc is comparable to 
other Eu complexes which have been reported utilising a quinoline sensitizing unit. The emission 
quantum yield is fairly low (< 10%) in both cases due to energy loss in the energy transfer process 
between the T1 state of the organic sensitizing unit and the 5D0 level of the Eu(III) ion. Indeed, both 
complexes show ligand fluorescence from the π* state of the quinoline group showing a competing 
pathway is active with the energy transfer process, in particular from EuQuinSAc with a large ligand 
emission being observed, hence a lower emission quantum yield. 
 
The excited state lifetime in deuterated solvents is higher than the non-deuterated analogue as a result 
of the quenching effect from the O-H vibration which is less efficient for O-D oscillations. EuQuinSAc 
in water shows bi exponential decay behaviour. Use of the Parker-Beeby equation for both compounds 
in D2O and H2O suggest q values of 1.1 ± 0.5 for EuQuinSAc (using the long component) and 1.0 ± 
0.5 for EuQSH, showing that each complex has one bound deactivating solvent molecule.  
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2.5 Synthesis of AuNPs 
The synthesis of the AuNPs used for this work was achieved via the well-known citrate reduction of 
HAuCl4 to prepare stable spherical particles of uniform size and shape (Cit@Au) in a simple one-pot 
synthesis at a concentration of 1.6 nM. The surface of the AuNPs is coated with citrate ions which can 
be easily displaced for the functionalisation of the surface of the gold. The NPs are characterised via 
UV Vis spectroscopy and transmission electron microscopy (TEM) (Figures 2.5.1. and 2.5.2.). 
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Figures 2.5.1. (Left) and 2.5.2. (Right) 
Left; UV Vis spectrum of 1.6 nM Cit@Au as synthesised, Right; TEM image of Cit@Au as synthesised. 
 
The UV Vis spectrum of Cit@Au shows a broad band with a λmax of 516 nm which is the characteristic 
absorption band of AuNPs known as the SPR band resulting from charge separation within the NP 
causing a dipole oscillation.36 This characteristic band of Cit@Au is sensitive to both the surface 
chemistry and the size of the NP. Changes in the SPR absorption band can be used to assess changes in 
either the surface chemistry or size of the gold colloid. The TEM image shows the particles of a 
spherical and uniform size distribution at a size of ca. 12 nm. Cit@Au is also characterised via 
(Dynamic light scattering) DLS which can be used to size spherical NPs via light scattering (Table 
2.5.1.) and zeta potential measurements for an indication of the stability of NPs. 
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Table 2.5.1. 
DLS sizing data for Cit@Au. 
Sample Intensity 
distribution / nm 
Number 
distribution / nm 
PDI 
Cit@Au 18 ± 3  12 ± 3 0.1 
 
DLS data is given in both intensity distribution and number distribution. The intensity distribution can 
be a somewhat misleading measurement which is weighted toward the measurement of larger particles 
as the scattering response is proportional to the square of the molecular weight of the particle, hence 
the presence of any agglomeration or aggregation can be measured. This is corrected for the number 
distribution whereby the size given is proportional to the scattering intensity whereby the presence of 
any small number of large aggregates is not picked up and a more accurate particle size is established.37 
The polydispersity (PDI) index measurement gives a measure of how uniform the size and shape of the 
particles are. A value of 0.1 indicates that the particles are uniform in size and shape, which is confirmed 
with TEM images of the particles. 
 
The zeta potential measurement gives a measure of the stability of the particles by passing an electrical 
current through the particles, causing the particles to migrate through solution based on their surface 
charge. For colloidal gold, a zeta potential measurement of lower than – 30 mV is considered to give 
stable particles. The zeta potential of Cit@Au gives a value of – 36 ± 16 mV which shows that stable 
particles have been formed, whereby the anionic coating is from the negative charge of the citrate ions.38  
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2.6 Functionalisation of AuNPs with Eu complexes 
The functionalisation of Cit@Au can be monitored via perturbations of the SPR wavelength of the NP. 
Herein the deposition of EuQSH and EuQuinSAc onto Cit@Au for the preparation of EuQS@Au 
and EuQuinSAc@Au is shown (Figure 2.6.1.). 
 
Figure 2.6.1. 
Preparation of EuQuinSAc@Au and EuQS@Au with the functionalisation of Cit@Au. 
 
The SPR wavelength of Cit@Au is altered whilst the EuQSH or EuQuinSAc complexes are deposited 
onto the gold surface, as monitored via UV Vis spectroscopy (Figures 2.6.2. and 2.6.3.). The 
nanoparticle surface is considered to be fully functionalised with EuQSH or EuQuinSAc at the point 
that no further bathochromic shift can be observed. At this point, an excess of Eu complex is present 
and this is removed with the use of size exclusion chromatography, using Sephadex G15, whereby the 
large size difference between the functionalised AuNP and the probe allow the two to be separated. It 
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is interesting to note that citrate stabilised AuNPs, do not pass through the Sephadex, or indeed particles 
which only have a partial coating of Eu(III) complex on the surface, which is possibly a result of the 
interaction of the surface citrate anions with the sugar. In all cases the SPR wavelength recorded is 
worked out via the full width at half maximum (FWHM) of the curve, at a point where the curve 
resembles a parabolic shape (see general experimental, Section 6). 
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Figure 2.6.2.  
Change in SPR wavelength of Cit@Au (3.2 nM in water, 2 mL) as a methanolic solution of EuQuinSAc 
(0.2 mM in MeOH, 5 µL aliquots) is titrated in to a final concentration of 4.87 µM. The yellow curve is 
post Sephadex chromatography to show that no aggregation occurs from the purification method. 
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Figure 2.6.3.  
Change in SPR wavelength of Cit@Au (3.2 nM in water, 2 mL) as a methanolic solution of EuQSH 
(0.2 mM in MeOH, 5 µL aliquots) is titrated in to a final concentration of 4.87 µM. The yellow curve is 
post Sephadex chromatography to show that no aggregation occurs from the purification method. 
 
SPR 
SPR 
 
 
79 
 
Both EuQSH and EuQuinSAc show positive shifts in the SPR wavelength of the NP as the surface is 
functionalised with the Eu complexes which reaches a saturation point at 521 nm for EuQS@Au and 
520 nm for EuQuinSAc@Au indicating the surface is fully functionalised at this concentration of ca. 
3800 nM. This suggests ca. 1200 Eu complexes per particle in both cases, although a more accurate 
method of determining the surface coverage of the AuNP is described at a later section. The absorption 
spectrum for both show the SPR wavelength of the NP is unaltered post purification which shows that 
the NP is unaltered during the Sephadex column chromatography. Particles were further characterised 
with TEM (Figure 2.6.4.) and DLS data (Table 2.6.1.). 
 
 
 
 
 
 
 
Figure 2.6.4.  
Left: TEM image of EuQuinSAc@Au; Right: TEM image of EuQS@Au. 
 
Table 2.6.1.  
DLS characterisation data for EuQS@Au and EuQuinSAc@Au. 
Sample Intensity 
distribution / nm 
Number 
distribution / nm 
PDI 
EuQS@Au 23 ± 10 12 ± 4 0.3 
EuQuinSAc@Au 24 ± 11 12 ± 3 0.5 
 
TEM images of both sets of particles show that both EuQS@Au and EuQuinSAc@Au are spherical 
in nature and of uniform morphology with a diameter of ca. 12 nm for both EuQS@Au and 
EuQuinSAc@Au as averaged over five particles in the image in each case which agrees with the DLS 
data for the Eu coated AuNPs. Indeed, this is in agreement with the UV Vis spectroscopy data which 
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shows that particle stability is maintained after both the addition of the Eu probes and from the action 
of the size exclusion column. A change in zeta potential from – 36 mV (Cit@Au)  to – 11 ±  4 mV 
(EuQS@Au) shows that the AuNP surface has been functionalised with respect to Cit@Au. The 
positive change in the zeta potential suggests that particle stability is lost when the particles are coated 
with Eu probes in comparison to the negative citrate anions. 
 
An advantage to using NPs as a support for luminescent probes is that the luminescent properties of the 
NP are independent of the nanostructure and hence the luminescent properties of both EuQS@Au and 
EuQuinSAc@Au are expected to mirror that of EuQSH and EuQuinSAc. The emission spectra of the 
probes demonstrates this (Figure 2.6.5.). 
 
550 600 650 700 750
E
m
is
s
io
n
 I
n
te
n
s
it
y
 / nm  
Figure 2.6.5.  
Emission spectra of EuQuinSAc@Au (_____) vs EuQS@Au (-----), both (2.7 nM in water, λexc = 320 
nm) corrected for PMT response. 
 
The steady state emission spectra of both EuQuinSAc@Au and EuQS@Au show the same Eu(III) f-f 
luminescence from the 5D0 to the ground states of 7FJ (J = 0 – 5), whereby the J = 2 band at 614 nm is 
the most prominent in both cases. The excited state lifetime of EuQS@Au is 580 μs which is 
comparable to the free probe in water. The time resolved signal from EuQS@Au shows bi-exponential 
behaviour whereby a short component of 2 μs is observed which can be attributed to scattering from 
the presence of the AuNP and the long component is the signal from the Ln ion. The signal from 
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EuQuinSAc@Au is difficult to distinguish from the scattering signal. The optical signal from 
EuQS@Au is much stronger in intensity than that of EuQuinSAc@Au. The steady state emission 
spectra suggests that EuQuinSAc@Au is quenched to a much larger degree than that of EuQS@Au in 
aqueous environments. 
 
Whilst the amount of Eu(III) complex on the surface of the colloid can be estimated via the changes in 
the SPR wavelength of the particle via UV Vis spectroscopy, this method has a high level of error 
associated with it. Inductively coupled plasma mass spectrometry (ICPMS) is a highly accurate 
analytical technique whereby metal ions are dissolved in acidic solution and their concentration 
measured via the characteristic MS of the metal ions. Indeed, this technique can be used to determine 
the concentration of both Au and Eu in solution, which can in turn give the ratio of Au : Eu and hence 
the amount of metal complex loading per AuNP. This was used for analysis of EuQS@Au and 
EuQuinSAc@Au (Table 2.6.2.) whereby NPs were digested into ultrapure aqua regia for analysis. 
 
Table 2.6.2. 
ICPMS data for EuQS@Au and EuQuinSAc@Au. 
Sample Eu complexes per particle 
EuQS@Au 800 
EuQuinSAc@Au 850 
 
The ICPMS data shows that the fully functionalised AuNPs have ca. 800 (EuQS@Au) or 850 
(EuQuinSAc@Au) luminescent probes per particle. These results are similar to those reported in the 
literature whereby Davies et. al. found that 1335 EuQuinSAc molecules could be deposited on the 
surface of 13 nm AuNPs.39 Osborne et. al. used a similar technique to determine the amount of 
[Ru(bpy)3]2+ based probes on the surface of 13 nm AuNPs treated with a Zonyl FSA® fluorinated 
surfactant, and that between 550 and 700 transition metal probes were deposited onto the surface of 
surfactant modified AuNPs.40  
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2.7 Functionalisation of AuNPs with FLCs 
All FLCs are composed of a Vr and a Cr (Section 5.6), whereby the Cr for each FLC is terminated with 
a sulphur containing cysteine group, ordinarily used for binding the LC to the Fc region of an antibody. 
Cysteine has been shown to bind to a AuNP surface via the strong Au – S bond.41,42,43 As well as the 
terminal sulphur containing cysteine amino acid, all twenty naturally occurring amino acids can have 
been shown to interact with a AuNP surface via N – Au and O – Au bonds, and non-covenant hydrogen 
bonding, albeit with different strengths and orientations, depending on the amino acid in question.44,45 
There are many established methods for the conjugation of biomolecules to NP based materials, some 
of which are described in an earlier section of this thesis. Indeed, the use of EDC facilitated amide 
coupling to lysine residues of a protein, or simple adsorption are amongst the most common reported 
in the literature. Whilst the conjugation of a wide variety of biomolecules to AuNPs has been reported, 
as far as we are aware, the functionalisation of AuNPs with FLC material has never been studied. In the 
first instance examination of whether binding to the surface of the gold colloid is a possibility whilst 
maintaining NP stability via their natural amino acid groups was carried out. 
 
κstandard and λstandard are FLC samples which were isolated from patients who have either κ or λ 
myeloma respectively. As previously discussed, the Cr for all human κFLCs are identical with Vr chains 
differing between each type of κFLC. The Cr for all λFLCs are identical, with Vr chains differing 
between each type of λFLC. κFLCs and λFLCs have a different Cr. Herein the deposition of κstandard 
and λstandard onto Cit@Au is described for the preparation of κstandard@Au and λstandard@Au 
(Figure 2.7.1.) via displacement of the citrate ions on the gold surface as measured by a change in the 
absorption spectrum of the NP as the proteins bind to the gold surface (Figures 2.7.2. and 2.7.3.). Coated 
NPs were again purified via size exclusion chromatography. The positive bathochromic shift in the UV 
Vis spectra of Cit@Au as either type of FLC is titrated into the solution showed that the method of 
adsorption of the FLC onto the AuNP surface was successful. Particles were examined via TEM (Figure 
2.7.4.) and DLS (Table 2.7.1.). 
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Figure 2.7.1. 
Preparation of LC@Au with the functionalisation of Cit@Au.  
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Figure 2.7.2. 
Change in SPR wavelength of Cit@Au (3.2 nM in water, 2 mL) as a solution of standard (8 µM in 
0.001 M PBS, 8 µL aliquots) is titrated to a final concentration of 170 nM (48 µL). The orange curve 
is post size exclusion chromatography to show that no aggregation occurs from the purification method. 
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Figure 2.7.3. 
Change in SPR wavelength of Cit@Au (3.2 nM in water, 2 mL) as a solution of λstandard (8 µM in 
0.001 M PBS, 8 µL aliquots) is titrated to a final concentration of 170 nM (48 µL). The orange curve 
is post size exclusion chromatography to show that no aggregation occurs from the purification method. 
 
Table 2.7.1.  
DLS characterisation data for κstandard@Au and λstandard@Au. 
Sample Intensity 
distribution / nm 
Number 
distribution / nm 
PDI 
κstandard@Au 52 ± 38 15 ± 4 0.2 
λstandard@Au 47 ± 26 17 ± 4 0.3 
 
                       
 
Figure 2.7.4. 
Left: TEM image of κstandard@Au; Right: TEM image of λstandard@Au 
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The change in the UV Vis spectrum of Cit@Au as either κstandard or λstandard is added shows that 
between 30 and 40 LCs can be functionalised onto Cit@Au, and that the concentration of surface bound 
LC is between two and three mg L-1. This concentration of surface bound LC is comparable to that of 
the normal serum concentrations of FLC in an apparently healthy individual (Section 1.6).  
 
TEM images of both sets of particles show that both κstandard@Au and λstandard@Au are spherical 
in nature and of uniform morphology with a diameter of ca. 15 nm for κstandard@Au and ca. 17 nm 
for λstandard@Au which agrees with the DLS data for the FLC coated AuNPs. The increase in size 
of the particles is attributed to LC binding hence a larger hydrodynamic diameter is observed. The larger 
particle size for λstandard@Au is attributed to the tendency of λFLC to dimerise.  
 
The functionalisation of Cit@Au with both surface active, luminescent Eu(III) complex and FLC can 
be combined to develop particles functionalised with both luminescent material and LC material. 
EuQSH and EuQuinSAc can be grafted onto a AuNP surface and retain the luminescent properties of 
the complex, whilst both κFLC and λFLC can be deposited onto the surface of AuNPs at a concentration 
which is comparable to that of normal serum concentrations of FLCs in an apparently healthy 
individual.   
 
Herein the combination of these ideas is shown with the deposition of EuQSH onto Cit@Au for a 
partial coating of Eu(III) complex onto the gold colloid, followed by κstandard (Figure 2.7.5.). In both 
cases the surface functionalisation of the AuNP was monitored via UV Vis spectroscopy (Figure 2.7.6.) 
via shifts of the SPR wavelength of the AuNP.  Previous work within the research group of Professor 
Pikramenou by Dr Alison Savage has showed how a similar method involving AuNPs coated with Eu 
complex and peptide sequences could be used to develop luminescent AuNPs coated with Eu complex 
and peptides. 
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Figure 2.7.5. 
Preparation of LC.EuQS@Au with the functionalisation of Cit@Au with EuQSH then LC. 
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Figure 2.7.6. 
Change in SPR wavelength of Cit@Au (3.2 nM in water, 2 mL) as a methanolic solution of EuQSH 
(0.2 mM, 10 μL) is added in to a final concentration of 1 μM, followed by the addition of a solution of 
standard (5 µL, 20 µM in 0.001 M PBS) to a final concentration of 60 nM. The yellow curve is post 
chromatography to show that no aggregation occurs from the purification method. 
 
 
The initial addition of EuQSH to Cit@Au shows a bathochromic shift in the SPR wavelength of the 
AuNPs of 2 nm from 516 nm to 518 nm, because of partial surface functionalisation of Cit@Au with 
EuQSH. The afore mentioned, partially functionalised Cit@Au do not pass through a size exclusion 
column and indeed, this is the case for this partially coated gold colloid species. An identical UV Vis 
spectrum is obtained after the sample is left for fifteen minutes indicating that any extra bathochromic 
shift observed is not due to excess EuQSH in the sample. The addition of standard at 60 nM into the 
solution results in a further bathochromic shift of 1 nm from 518 nm to 519 nm as a result of surface 
modification of partially coated Cit@Au with LC, again at a concentration which is comparable to 
that of normal serum concentrations of FLCs. Particles were purified via size exclusion chromatography 
to produce κstandard.EuQS@Au and characterised via DLS (Table 2.7.2.), TEM (Figure 2.7.3.), zeta 
potential data and steady state emission spectroscopy (Figure 2.7.4.). 
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Table 2.7.2. 
DLS characterisation data for κstandard.EuQS@Au 
Intensity 
distribution / nm 
Number 
distribution / nm 
PDI 
56 ± 54 14 ± 4 0.4 
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Figures 2.7.3. (Left) and Figures 2.7.4. (Right). 
Left: TEM image of κstandard.EuQS@Au; Right: Emission spectrum of κstandard.EuQS@Au,          
λexc = 320 nm, corrected for PMT response.  
 
TEM images of κstandard.EuQS@Au particles show that the particles are spherical in nature and of 
uniform morphology with a diameter of ca. 15 nm which agrees with the DLS data for the LC and 
EuQSH coated AuNPs. The particles show a zeta potential of – 23 ± 6 mV which shows a change in 
the surface chemistry of κstandard.EuQS@Au when compared to that of EuQS@Au. Indeed, the 
emission spectrum shows emission from the surface bound EuQSH complexes due to sensitized 
luminescence and show a lifetime of 580 μs (Figure 2.7.5.), comparable to that of EuQSH in water. 
ICPMS data shows that these partially Eu coated κstandard.EuQS@Au particles have ca. 250 EuQSH 
luminescent complexes per particle, which shows κstandard.EuQS@Au are ca. 30% coated with 
EuQSH when compared to that of fully coated EuQS@Au.  
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Figure 2.7.5. 
Lifetime curve of κstandard.EuQS@Au, λexc = 320 nm and λem = 614 nm. 
 
This method can be also be applied to the loading of Cit@Au with both κstandard and λstandard and 
EuQuinSAc in all cases whereby a partial coating of Eu(III) is achieved followed by the addition of 
LC and monitored via UV Vis spectroscopy (Figures 2.7.6., 2.7.7. and 2.7.8.) and characterised with 
TEM (Figure 2.7.9., 2.7.10. and 2.7.11.). In all cases Eu(III) luminescence is observed from the particles 
when excited at 320 nm, albeit much stronger from the EuQSH coated particles in comparison to the 
EuQuinSAc probe. Indeed, positive bathochromic shifts are observed in all cases as both Eu complex 
both Eu complex and LC is added. 
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Figures 2.7.6. (Left) and Figures 2.7.9. (Right). 
Left; Change in SPR wavelength of Cit@Au (3.2 nM in water, 2 mL) as a methanolic solution of 
EuQuinSAc (0.2 mM, 10 μL) is added in to a final concentration of 1 μM, followed by the addition of 
a solution of standard (5 µL, 20 µM in 0.001 M PBS) to a final concentration of 60 nM. The yellow 
curve is column chromatography to show that no aggregation occurs from the purification method; 
Right: TEM image of standard.EuQuinSAc@Au. 
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Figures 2.7.8. (Left) and Figures 2.7.10. (Right). 
Left: Change in SPR wavelength of Cit@Au (3.2 nM in water, 2 mL) as a methanolic solution of 
EuQuinSAc (0.2 mM, 10 μL) is added in to a final concentration of 1 μM, followed by the addition of 
a solution of standard (5 µL, 20 µM in 0.001 M PBS) to a final concentration of 60 nM. The yellow 
curve is post column chromatography to show that no aggregation occurs from the purification method; 
Right: TEM image of standard.EuQuinSAc@Au. 
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Figures 2.7.9. (Left) and Figures 2.7.11. (Right). 
Left: Change in SPR wavelength of Cit@Au (3.2 nM in water, 2 mL) as a methanolic solution of EuQSH 
(0.2 mM, 10 μL) is added in to a final concentration of 1 μM, followed by the addition of a solution of 
standard (5 µL, 20 µM in 0.001 M PBS) to a final concentration of 60 nM. The yellow curve is post 
column chromatography to show that no aggregation occurs from the purification method; Right: TEM 
image of standard.EuQS@Au. 
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Both κstandard and λstandard can be dual coated onto Cit@Au with Eu complex to develop particles 
which show f-f luminescence whereby EuQSH is more emissive than EuQuinSAc on Cit@Au, and 
the Vr for each κLC is different.  
 
The binding of pure κLC samples onto Cit@Au as well as EuQSH complex was examined, whereby 
the Vr sequence for each κLC is identical in each case. Two sets of pure κLC were examined and their 
properties are included (Table 2.7.3.).  
 
Table 2.7.3. 
properties of κnew and κfur. 
 
κLC Sample Details Monomer 
Size / Kda 
Monomer : 
Dimer Ratio 
κnew Pure, synthetic κLC 
Sample  
24 50 : 50 
κfur Pure, κLC Sample 
isolated from patient 
sample 
20 75 : 25 
 
 
Indeed, the dual coating of κLC samples and EuQSH were also successful whereby similarly the 
surface of Cit@Au was partially coated with luminescent Eu complex followed by addition of κFLC 
sample as monitored via UV Vis (Table 2.7.4.) and purified via Sephadex column chromatography. 
 
Table 2.7.4. 
Data for κnew.EuQS@Au and κfur.EuQS@Au.  
 
 
κLC Sample SPR λ / 
nm 
DLS Number 
distribution / nm 
PDI Eu : Au ratio by 
ICPMS 
κnew.EuQS@Au 519 14 ± 4 0.3 100 
κfur.EuQS@Au 519 16 ± 5 0.3 100 
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2.8 Functionalisation and properties of BUCIS04-AF647 
To act as a FRET acceptor, the organic molecule Alexa Fluor® 647 (AF647) (Figure 2.8.1.) was used 
which shows a large J(λ) with the emission spectrum of EuQSH (Figure 2.8.2.). 
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Figures 2.8.1. (Left) and Figures 2.8.2. (Right). 
Left: Structure of AF647; Right: Absorption spectrum of AF647 (Blue) and EuQSH emission spectrum 
(Red). 
 
 
AF647 is a suitable FRET acceptor for Eu(III) as seen from the large J(λ) between the absorption 
spectrum of AF647 and the emission spectrum of EuQSH, in particular the band observed at 614 nm 
from the 5Do  7F2 band. The absorption spectrum of AF647 shows a λmax at 650 nm with a large molar 
extinction coefficient of 240,000 M-1 cm-1 which enhances its suitability as a FRET acceptor. The 
emission spectra of AF647 shows a broad band, typical of organic fluorescence centered at 668 nm 
showing red emission with an emission quantum yield of 0.33 and a lifetime of 1.0 ns as measured by 
ATDBio.46 The lifetime of EuQSH is ca. five orders of magnitude larger than that of AF647 which is 
important for this system as any signal observed from the emission of the AF647 dye can be sufficiently 
eliminated with time resolved measurements and the huge difference in the lifetime means that one 
acceptor can quench multiple donors, as the acceptor is almost instantaneously deexcited after excitation 
via FRET allowing the acceptor to quench a further Eu(III) ion.  
  
 
 
 
94 
 
AF647 was conjugated to anti-κFLC mAb, BUCIS04, which is an IgG structure, known to specifically 
bind the κFLC Cr using a Fluoraprobe 647 kit as supplied by Life Technologies, for the preparation of 
the FRET acceptor BUCIS04-AF647. The conjugate was shown to be successful using a conjugate 
check and go kit as supplied by Life Technologies which uses a lateral flow assay technique to bind 
antibodies. The lateral flow assay flows the sample through a nitrocellulose membrane which contains 
a test line consisting of Proteins A and G, both of which are known to bind and show high affinity for 
the Fc region of many IgG molecules. As the sample flows through the membrane towards the absorbent 
pad the IgG binds to the test line causing the sample to be seen on the test line visually as an effect of 
the AF647 dye (Figure 2.8.3.).  
 
Figure 2.8.3. 
Left stick: Positive control using a AuNP antibody conjugate as supplied by Life Sciences run in the 
presence of 1% BSA. Right stick: BUCIS04-AF647 conjugate run at a concentration of 60 ug / mL in 
the presence of 1% BSA. 
 
The lateral flow assay for the BUCIS04-AF647 shows a blue band on the test line consisting of proteins 
A and G as confirmed with the immunogold positive control. The blue band is a result of the colour of 
the AF647 dye, which shows that this dye is attached to the IgG which is in turn bound to the protein 
A / G test line of the lateral flow assay, confirming the success of the BUCIS04-AF647 conjugation. 
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The activity of the BUCIS04-AF647 conjugate was examined to ensure that BUCIS04 was still active 
for the binding of κFLC post conjugation to the organic fluorophore via an ELISA assay with κnew 
immobilized on the surface of a 96 well plate. After varying concentrations of BUCIS04-AF647 were 
incubated with the surface immobilized κnew, goat anti mouse IgG horseradish peroxidase (HRP), 
followed by a solution of 3,3′,5,5′-tetramethylbenzidine dihydrochloride (TMP) were added whereby 
the ELISA signal was obtained by the catalytic reaction of HRP and TMB followed by treatment with 
dilute H2SO4 which shows an absorption signal at 450 nm. The concentration of BUCIS04-AF647 is 
directly proportional to the absorbance of the TMP dye as measured at 450 nm (Figure 8.3.4.).  
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Figure 2.8.4. 
ELISA assay of BUCIS04-AF647 against surface immobilized κnew as measured via the absorbance 
signal obtained with TMP and HRP.  
 
The ELISA assay shows that BUCIS04 remains active against κnew as the organic fluorophore is 
attached down to a concentration of ca. 0.1 nM with this experimental setup, which showed the same 
absorbance as the background control. A further control showing the ELISA signal was not affected by 
the AF647 showed the same absorbance as the background buffer signal as the absorbance of AF647 
is negligible at 450 nm. Whilst BUCIS04-AF647 shows activity at this concentration, the same 
experimental setup with BUCIS04 shows that antibody activity is lost post conjugation and 
concentrations lower than 0.01 nM of BUCIS04 continue to show activity.  
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The combination of the lateral flow assay and the ELISA assay show that BUCIS04-AF647 is 
successfully conjugated and that the antibody is still functional down to concentrations of 0.1 nM, albeit 
not as active as non-functionalised BUCIS04. 
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2.9 FRET Assay 
The large J(λ) between the emission spectrum of κLC.EuQS@Au samples and the absorption spectrum 
of BUCIS04-AF647 allow for a FRET signal from the two species to be observed, in particular from 
the 7F2  5Do band at 614 nm but also from the bands arising from 7F0, 7F1, and 7F3, although the 
emission intensity is strongest from the 7F2 transition. The signal can be measured via time resolved 
emission spectroscopy considering the long lived lifetime of the Eu(III) donor which is quenched as an 
effect of the organic dye as the two come together close in space, given that FRET is a distance 
dependent process (Section 1.2).  
 
It has been shown that FLCs can be bound to their respective antibody in a variety of buffered solutions 
including tris HCl and PBS, both of which the stability of the particles were examined in via UV Vis.47,48 
κstandard.EuQS@Au shows a broadening and positive shift of 7 nm in the SPR wavelength of the 
particles when suspended in PBS which shows that the particles become destabilised as an effect of the 
salt and therefore inappropriate to be used in the FRET assay. This is not observed for tris HCl buffer 
at pH 8.0 whereby the SPR wavelength of κstandard.EuQS@Au is identical in and out of buffered 
solution.  
 
The effect BUCIS04-AF647 on κstandard.EuQS@Au was measured for particle stability via UV Vis 
spectroscopy to examine any perturbations in the SPR wavelength of the functionalised gold colloid 
(Figure 2.9.1.) in both aqueous and tris HCl buffered solution. 
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Figure 2.9.1. 
Left, Change in SPR wavelength of κstandard.EuQS@Au (2.7 nM, 2 mL) upon incubation with 
BUCIS04-AF647 (1.0 mg / mL, 8 µL) to a concentration of 20 nM, green curve) in tris HCl buffered 
aqueous solution; Right: Change in SPR wavelength of κstandard.EuQS@Au (2.7 nM, 2 mL) upon 
incubation with BUCIS04-AF647 (1.0 mg / mL, 8 µL) to a concentration of 20 nM in aqueous solution.  
 
On addition of BUCIS04-AF647 at 20 nM the SPR wavelength of κstandard.EuQS@Au remains 
constant and no broadening or λmax perturbation is observed which shows that particle stability is 
maintained and the surface of the functionalised AuNP is unaltered, as measured via UV Vis, in both 
aqueous and tris HCl buffered solution. The band observed at ca. 650 nm is from the absorption of the 
AF647 dye. 
 
The addition of 100 nM of BUCIS04-AF647 into κLC.EuQS@Au at 2.7 nM a concentration 
comparable to that of the surface bound κLC shows a drop in the lifetime of the Eu(III) ion for all κLC 
samples which can be attributed to a FRET process occurring from EuQSH to the AF647 dye with a 
λexc of 320 nm, monitoring emission at 614 nm, from the 7F2  5Do emission band of the Eu(III) ion 
(Table 2.9.1.), (Figures 2.9.1., 2.9.2. and 2.9.3.). Indeed, addition of non-functionalised BUCIS04 at 
the same concentration shows no change in the lifetime of the Eu(III) ion showing that the observed 
FRET signal is a result of quenching from the AF647 dye. Steady state measurements of the system 
were not possible as AF647 shows a slight absorption at 320 nm, leading to a broad emission signal 
from the AF647 dye centered at 665 nm.  
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Table 2.9.1. 
Lifetime data for addition of BUCIS04-AF647 (1.0 mg / mL, 4 µL) into κLC.EuQS@Au, 
κnew.EuQS@Au or κfur.EuQS@Au (2.7 nM, 200 µL), λexc = 320 nm, λem = 614 nm. 
 
 
AuNP sample / 2.7 nM Tris HCl / µM BUCIS04-AF647 / 
nM 
τ / µs χ2 
κstandard.EuQS@Au 0 0 570 1.3 
κstandard.EuQS@Au 50 0 560 1.2 
κstandard.EuQS@Au 0 100 520 1.3 
κstandard.EuQS@Au 50 100 490 1.3 
κnew.EuQS@Au 0 0 570 1.1 
κnew.EuQS@Au 50 0 560 1.1 
κnew.EuQS@Au 0 100 520 1.1 
κnew.EuQS@Au 50 100 480 1.1 
κfur.EuQS@Au 0 0 570 1.1 
κfur.EuQS@Au 50 0 560 1.1 
κfur.EuQS@Au 0 100 540  1.1 
κfur.EuQS@Au 50 100 510 1.1 
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Figure 2.9.1 
Left: Normalised lifetime plot for κstandard.EuQS@Au (2.7 nM, 200 µL) in tris HCl buffer (Black) 
showing the addition of BUCIS04-AF647 (1.0 mg / mL, 4 µL) (Red); Right: Normalized lifetime plot 
for κstandard.EuQS@Au (2.7 nM, 200 µL) (Black) showing the addition of BUCIS04-AF647 (1.0 mg 
/ mL, 4 µL) (Red). 
 
 
 
 
 
 
 
 
Figure 2.9.2. 
Left: Normalised lifetime plot for κnew.EuQS@Au (2.7 nM, 200 µL) in tris HCl buffer (Black) showing 
the addition of BUCIS04-AF647 (1.0 mg / mL, 4 µL) (Red); Right: Normalized lifetime plot for 
κnew.EuQS@Au (2.7 nM, 200 µL) (Black) showing the addition of BUCIS04-AF647 (1.0 mg / mL, 4 
µL) (Red). 
 
 
        
 
 
 
Figure 2.9.3. 
Left: Normalised lifetime plot for κfur.EuQS@Au (2.7 nM, 200 µL) in tris HCl buffer (Black) showing 
the addition of BUCIS04-AF647 (1.0 mg / mL, 4 µL) (Red); Right: Normalized lifetime plot for 
κfur.EuQS@Au (2.7 nM, 200 µL) (Black) showing the addition of BUCIS04-AF647 (1.0 mg / mL, 4 
µL) (Red). 
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For all examined κLC.EuQS@Au samples, as BUCIS04-AF647 is added at 100 nM, in all cases a 
FRET signal is observed which is seen via a decrease in lifetime of the Eu(III) ion. Indeed, the ΦT 
between the FRET pair can be estimated in all cases by comparing the lifetime of the Eu(III) ion with 
and without the FRET signal being active (Section 1.2.). The FRET pair of EuQSH and AF647 has 
never before been reported, hence the value of R0 is estimated based on the FRET pairing between a 
terpryridine sensitized Eu complex and AF647, used in a DNA assay, to be 58 Å. Values for the energy 
transfer efficiency for the FRET pair are included (Table 2.9.2.).49  
 
Table 2.9.2. 
FRET efficiency data for the addition of BUCIS04-AF647 into κLC.EuQS@Au. 
AuNP sample / 2.7 
nM 
Tris HCl / 
µM 
BUCIS04-
AF647 / nM 
ΦT 
κstandard.EuQS@Au 0 100 0.09 
κstandard.EuQS@Au 50 100 0.14 
κnew.EuQS@Au 0 100 0.09 
κnew.EuQS@Au 50 100 0.14 
κfur.EuQS@Au 0 100 0.05 
κfur.EuQS@Au 50 100 0.09 
 
The observed FRET signal from the dual coated particles show that the average distance from the 
Eu(III) donors to the AF647 acceptor is ca. 9 nm and the energy transfer efficiency is ca. 10% efficient, 
although this is variable based on the κLC sample used. This result implies that FRET is not observed 
between all Eu(III) ions and every acceptor as the gold colloids used are 12 nm in diameter, whereas 
the FRET range is 9 nm (Figure 2.9.4.). Whilst FRET is active in this novel nanoparticle system, the 
energy transfer efficiency, although low, is comparable to the literature. Harma et. al. report energy 
transfer efficiencies of between 0.13 and 0.15 for the FRET signal between Eu loaded luminescent 
polystyrene NPs and QDs in an assay for BSA.50 Whilst similar energy transfer efficiencies have been 
reported, Casanova et. al. reported the FRET transfer efficiency between the FRET pair of luminescent 
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Ln-doped Oxide NPs and Cy5 dye to be up to 0.80, which was variable based on the donor : acceptor 
ratio.51  
 
Figure 2.9.4.  
Schematic showing distances with FRET assay, Not to scale. 
O, acceptor label; dashed blue line, area where acceptor is within potential FRET range; •, Eu donor 
label. 
 
Homogenous FRET assays are designed to be much easier and quicker on the experimentalist to perform 
without the need for complex washing procedures as are necessary for surface based assay systems. In 
a clinical environment, it would be required for this assay to be easy to perform for the experimentalist, 
upon an automated system, designed to achieve accurate and reliable results. It was able to be shown 
show how this system thus far, can be run on a PHERAstar® multimode plate reader, whereby 96 wells 
can be examined in quick succession for the Eu(III) excited state lifetime. Using a time resolved 
fluorescence (TRF) optic module to gather lifetime data, it is shown how this system can be applied 
from an emission spectrometer to a clinically relevant system. Indeed, lifetime data from the 
PHERAstar® multimode plate reader shows the addition of BUCIS04-AF647 into 
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κstandard.EuQS@Au and how the excited state lifetime of κstandard.EuQS@Au can be monitored 
(Table 2.9.3.), (Figure 2.9.5.).  
 
Table 2.9.3. 
Lifetime data for addition of BUCIS04-AF647 (20 µL, 100 µg / mL in PBS) into κstandard.EuQS@Au 
(110 µL 2.7 nM),  λexc = 337 nm, λem = 615 nm using the TRF optic module, in the presence of tris HCl 
 
AuNP sample / 2.7 nM BUCIS04-AF647 / 
nM 
τ / µs 
κstandard.EuQS@Au 0 550 
κstandard.EuQS@Au 100 500 
 
 
 
Figure 2.9.5. 
Normalised lifetime plot for κstandard.EuQS@Au (2.7 nM, 100 µL) in tris HCl buffer (Black) showing 
the addition of BUCIS04-AF647 (20 µL, 100 µg / mL in PBS) to a concentration of 100 nM (Red). 
 
It has been shown that this system can be operated in a clinical setting via a multimodal plate reader. 
Indeed, this is promising for a clinical environment, whereby 96 pieces of data can be gathered in quick 
succession, effectively removing any experimental complexity as is involved with heterogeneous assay 
systems. Whilst this was possible with this plate reader, the PHERAstar® instrument is not optimized 
for this system. Indeed, the TRF optic module has an excitation wavelength of 337 nm which is not 
ideal for the excitation of EuQSH as can be shown via its excitation spectrum (Section 2.4) and leads 
to a weak signal being observed.  
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2.10 Concluding Remarks 
The synthesis of Eu(III) complexes with built in surface active groups for binding to a gold surface and 
sensitizers based on quinoline groups, which are known to population the emissive energy level of 
Eu(III) via its T1 energy level have been reported which shown Eu(III) luminescence. These were able 
to be attached to the surface gold nanoparticles to develop luminescent nanostructures which display 
Eu(III) luminescence and for the case of EuQS@Au, show a long lived excited state lifetime of 580 
µs.  
 
This was taken forward and the surface of a gold nanoparticle was able to be functionalised with LC 
samples via their natural amino acid groups and it was able to be shown how the surface of a gold 
nanoparticle can be decorated with both Eu(III) complex and LC sample simultaneously, whilst 
maintaining Eu(III) luminescence from the particles, and the excited state lifetime of 580 µs. 
 
It was possible to use these particles to show a FRET signal between the surface bound Eu(III) ions and 
the organic dye AF647, which was bound to κLC specific antibody, BUCIS04, as monitored via the 
excited state lifetime of the Eu(III) ion. Upon addition of the energy acceptor, a quench in the Eu(III) 
lifetime of ca. 10% can be measured whilst maintaining particle stability. Whilst a FRET signal can be 
observed, this is lower than that of many similar systems within the literature, whereby a quench of up 
to 80% has been reported. 
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3 Introduction of blocking agents into FRET 
assay   
3.1 Introduction 
Commercial immunoassay systems such as ELISA or DELFIA and others on the market place are 
reliant on the specific interaction between antibody and antigen. For the most effective readout from a 
given system, it is crucial to eliminate any background interference from the system. Background 
interference is often a result of non-specific binding (NSB) within the system whether it be NSB 
between biomolecules or within the actual system itself.  
 
To combat this, immunoassay systems are designed with components to inhibit NSB from both non-
specific protein interactions and from binding to other assay components used during detection. Indeed, 
the ideal NSB blocking agent would accomplish this whilst showing no cross reactivity with assay 
components, and without disrupting bonds between biomolecule and the surface involved. NSB 
blocking reagents can generally be grouped into two categories (Table 3.1.1.) and can be used to block 
on a variety of surfaces including polymer based surfaces, silica and gold.1,2 
 
Table 3.1.1. 
NSB blocking reagents and their properties.3,4,5,6,7,8,9,10,11 
Category General Properties Examples 
Detergent • Disrupt ionic and hydrophobic biomolecule – surface bonds 
• Inhibition of enzyme – substrate reactions 
• Inexpensive and stable 
• Can disrupt non-covalent biomolecule – surface bonds 
Tween 20, Triton – 
X 100, Zonyl FSA 
Protein • Block non-occupied sites on the surface 
• Can be used to ‘space out’ surface bound biomolecules 
BSA, Foetal calf 
serum (FCS) 
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Whilst detergent and protein NSB blocking agents are the most commonly employed, other polymer 
based blocking agents have been used such as polyethylene glycol, polyvinyl alcohol and 
polyvinylpyrrolidone, which can be used to coat hydrophobic surfaces.12,13,14 Indeed, the inclusion of 
NSB blocking agents into a model ELISA system is included to highlight the necessity of eliminating 
background interference from a biological diagnostic device (Figure 3.1.1.).       
 
 
 
         
 
Figure 3.1.1. 
Model ELISA assay showing the NSB within a system. 
 
Blue square, Blocking agent. 
 
NSB within a system can lead to assay readouts whereby a false readout is observed. Indeed, in the 
model ELISA system, the concentration of the antigen is directly proportional to the enzymatic action 
on the substrate. When the system exhibits NSB, a false positive readout in the concentration of antigen 
is measured as a result of the enzyme linked antibody binding to the surface, continuing to show activity 
upon addition of the substrate (Figure 3.1.2.).  
Blocking agent used Blocking agent not used 
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Figure 3.1.2. 
False positive result observed if NSB is not controlled from model ELISA assay. 
Green line, NSB signal; Blue line, specific binding signal; Red line, signal observed. 
 
In general, finding the most efficient and best NSB blocking agent combination is exhaustive and 
empirical testing is required to both choose and optimise the blocking of NSB within a given system, 
which can often consist of a combination of protein and detergent based blocking agents.  
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3.2 Chapter Outline 
All immunoassay systems are developed with the use of a NSB blocking agent or combination of 
blocking agents to minimise NSB and get the best assay readout possible from the system. With the 
FRET assay with κnew.EuQS@Au and BUCIS04-AF647 for κFLC, with the introduction of NSB 
blocking agents we can get the best signal possible from the assay (Figure 3.2.1.).  
                
 
Figure 3.2.1. 
General schematic of FRET assay between κnew.EuQS@Au and BUCIS04-AF647 for κFLC with the 
inclusion of NSB blocking agents. 
 
Herein, the effect of NSB blocking agents on κnew.EuQS@Au are examined, and how this can be used 
for a competitive assay for the detection of κnew.  
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3.3 NSB interaction  
As previously discussed, AuNPs are widely employed in bioassay applications for their aqueous 
solubility, non-toxic nature and their ease of functionalisation. Whilst the ease of functionalisation is 
useful for the deposition of biomolecules and other material when working with gold colloids, this can 
lead to issues with unwanted biomolecules showing a level of interaction with the gold surface involved. 
In the field of medical diagnostics, as discussed, NSB can lead to false and inaccurate results.15,16 
 
Indeed, an unwanted interaction between EuQS@Au and BUCIS04-AF647 can be observed as 
measured via lifetime measurements, whereby a quench in the lifetime of EuQS@Au is observed upon 
incubation with BUCIS04-AF647 (Table 3.3.1.) (Figure 3.3.1.). 
 
 
Figure 3.3.1.  
Schematic showing NSB interaction between EuQS@Au and BUCIS04-AF647, Not to scale. 
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Table 3.3.1. 
Lifetime data showing the affect of BUCIS04-AF647 (1.0 mg / mL, 4 µL), upon the lifetime of 
EuQS@Au (200 µL, 2.7 nM). 
 
AuNP sample 
/ 2.7 nM 
Tris HCl / µM BUCIS04-
AF647 / nM 
τ / µs χ2 
EuQS@Au 0 0 580 1.1 
EuQS@Au 50 0 580 1.1 
EuQS@Au 0 100 550 1.1 
EuQS@Au 50 100 530 1.1 
 
 
Upon incubation of EuQS@Au at 2.7 nM with BUCIS04-AF647 at 100 nM in both tris HCl buffered 
and non buffered solution leads to a decrease in the Eu lifetime. Since FRET is a distant dependent 
interaction which can occur up to ca. 10 nm, when the two chromophores become close in space, this 
can be considered a NSB interaction between EuQS@Au and the AF647 dye. The nature of the 
interaction is unclear, but a likely cause is the interaction of amino acid residues from BUCIS04-AF647 
showing an interaction with the gold surface.  
 
Whilst the comparison of the FRET between AF647 and EuQS@Au cannot be directly compared with 
that of AF647 and κnew.EuQS@Au due to the different AuNP surface functionalisation, clearly this 
interaction cannot be ignored. To combat this interaction within the system with κnew.EuQS@Au and 
BUCIS04-AF647, the addition of blocking agents to the system are examined in an attempt to block 
out this interaction. 
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3.4 Protein blocking agents 
The use of non-reactive proteins as a blocking agent is common. Indeed, it is necessary to use proteins 
which show no cross reactivity with the reagents involved to be a successful blocking reagent. The use 
of BSA as a blocking agent at between 1 and 3% is common as it is a non-reactive protein, which shows 
no activity with human IgG. Another common protein based blocking agent is FCS (Foetal calf serum), 
of which BSA is a major component, also comprising of other serum based proteins, which is also 
typically used between 1 and 3%. FCS is also comprised of calf FLCs, which are secreted into calf 
serum which are of a different structure to human FLC, hence no cross reactivity between BUCIS04-
AF647 and calf FLC is observed.  
 
We examine the effect of the addition of both BSA and FCS, each at 1% on the SPR wavelength of 
EuQS@Au which is sensitive any changes or functionalisation of its surface via UV Vis (Figure 3.4.1.). 
It was necessary to add in the blocking reagent at the lower concentration to minimise any particle 
aggregation, which could be observed when higher concentrations of the blocking agent were added to 
functionalised gold colloids.  
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Figure 3.4.1.  
Left: EuQS@Au, (2 ml, 2.7 nM) in water (Black curve), EuQS@Au, (2 ml, 2.7 nM) in water in 1% BSA 
solution after 30 minutes incubation (Blue curve); Right: EuQS@Au, (2 ml, 2.7 nM) in water (Black 
curve), EuQS@Au, (2 ml, 2.7 nM) in water in 1% FCS solution after 30 minutes incubation (Blue 
curve).  
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The incubation of both BSA and FCS at 1% to EuQS@Au show perturbations in the SPR wavelength 
of the functionalised gold colloids. A bathochromic shift of 2 nm is seen for the addition of BSA and 
that of 3 nm for FCS. We attribute the positive change in the SPR wavelength to the proteins acting as 
blocking agents and blocking any remaining sites on the AuNP where NSB can occur. Eu(III) 
luminescence is observed from the blocking agent modified particles.   
 
Incubation of protein blocking reagent treated EuQS@Au with BUCIS04-AF647 was examined via 
excited state lifetime measurements (Table 3.4.1.). 
 
Table 3.4.1. 
Lifetime data showing the effect of BUCIS04-AF647 (1.0 mg / mL, 4 µL), upon the lifetime of protein 
blocking agent modified EuQS@Au (200 µL, 2.7 nM). 
 
Blocking Agent 
Present 
Tris HCl / 
µM 
BUCIS04-AF647 / 
nM 
τ / µs χ2 
BSA 0 0 570 1.1 
BSA 50 0 570 1.1 
BSA 0 100 560 1.1 
BSA 50 100 550 1.0 
FCS 0 0 570 1.1 
FCS 50 0 580 1.1 
FCS 0 100 560 1.1 
FCS 50 100 550 1.1 
 
The incubation of both BSA and FCS into EuQS@Au show that as BUCIS04-AF647 is added at 100 
nM, the FRET signal is decreased in comparison to raw EuQS@Au without the use of a blocking agent 
showing the effect of the blocking agent. Despite this, a small FRET signal is measured in both cases 
as seen with the slight decrease in Eu(III) lifetime. 
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3.5 Detergent blocking agents 
The use of detergent based blocking agents is common, and indeed in many surface based techniques, 
detergent based species are often included in washing buffers during operation to inhibit NSB as much 
as is possible. Detergent blocking agents are generally used at a much lower concentration to their 
protein counterparts, and as such, the use of detergent based blocking agents at between 0.01 – 0.1% is 
common. Tween 20 is a nonionic surfactant which is commonly used as a blocking agent in biological 
systems, which has been shown to have an interaction with surface of a gold colloid.17,18 Fluorinated 
surfactant Zonyl has also been shown to have an interaction with the surface of AuNPs by our group 
and others.19,20 
  
The effect of the addition of both Tween 20 and Zonyl® FSA surfactants, each at 0.05 % on the SPR 
wavelength of EuQS@Au was examined, which is sensitive any changes or functionalisation of its 
surface via UV Vis (Figure 3.5.1.).  
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Figure 3.5.1.  
Left: EuQS@Au, (2 ml, 2.7 nM) in water (Black curve), EuQS@Au, (2 ml, 2.7 nM) in water in 0.05% 
Tween 20 solution after 30 minutes incubation (Blue curve); Right: EuQS@Au, (2 ml, 2.7 nM) in water 
(Black curve), EuQS@Au, (2 ml, 2.7 nM) in water in 0.05% Zonyl FSA solution after 30 minutes 
incubation (Blue curve).  
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No SPR λmax perturbation is observed for the addition of Tween 20 or for Zonyl® FSA, although a slight 
decrease in intensity and broadening is seen for the addition of Zonyl® FSA. Both samples continue to 
show Eu(III) luminescence both in and out of tris HCl buffered solution.  
 
Incubation of detergent blocking reagent treated EuQS@Au with BUCIS04-AF647 was examined via 
excited state lifetime measurements (Table 3.5.1.). 
 
Table 3.5.1. 
Lifetime data showing the affect of BUCIS04-AF647 (1.0 mg / mL, 4 µL), upon the lifetime of detergent 
blocking agent modified EuQS@Au (2.7 nM, 200 µL). 
 
 
Blocking Agent 
Present 
Tris HCl / 
µM 
BUCIS04-AF647 / 
nM 
τ / µs χ2 
Tween 20 0 0 580 1.1 
Tween 20 50 0 580 1.2 
Tween 20 0 100 540 1.1 
Tween 20 50 100 520 1.1 
Zonyl® FSA 0 0 570 1.0 
Zonyl® FSA 50 0 570 1.1 
Zonyl® FSA 0 100 540 1.1 
Zonyl® FSA 50 100 520 1.0 
 
The incubation of both Tween 20 and Zonyl® FSA into EuQS@Au show that as BUCIS04-AF647 is 
added at 100 nM, the FRET signal is similar in comparison to raw EuQS@Au without the use of a 
blocking agent, showing that detergent based blocking agents are inappropriate for the gold nanoparticle 
FRET assay.  
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3.6 Competition assay for κnew  
Whilst the NSB signal between EuQS@Au and BUCIS04-AF647 was not fully eliminated, the FRET 
assay for the detection of κnew with κnew.EuQS@Au was examined with the addition of protein 
blocking agents. The incubation of κnew.EuQS@Au with BSA and FCS, each at 1%, on the SPR 
wavelength of κnew.EuQS@Au via UV Vis was recorded (Figure 3.6.1.). 
0
0.2
0.4
0.6
0.8
1
350 400 450 500 550 600 650 700
A
b
s
o
rb
a
n
c
e
/ nm
 
0
0.2
0.4
0.6
0.8
1
350 400 450 500 550 600 650 700
A
b
s
o
rb
a
n
c
e
 / nm  
Figure 3.6.1. 
 
Left: κnew.EuQS@Au, (2 ml, 2.7 nM) in water (Black curve), κnew.EuQS@Au, (2 ml, 2.7 nM) in 
water in 1% BSA solution after 30 minutes incubation (Blue curve); Right: κnew.EuQS@Au, (2 ml, 2.7 
nM) in water (Black curve), κnew.EuQS@Au, (2 ml, 2.7 nM) in water in 1% FCS solution after 30 
minutes incubation (Blue curve).  
 
The incubation of both BSA and FCS at 1% to κnew.EuQS@Au show perturbations in the SPR 
wavelength of the functionalised gold colloids. A bathochromic shift of 2 nm is seen for the addition of 
BSA and that of 3 nm for FCS.  
 
Incubation of protein blocking reagent treated κnew.EuQS@Au with BUCIS04-AF647 was examined 
via lifetime measurements (Table 3.6.1.) and shows that FRET between κnew.EuQS@Au incubated 
with blocking agents and BUCIS04-AF647 is active. 
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Table 3.6.1. 
 
Lifetime data showing the affect of BUCIS04-AF647 (1.0 mg / mL, 4 µL), upon the lifetime of protein 
blocking agent modified κnew.EuQS@Au (2.7 nM 200 µL). 
 
Blocking Agent 
Present 
Tris HCl / µM BUCIS04-AF647 / 
nM 
τ / µs χ2 
BSA 0 0 580 1.1 
BSA 50 0 570 1.1 
BSA 0 100 510 1.1 
BSA 50 100 500 1.1 
FCS 0 0 580 1.1 
FCS 50 0 550 1.2 
FCS 0 100 490 1.1 
FCS 50 100 460 1.2 
 
 
On addition of BUCIS04-AF647 at 100 nM into protein incubated κnew.EuQS@Au, FRET is 
observed as seen by a decrease in the lifetime of the Eu(III) ion. Indeed, as previously observed, the 
FRET signal is larger in the presence of tris HCl buffered solution and the energy transfer efficiency is 
similar to κnew.EuQS@Au without the presence of the blocking agent of between 10 and 15%. In both 
cases, the presence of the blocking agent slightly affects the excited state lifetime of the Eu(III) ion 
from the incubation period.  
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For the competitive assay it was decided chose to incubate the κnew sample for detection with 
BUCIS04-AF647 prior to adding this premixed sample into κnew.EuQS@Au. It was necessary to 
ensure that the active sites of BUCIS04-AF647 had bound to the κnew sample to allow no binding of 
BUCIS04-AF647 to κnew.EuQS@Au (Figure 3.6.2.). The FRET assay is successful for the detection 
of κnew at high concentrations as measured by lifetime data (Table 3.6.2.). 
 
 
 
Figure 3.6.2. 
FRET assay for detection of κnew using BUCIS04-AF647 and κnew.EuQS@Au. Not to scale. 
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Table 3.6.2. 
Lifetime data after addition of premixed κnew (4.9 mg / ml in PBS 5 μL) and BUCIS04-AF647 (1.0 mg 
/ mL, 4 µL), into κnew.EuQS@Au (200 µL, 2.7 nM). 
 
Blocking Agent 
Present 
Tris HCl / 
µM 
BUCIS04-
AF647 / nM 
κnew / µM τ / µs χ2 
None 0 100 0 520 1.1 
None 50 100 0 480 1.1 
None 0 100 45 550 1.1 
None 50 100 45 550 1.1 
1% BSA  0 100 0 510 1.1 
1% BSA 50 100 0 500 1.1 
1% BSA 0 100 45 550 1.1 
1% BSA 50 100 45 540 1.1 
1% FCS 0 100 0 490 1.1 
1% FCS 50 100 0 460 1.2 
1% FCS 0 100 45 550 1.1 
1% FCS 50 100 45 500 1.0 
 
 
In all cases, the FRET signal without the presence of κnew at 45 µM is larger, which shows competition 
between κnew and κnew.EuQS@Au. In all cases, a degree of NSB continues to be an issue whereby 
the Eu(III) lifetime is not completely unaffected by the addition of BUCIS04-AF647 premixed with 
the analyte as seen by the Eu(III) lifetime showing a slight decrease upon the addition of premixed 
analyte and BUCIS04-AF647.  
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3.7 Concluding remarks 
A major issue relating to immunoassay technology where a surface is used for heterogeneous systems 
or indeed homogeneous systems using nanotechnology is NSB, whereby a small, unwanted interaction 
between a biomolecule and one of the surfaces involved happens and leads to a false positive result 
being obtained and hence a potential incorrect diagnosis. Because of this, NSB blocking agents are 
added to physically block out biomolecules from showing NSB to a surface.  
 
It was found that indeed a large NSB signal is seen between Eu functionalised AuNPs and FRET 
acceptor BUCIS04-AF647 with a decrease in the Eu(III) excited state lifetime on incubation of 
EuQS@Au with BUCIS04-AF647. To combat this interaction, it was found that non-reactive proteins 
BSA and FCS were able to partially block this NSB and this was taken forward to use these to block 
any NSB between BUCIS04-AF647 and κnew.EuQS@Au. Whilst the NSB was not fully controlled 
with the addition of BSA or FCS at 1% it was possible to see competitive binding between 
κnew.EuQS@Au and κnew sample.  
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4 Preparation of novel gold nanoparticles 
which bind and sensitize lanthanides 
4.1 Introduction 
A major drawback of the use of sensitized luminescence for the population of the emissive energy state 
of the Ln ion, especially for imaging applications, is that a high energy excitation wavelength is often 
required to excite the organic based sensitizing unit, often in the ultraviolet area of the electromagnetic 
spectrum. High energy wavelengths are not only dangerous and damaging to tissue, but also do not 
penetrate deep, thus are not transmitted far into the body.1 Indeed, UCPs can be used in intercellular 
imaging to avoid this as the excitation wavelength used is a two – photon process often at 980 nm, 
which requires high power lasers to achieve sufficient signal from the emissive Ln ion.2,3 As a result, 
whilst the emissive properties of the Ln are favoured for imaging type applications, it is organic and 
transition metal based probes such as [Ru(bpy)3]2+ and Ir(ppy)3 which are often used, despite their 
emissive properties being less favoured for this type of application, resulting from their excitation 
wavelength in the visible area of the electromagnetic spectrum.4,5,6,7 Although organic fluorescent 
probes can show high quantum yields, their excited state lifetime is short and often less than 10 
nanoseconds, which means that time gated measurements are not possible and their broad emission 
signal is often difficult to identify from background fluorescence. Transition metal probes show longer 
lifetimes extending into the hundreds of nanoseconds range meaning that time gated measurements are 
possible, although their optical signal is broad and not as characteristic as the Ln series. 
 
Whilst the structures of new luminescent Ln complexes can appear complicated, the two basic 
requirements of a luminescent Ln complex are the same. A suitable Ln binding site which can protect 
the central Ln ion from quenching oscillations present in aqueous and alcoholic solvents is required, 
along with a suitable organic sensitizing unit which can successfully transfer energy to the Ln ion via 
its T1 state. Indeed, reports of new sensitizer – binding site combinations are common.8,9 
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β-diketone units such as acac in their anionic form can be used to bind to Ln and other metal ions and 
form stable complexes (Figure 4.1.1.). As such Ln β-diketone systems have found applications as chiral 
shift reagents, antibody labels, electroluminescent materials, and others.10,11,12,13,14,15 
 
 
Figure 4.1.1. 
Structure of anionic β-diketone binding to a metal ion. 
 
The aryl functionalised β-diketone, DBM can be used in the same fashion for binding to Ln ions, 
including Eu which can commonly form stable complexes of Eu(DBM)3 via coordination from the β-
diketone unit in its deprotonated form (Figure 4.1.2.). Excess coordination sites are filled with 
coordinating solvent molecules. Eu[(DBM)4]- salts have also been reported.16  
 
Figure 4.1.2. 
Structures of DBM (Left) and Eu(DBM)x where x can be 3 or 4 (Right). 
 
For the efficient sensitization of Eu(III), DBM is one of the most widely used and popular units to bind 
and sensitize Eu(III) ions, which has been studied since the 1940s, showing characteristic f-f 
luminescence from the Eu(III) ion. The 5D0  7F2 band is particularly prominent in comparison to other 
Eu(III) complexes due to the symmetrical nature of the complex.17 It is possible to excite Eu(DBM)3 
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derivatives up to 400 nm in the long wave ultraviolet area of the electromagnetic spectrum, an 
improvement on harsh wavelengths traditionally used for the absorption of light within a luminescent 
Ln complex.18,19 
 
Many derivatives of the classical Eu(DBM)3 have been synthesised in attempts to increase the 
luminescence of the original complex. Basset et. al. developed complexes whereby two benzoyl               
β-diketonate sites joined by a 1,3-phenylene spacer unit were synthesised, allowing two binding sites 
for Lns to be coordinated, thus making the complex twice as luminescent as Ln(DBM)3 (Figure 4.1.3.).20 
Indeed, taking advantage of the extra coordination sites on Ln(DBM)3 is also common whereby the use 
of phenanthroline (phen) is common which can provide extra sensitization, whilst further protecting the 
complex from quenching solvent oscillations (Figure 4.1.4.).21,22 Changes in sensitizer, and the use of 
fluorinated ligands to protect from quenching C-H oscillations have also been studied.23,24 
 
                         
Figures 4.1.3. (Left) and 4.1.4. (Right) 
New strategies to improve the luminescence of Eu DBM complexes. 
 
The use of Ln DBM complexes combined with NP technology is fairly common and using these type 
of complexes as dopants within both silica and polymer based luminescent Ln NPs is popular, as 
previously discussed (Section 1.5), in the preparation of highly luminescent NPs showing strong f-f 
luminescence, which can be in used in bioassay applications.  
 
Ln based DBM complexes and their derivatives have been used for functionalised surfaces and NPs. 
Indeed, in 2009 Gulino et. al. showed how a self-assembled monolayer of a luminescent Eu(III) 
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complex could be attached to a silica surface. A [Eu(DBM)3(phen)] complex with a terminal Si(OMe)3 
complex was synthesised, whereby incubation with a glass surface allowed the complex to be grafted 
onto the surface (Figure 4.1.5.).25 Indeed, after copious washing of the surface to remove excess 
complex, Eu(III) luminescence was observed with an excitation wavelength of 340 nm. A similar 
system was developed by Armelao et. al. whereby a silica surface was again functionalised with a 
Eu(III), DBM complex and showed f-f emission.26 Unpublished work within the Pikramenou group 
performed by Dr Suleman Khan has shown how DBM and other small organic molecules can be used 
to make luminescent NPs and surfaces via coordination to a silica functionalised DTPA molecule bound 
to a silica surface (Figure 4.1.6.). Coordination of DBM into the DTPA cavity allows sensitization of 
the Ln ion and luminescence can be observed. This was also shown for a EuQuinSAc functionalised 
Au surface whereby coordination of DBM into the DTPA cavity allowed for a luminescent 
enhancement of the central Eu(III) ion via extra sensitization from the DBM unit as well as the dual 
quinoline sensitizer present.  
 
 
Figures 4.1.5. (Left) and 4.1.6. (Right) 
Left: Development of luminescent Eu(III) self assembling monolayers on a glass surface; Right: 
Development of luminescent Eu(III) self assembling monolayers on a glass surface or silica NP. 
 
The combination of AuNPs and DBM is yet to be studied and is the focus of this piece of work, whereby 
the favourable properties of AuNPs are combined with a Ln DBM complex.  
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4.2 Chapter outline 
This chapter is concerned with the preparation of a functionalised DBM molecule with a thiol surface 
active group as to functionalise AuNPs with a DBM group, which can bind and sensitize Eu(III) ions 
(Figure 4.2.1.).  
 
 
 
 
 
 
 
  
 
Figure 4.2.1. 
General schematic of surface active DBM unit on AuNPs, binding Eu(III) ions. 
 
Herein, the synthesis of a surface active DBM group, its photophysical properties and the surface 
functionalisation of AuNPs with the DBM unit are reported. The functionalised AuNPs are then shown 
to successfully bind and sensitize Eu(III) ions on the surface on the AuNP to develop novel luminescent 
AuNPs. 
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4.3 Synthesis of DBMSS 
The molecule DBMSS was chosen as the synthetic target (Figure 4.3.1.). DBMSS contains the afore 
mentioned DBM unit for the binding and sensitization of Eu(III) ions and is functionalised with a 
thioctic acid side chain which is terminated with thiol groups for binding to a AuNP surface via the 
strong Au – S bonding moiety. 
 
 
Figure 4.3.1. 
Structure of DBMSS. 
 
The synthesis of DBMSS was achieved in a three step synthesis via two intermediates from amino 
functionalised acetophenone, 7 (Figure 4.3.2.). 
 
 
 
Figure 4.3.2. 
Synthetic scheme for DBMSS. 
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The synthesis of the ligand was achieved via Boc protection of amine 7 to produce 8 which was then 
used in a one pot Claisen condensation with ethyl benzoate and subsequent removal of the protecting 
group with TFA to yield amine functionalised DBM molecule 9, which could be used in an amide 
coupling reaction with thioctic acid to include the sulphur terminus on the target DBMSS in an overall 
6% yield with respect to the starting amount of 7. Characterisation spectra for compounds 8 and 9 are 
found in the appendix attached to this chapter. 
 
Indeed, the preparation of amine functionalised DBM derivative 9, allows the possibility of easy 
functionalisation of DBM derivatives via amide coupling with further functional groups, allowing the 
facile preparation of functionalised DBM molecules. 
 
The identity of the product was confirmed with NMR spectroscopy and MS. MS of DBMSS shows a 
peak with m/z: 450.1 which is assigned to [M + Na]+. Peaks with m/z values corresponding to compound 
3 or thioctic acid were not observed. The 1H NMR spectrum of DBMSS (Figure 4.3.3.) shows the 
expected number of resonances and was assigned using 2D COSY NMR spectroscopy (Figures 4.3.4. 
and 4.3.5.). 
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Figure 4.3.3.  
 
1H NMR spectrum of DBMSS in d6-DMSO. Aliphatic and aromatic reigions are presented separately. 
*, residual solvent resonance; •, water. 
* • 
• * 
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The 1H NMR spectrum of DBMSS confirms the formation of the product. The signal observed at 10.1 
ppm is a singlet from the amide group (H9) which is a new resonance in comparison to amine substituted 
DBM, 9, whereby the signal corresponding to the amine group is no longer observed. The singlet at 7.3 
ppm is a result of the central β-diketone proton (H4) which is characteristic of this type of resonance of 
an aryl β-diketone. The relative integration of this resonance is one, which shows that this molecule 
exists primarily in its enol tautomer. The aromatic region of the spectrum shows the expected nine 
protons and each ring was assigned via COSY NMR spectroscopy, showing the coupling of protons on 
each substituted benzyl ring. Resonances at 8.2 ppm, 7.7 ppm and 7.6 ppm were found to couple to each 
other and all show splitting patterns indicating a 3J value of 7.3 Hz and are assigned to protons H3, H1 
and H2. Signals on the next ring showed a signal shifted downfield at 8.3 ppm as a triplet which is 
assigned to H8, as a result of its proximity to electron withdrawing groups of the amide and carbonyls 
of the β-diketone unit. H5 and H7 are overlapping signals at 7.9 ppm. The remaining aromatic proton is 
H6 which appears as a triplet at 7.5 ppm. The aliphatic region of the spectrum shows the presence of the 
thioctic acid linker which integrates with the aliphatic area of the spectrum. This area of the spectrum 
is analogous with others who have reported similar compounds with a thioctic acid linker.27 Peaks at 
3.6 ppm, 3.1 – 3.2 ppm, 2.4 ppm and 1.8 ppm are from the five membered ring with the disulphide bond 
and are assigned to H14, H16 and H15, where H15 is split into two resonances at 2.4 ppm and 1.8 ppm. 
Protons in the four carbon chain show a triplet at 2.4 ppm from H10 which is shifted downfield in relation 
to the rest of the chain due to its proximity to the amide group, which are seen as a multiplet between 
1.8 and 1.5 ppm with a relative integration of four showing protons H11 and H13 and finally a signal at 
1.4 ppm corresponding to H12.  
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Figures 4.3.4. 
 
1H COSY NMR spectrum of DBMSS in d6-DMSO for the aromatic region. 
 
 
 
Figure 4.3.5. 
1H COSY NMR spectrum of DBMSS in d6-DMSO for the aliphatic region.  
 
*, residual solvent resonance; •, water. 
 
 
 
* 
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The identity was further confirmed via 13C NMR spectroscopy (Figure 4.3.6.). 
 
Figure 4.3.6. 
13C NMR spectrum of DBMSS in d6-DMSO.  
 
*, residual solvent resonance 
 
 
The 13C NMR spectrum of DBMSS further confirms the presence of DBMSS. From an expected 21 
13C resonances, 20 are observed and the remaining resonance is seen to be overlapping with the excess 
solvent at 39.5 ppm. Two resonances are observed at 185.3 and 185.2 ppm which are attributed to 
carbonyl resonances making up the β-diketone unit. The other carbonyl resonance at 171.4 ppm 
corresponds to the amide carbon. The aromatic region of the spectrum between 145 and 115 ppm show 
the expected ten signals, of which the three phenyl ring substitutions are observed. The signal at 93.3 
ppm is from the centre of the β-diketone unit which shows a resonance meaning only one proton is 
attached to this carbon which gives further proof to the molecule existing in its enol form. The remainder 
of the resonances observed between 60 and 20 ppm show the thioctic acid linker unit in the molecule 
with the expected seven resonances. 
 
 
 
 
* 
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4.4 Photophysical properties of DBMSS and lanthanide binding 
The UV Vis spectrum of DBMSS (Figure 4.4.1.) in methanol shows a spectrum similar to that of DBM. 
 
Figure 4.4.1. 
UV Vis spectrum of 4.8 µM DBMSS in MeOH. 
 
The UV Vis spectrum in MeOH of DBMSS shows two intense bands with λmax values of 350 nm              
(ε = 19900 M-1 cm-1) and 240 nm (ε = 23200 M-1 cm-1). These bands can be attributed to S1  S0 and                
S2  S0 absorption bands both π*  π in nature from the aryl groups. This is comparable with other 
functionalised DBM molecules synthesised in the literature.28  
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Eu(III) was able to be successfully coordinated into the ligand by addition of EuCl3.6H2O into a solution 
of deprotonated DBMSS via treatment with TEA. To examine the binding between the Eu(III) ion and 
DBMSS, Eu(III) was titrated into the ligand, whilst the subsequent f-f emission signal was monitored 
(Figure 4.4.2.), with an excitation wavelength of 350 nm. Indeed, such is the weakly absorbing nature 
of the Eu(III) ion, in particular at 350 nm, the emission signal observed can be exclusively attributed to 
sensitization from the DBMSS ligand. Indeed, after the coordination of Eu(III) into DBMSS, the 
excitation spectrum shows how the emissive Eu(III) state can be populated and confirms that sensitized 
luminescence of the Eu(III) ion as a result of the DBMSS unit is active (Figure 4.4.2.). 
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Figure 4.4.2. 
Top left: Emission titration of EuCl3.6H2O (0.8 mM, 6 µL aliquots) into a solution of DBMSS (60 μM 
in MeOH, 2 ml) with 0.05% TEA to a final concentration of 28 μM (72 µL) λexc = 350 nm, Emission 
spectra corrected for PMT response; Top right: Growth of Eu(III) emission peak as integrated between 
limits of 607 and 621 nm; Bottom: Excitation spectrum of DBMSS after final addition of EuCl3.6H2O, 
monitoring the emission at 614 nm. 
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As Eu(III) is introduced into the system the characteristic Eu(III) emission spectra is observed from the 
5Do  7FJ energy levels whereby the J = 2 transition is the most intense transition at 612 nm. Indeed, 
the J = 2 transition is more intense in comparison to other transitions for the DBMSS system than for 
the DTPA quinoline sensitized Eu(III) complexes which show an increase in symmetry of the DBMSS 
ligand and the subsequent complex in comparison to EuQuinSAc and EuQSH. The emission of the 
Eu(III) ceases to rise when the ratio of DBMSS : Eu(III) reaches 3 : 1 which shows the formation of a 
Eu(DBMSS)3 complex.  
 
The excitation spectrum shows that sensitized emission of the Eu(III) ion as a result of the DBMSS unit 
is active and the Eu(III) emission can be observed up to ca. 380 nm. As the use of invasive high energy 
wavelengths, is often used in the sensitization of Ln complexes, excitation up to this wavelength is an 
advantage, especially when combined with the properties of AuNPs. Lifetime studies of the methanolic 
solution of mixed DBMSS and EuCl3.6H2O gave rise to biexponential decay behaviour, whereby the 
long lived Ln lifetime is present with values of 100 μs (45%) and 240 μs (55%) (χ2 = 0.9) and that in 
the deuterated solvent analogue was 170 μs (33%) and 450 μs (67%) (χ2 = 1.1). Use of the Parker-Beeby 
equation on the long component of each lifetime shows four solvent molecules are bound to the central 
Eu(III) ion. The coordination number of Eu(III) is usually high between eight and ten, hence this result 
confirms three DBMSS units are coordinated to the central metal ion as a β-diketone unit is bidentate 
via its two oxygen atoms.  
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4.5 Functionalisation of gold nanoparticles with DBMSS 
To create luminescent AuNPs with DBMSS and Eu(III), it was decided to functionalise the surface of 
AuNPs with DBMSS, from which excess DBMSS could be removed, followed by coordination of 
Eu(III) ions into the functionalised AuNPs. This methodology was adopted to ensure that only Au 
surface immobilised DBMSS units were involved in the Eu(III) coordination. Indeed, this methodology 
has been applied in a similar system whereby Savage et. al. showed the addition of Eu(III) into Ln 
binding peptides, which were immobilised on 13 nm AuNPs.29 
 
The addition of DBMSS in methanolic solution to Cit@Au, synthesised as previously described, gives 
rise to a large change in the SPR wavelength of Cit@Au (Figure 4.5.1.). 
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Figure 4.5.1. 
Change in SPR wavelength of Cit@Au (3.2 nM in water, 2 mL) as a methanolic solution of DBMSS 
(0.2 mM in MeOH, 10 µL aliquots) is titrated in to a final concentration of 4.87 µM (50 µL).  
 
The large perturbation in the UV Vis spectrum of Cit@Au observed shows a widening and large shift 
in the nanomaterial SPR wavelength which is characteristic of AuNPs which have become destabilised 
and aggregated, which shows that the addition of DBMSS to Cit@Au causes destabilised particles. 
Attempts to functionalise the AuNP with DBMSS at different concentrations of DBMSS also resulted 
in NP aggregation.  
SPR 
SPR 
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The stability of AuNPs can be improved via functionalisation of the gold colloid with commercial 
surfactant or polymer.30,31 Indeed, the increased stability and necessity for a surfactant molecule in the 
preparation of [Ru(bpy)3]2+ coated AuNPs has been shown due to the charge of the complex with the 
use of Zonyl®, TritonTM and Tween® functionalised AuNPs.32,33 Herein, it is shown how the stability of 
Cit@Au can be improved with a preloading of fluorinated polymer Zonyl® FSA (Figure 4.5.2.) to the 
surface of the AuNP whereby the DBMSS probe is expected to bind to the surface after the Zonyl® 
FSA has been preloaded onto the NP. 
 
 
Figure 4.5.2.  
Structure of Zonyl® FSA 
 
The interaction of Zonyl® FSA leads to a small change in the SPR wavelength of the AuNP of 1 nm 
(Figure 4.5.3.) and excess Zonyl® FSA was removed via centrifugation in the development of Z@Au, 
after which DLS and were recorded (Table 4.5.1.). Particle size and morphology was further determined 
via TEM (Figure 4.5.4.). 
 
Table 4.5.1. 
NP characterisation data for Z@Au. 
Sample Intensity 
distribution / nm 
 
Number 
distribution / nm 
PDI 
Cit@Au 18 ± 3  12 ± 3 0.1 
Z@Au 25 ± 3 15 ± 3 0.1 
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Figures 4.5.3. (Left) and 4.5.4. (Right). 
Left; Change in SPR upon addition of Zonyl® FSA (50 ng / mL) into Cit@Au, the Blue curve represents 
the addition of the surfactant, Right; TEM image of Z@Au after removal of excess Zonyl® FSA. 
 
The increased stability of the NPs is highlighted with a negative change in zeta potential of the particles 
from – 30 mV to – 50 mV. DLS sizing suggests that the particles are 15 nm which shows an increase 
in relation to Cit@Au which is in agreement with the TEM data which show the particles are                    
ca. 15 nm and of a spherical morphology. 
 
The surface of Z@Au was successfully functionalised with DBMSS in the production of 
DBMSS.Z@Au (Figure 4.5.5.). 
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Figure 4.5.5. 
Preparation of DBMSS.Z@Au with the functionalisation of Cit@Au with Zonyl® FSA followed by 
DBMSS. 
 
 
The surface functionalisation of Z@Au was monitored via UV Vis spectroscopy (Figure 4.5.6.). Excess 
DBMSS was removed via size exclusion chromatography using Sephadex G15 taking into account the 
large difference between the functionalised NP and DBMSS, whereby the SPR wavelength is unaltered 
showing that no aggregation occurs from the purification method. 
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Figure 4.5.6. 
Change in SPR wavelength of Z@Au (3.2 nM in water, 2 mL) as a methanolic solution of DBMSS (0.2 
mM, 10 µL aliquots in MeOH) is titrated in to a final concentration of 11.32 µM (120 µL). The pink 
curve is post chromatography. 
 
SPR 
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A positive shift in the SPR wavelength of the AuNP is observed as the surface is functionalised with 
DBMSS which reaches saturation point at 524 nm showing an overall SPR wavelength shift of 7 nm 
with respect to Z@Au. This SPR wavelength is the same post chromatography hence the particles are 
not destabilised during the purification process. The SPR wavelength of the particles are not widened 
with the fluorinated surfactant present hence the particles are stabilised whilst functionalised with 
DBMSS and the use of Zonyl® FSA was successful in stabilising the particles. The growing band 
observed at 350 nm is from the absorption by the aryl β-diketone unit from DBMSS which appears less 
intense post purification as a result of the excess DBMSS being removed. The concentration at which 
saturation point is reached suggests ca. 2000 DBMSS units per particle, although the error associated 
with this measurement via UV Vis spectroscopy data is large.  
 
Post chromatography the particles were examined with DLS (Table 4.5.2.). Particle size and 
morphology was determined with TEM (Figure 4.5.7.). 
 
Table 4.5.2. 
DLS characterisation data for DBMSS.Z@Au after Sephadex G15. 
Intensity 
distribution / nm 
 
Number 
distribution / nm 
PDI 
24 ± 4 15 ± 4 0.2 
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Figure 4.5.7. 
TEM image of DBMSS.Z@Au after Sephadex G15. 
 
DLS sizing suggests that the particles are ca. 15 nm which is in agreement with the TEM data which 
show that the DBMSS functionalised AuNPs are ca. 15 nm and of a spherical morphology.  
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4.6 Loading of lanthanides into DBMSS functionalised AuNPs 
DBMSS functionalised AuNPs, were able to show the binding and sensitization of Eu(III) ions. An 
aqueous solution of EuCl3.6H2O was titrated into DBMSS.Z@Au, in the presence of TEA, in the 
preparation of Eu.DBMSS.Z@Au (Figure 4.6.1.).  
 
 
 
 
 
 
 
 
 
Figure 4.6.1. 
Preparation of Eu.DBMSS.Z@Au from DBMSS.Z@Au 
 
 
The process was monitored via emission spectroscopy whereby as the Eu(III) ion binds to 
DBMSS.Z@Au, sensitized emission from the aryl β-diketone unit was observed (Figure 4.6.2.). 
Indeed, after the coordination of Eu(III) the excitation spectrum shows how the emissive Eu(III) state 
can be populated and confirms that sensitized emission of the Eu(III) ion as a result of the DBMSS unit 
is active (Figure 4.6.2.). 
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Figure 4.6.2. 
Top left: Emission titration of EuCl3.6H2O (0.08 mM, 2 µL aliquots) into a solution of DBMSS.Z@Au 
(2.7 nM in water) with 0.05% TEA to a final concentration of 2.18 μM of EuCl3.6H2O (14 µL), λexc = 
350 nm, Emission spectra corrected for PMT response; Top right: Growth of Eu(III) emission peak as 
integrated between limits of 607 and 621 nm; Bottom, Excitation spectrum of DBMSS.Z@Au after final 
addition of EuCl3.6H2O, monitoring the emission at 614 nm. 
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The incubation of Eu(III) in DBMSS.Z@Au shows an increase in the characteristic Eu(III) 
luminescence signal, which shows a plateau at ca. 950 nM as the particles binding sites for Eu(III) are 
all occupied and no further Eu sensitization is observed. Control experiments of incubating Eu(III) with 
Z@Au showed no luminescence hence the optical signal observed can be attributed to the DBMSS unit 
on the surface of the AuNP. This would suggest a binding of ca. 350 Eu ions per particle, although there 
is a large error associated with this estimation. The previous estimation of ca. 2000 DBMSS units per 
particle would suggest that some of the DBMSS units on the AuNP are unoccupied given that the ratio 
of DBMSS : Eu(III) is 3 : 1. With this approximation, it can be estimated that around half the binding 
sites on the Au surface are not filled. The excitation spectrum shows that the emissive Eu(III) state can 
be populated up to ca. 380 nm and confirms that sensitized emission of the Eu(III) ion as a result of the 
DBMSS unit is active. This is an improvement on the previously presented quinoline sensitized 
luminescent AuNPs of EuQS@Au and EuQuinSAc@Au, as the particles can be excited at a much less 
harsh wavelength, and the initial absorption from the ligand is much larger with respect to their molar 
absorptivity values. The lifetime of DBMSS.Z@Au in the presence of Eu(III), in water was found to 
be biexponential showing a 30 μs (30%) and 130 μs (70%) (χ2 = 1.0). Whilst this is shorter than that 
observed for EuQS@Au complexes, the Eu.DBMSS.Z@Au type particles can still be used in time 
resolved luminescence type applications such as acting as a FRET donor.  
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The DBMSS.Z@Au particles were found not to show any destabilisation from the Ln(III) ion during 
the binding process as monitored via UV Vis spectroscopy (Figure 4.6.4.) and DLS (Table 4.6.1.). The 
TEM image of Eu.DBMSS.Z@Au (Figure 4.6.5.) also shows that there is no change in the size or 
morphology of the AuNPs when functionalised with Eu ions. 
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Figures 4.6.4. (Left) and 4.6.5. (Right) 
Left, Change in SPR wavelength as DBMSS.Z@Au (2.7 nM in water) is incubated with TEA (0.05%), 
blue curve, followed by addition of EuCl3.6H2O (0.08 mM, 40 µL)1.7 μM, green curve; Right, TEM 
image of Eu.DBMSS.Z@Au. 
 
Table 4.6.1. 
DLS characterisation data for Eu.DBMSS.Z@Au. 
 
Intensity 
distribution / nm 
 
Number 
distribution / nm 
PDI 
18 ± 3 15 ± 3 0.3 
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4.7 Concluding remarks 
The preparation and characterisation of a novel substituted DBM ligand with a thioctic acid group has 
been reported. This ligand was found to form a 3 : 1 complex with Eu(III) and the energy level of the 
T1 state showed efficient excitation of the Eu(III) excited state and show f-f emission. DBMSS was 
deposited on the surface of surfactant modified AuNPs and retains its luminescence, showing excitation 
up to ca. 380 nm on the surface of the AuNP when coordinated to Eu(III). 
 
The DBMSS system rivals the previously reported Eu coated AuNPs as the ligand shows a much 
stronger absorption of light at 350 nm (ε = 19900 M-1 cm-1) and three ligands coordinate to the central 
metal ion in comparison to EuQSH with absorption at 320 nm (ε = 3000 M-1 cm-1) and EuQuinSAc at 
321 nm (ε = 9000 M-1 cm-1). The τ of Eu.DBMSS.Z@Au in aqueous solvent is lower than that of 
EuQS@Au showing biexponential behaviour with a long component of 130 µs, in comparison to a 
single component of 580 µs observed for EuQS@Au, resulting from quenching oscillations from the 
solvent whereby four quenching oscillators are present for the DBMSS system in comparison to one 
for EuQSH. Despite this lower τ, Eu.DBMSS.Z@Au continues to show the long lived Ln τ to act as a 
FRET donor. 
 
It is envisaged that Eu.DBMSS.Z@Au will be able to be dual loaded onto AuNP with LC antibodies 
and used in a FRET assay as previously described (Section 2.9), again using BUCIS04-AF647 as a 
suitable FRET acceptor of Eu(III) emission at 614 nm. The necessity for Cit@Au to be modified with 
Zonyl® FSA may alter how the biomolecule interacts with the LC antibody meaning different 
conjugation methods may need to be explored.  
 
As well as use as a FRET donor, the strong luminescence observed from Eu.DBMSS.Z@Au, and the 
4 coordinated water molecules into the DBMSS system paves the way for a possible dual contrast 
imaging agent with Eu(III) showing luminescence and Gd(III) increasing the relaxation rate of 
coordinated water molecules. 
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5 Conclusions and further work 
5.1 Thesis Conclusions 
This thesis has shown how AuNPs can be capped with luminescent Eu(III) complexes to produce 
AuNPs which show the characteristic Eu(III) luminescence with a long lived excited state lifetime and 
this was shown for two Eu(III) complexes based on DTPA derivatives. These were grafted onto the 
surface of AuNPs alongside LC material to continue to show Eu(III) luminescence.  
 
On addition of anti-κFLC mAb, BUCIS04 which was conjugated to a suitable FRET acceptor for 
Eu(III) AF647, it was possible to observe FRET between κLC.EuQS@Au and BUCIS04-AF647 as 
measured via excited state lifetime measurements, whilst maintaining particle stability. This FRET 
signal was found to be low and between 10 – 15% of the energy was found to have been transferred 
when the BUCIS04-AF647 was incubated with κLC.EuQS@Au at 100 nM and 2.7 nM respectively. 
Indeed, it was also found that the inclusion of the gold surface leads to problems associated with NSB 
of biomolecules with the AuNP as seen via a FRET quench between EuQS@Au and BUCIS04-AF647 
as measured via excited state lifetime measurements. To block out this unwanted interaction, various 
different blocking agents were incubated with EuQS@Au prior to the addition of BUCIS04-AF647. 
Blocking agents based on detergent species were found to have no affect on the NSB although both 
non-reactive proteins BSA and FCS, both at 1%, showed a slight improvement of the signal by resisting 
a drop in the excited state lifetime of EuQS@Au at 2.7 nM when BUCIS04-AF647 was added at 100 
nM, although this NSB was not completely removed from the system. 
 
It was able to be shown that competitive binding can be seen between κnew and κnew.EuQS@Au 
when BUCIS04-AF647 was mixed with κnew at 45 µM, to use up the binding sites on BUCIS04-
AF647, before incubation with κnew.EuQS@Au, although the NSB is still an issue in this system.  
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5.2 Further Work 
Although EuQuinSAc and EuQSH both show Eu(III) luminescence and can be grafted onto the surface 
of the AuNP, the use of the quinoline sensitizing unit is not ideal. Indeed, excitation of the molecules 
at 320 and 315 nm respectively give molar absorptivity’s of less than 10000 in each case. To improve 
on these, DBMSS was developed which shows a λmax of 350 nm (ε = 19900 M-1 cm-1) to which three of 
these bind an Eu(III) ion. Despite Eu.DBMSS.Z@Au requiring the use of a surfactant species and the 
excited state lifetime of Eu.DBMSS.Z@Au being lower that EuQS@Au, it would be advantageous to 
develop similar ligands to DBMSS (Figure 5.2.1.).. Examples of such are the fluorinated analogue of 
DBMSS to remove quenching C-H oscillations, or a ligand incorporating two binding sites which 
would, in theory, show enhanced luminescence due to more luminescent material. 
 
 
Figure 5.2.1. 
Potential new synthetic targets further to DBMSS 
 
The quenching nature of water molecules to Eu.DBMSS.Z@Au, could be turned into an advantage 
with the incorporation of Gd(III) into these sites for MRI applications, and leads the way to a potential 
dual mode imaging agent with Gd(III) for MRI and Eu(III) for luminescence using nanotechnology.  
 
The inclusion of DBMSS over EuQSH in the AuNP FRET assay would be an advantageous step due 
to the favoured properties of the DBMSS over EuQSH, although the biexponential excited state 
lifetime of Eu.DBMSS.Z@Au could potentially prove problematic. 
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The initial FRET signal from the incubation of κLC.EuQS@Au and BUCIS04-AF647 at 2.7 nM and 
100 nM respectively leads to a quench of between 10 – 15% whilst maintaining particle stability. This 
figure is low in comparison to many systems in the literature, which can be as high as 80% energy 
transfer. To improve on this figure would be advantageous to achieve the maximum FRET quench 
possible. Indeed, the concentration of κLC.EuQS@Au at 2.7 nM is difficult experimentally to change 
with higher concentrations causing issues with particle stability and lower concentrations causing issues 
with a lower optical signal. The incubation of larger concentrations of BUCIS04-AF647 with 
κLC.EuQS@Au leads to a larger FRET signal being observed, although nanoparticle aggregation is 
also observed. In terms of the NSB observed in the system, it was possible to eliminate this partially 
with the addition of non-reactive proteins BSA and FCS, both at 1%, although particle stability is not 
maintained above these concentrations, which may indeed fully eliminate any NSB.  
 
The stability of AuNPs can be improved upon with the functionalisation of the AuNP with polymers or 
surfactants, which was seen with a change in the zeta potential of Cit@Au – 30 mV to – 50 mV on 
functionalisation with a fluorinated polymer Zonyl® FSA (Section 4.5.). Indeed, the incorporation of a 
nanoparticle stabilising unit into the system, prior to functionalisation with Eu complex and LC, may 
allow for larger concentrations of biomolecule to be incubated with the particles. Indeed, this would be 
a large advantage to the system as more BUCIS04-AF647 could be incubated with κLC.EuQS@Au, 
possibly showing a much larger FRET signal, and indeed, a larger protein blocking agent may also be 
achieved, further inhibiting NSB. The addition of a stabilising unit to the system could cause potential 
problems relating to the binding of the LC to the AuNP, given that a lot of polymers and surfactants 
have also been used to block biomolecule to surface interactions and it may be necessary to explore 
other AuNP to biomolecule coupling methodologies such as click chemistry, or amide coupling as 
previously discussed (Section 2.1.). 
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Whilst the gold particle has clear advantages of aqueous solubility, easy functionalisation and inert, 
non-toxic nature, this system is not limited to AuNPs. The use of other nanomaterials would be a very 
interesting comparison from how the AuNP system works in comparison to a silica or polymeric 
nanoparticle, which may allow for different NSB properties. Indeed, the size of the AuNP is not a 
limitation and the comparison of 12 nm AuNP with 100 nm AuNP could be very interesting.   
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6 General Experimental 
6.1 General Experimental 
General use of reagents  
All glassware was cleaned with deionised water and acetone and oven dried prior to use.  
 
All chemical starting materials and solvents were obtained from Sigma Aldrich UK, Fischer or Fluka 
and used as supplied unless otherwise stated.  
 
Antibody and Light chain samples were supplied by Serascience. 
 
NMR spectroscopy, FT-IR, mass spectrometry and HPLC  
 
1H NMR data was obtained on a Brüker AVIII300 at 300 or 400 MHz as stated whilst 13C NMR and 
2D NMR data were obtained on a Brüker AVIII400 NMR spectrometer at 101 MHz. Details of each 
scan are found in the appendix. Deuterated NMR solvents were used as supplied and the data was 
processed offline on MestReNova whereby the data was referenced to the appropriate residual peak 
solvent.  
 
MS data was obtained using a micro mass liquid chromatography - TOF using the electrospray positive 
mode unless otherwise stated.  
 
IR spectra were collected on a PerkinElmer Spectrum 100 FT-IR Spectrometer using an ATR 
attachment and processed using PerkinElmer software.  
 
HPLC was carried out on a Dionex summit system, using a Summit P580 quaternary low pressure 
gradient pump. The detector was a Summit UVD 170s UV VIS multi-channel detector with a prep flow 
cell for semi-prep HPLC. The column used was a preparative C18 column with a particle size of 10 μM. 
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UV Vis spectroscopy  
 
UV Vis data was obtained either on a Varian Cary 5000 or a Varian Cary 50 spectrometer at a scan rate 
of 300 nm / min, with a baseline correction for the appropriate solvent system. Quartz cuvettes with a 
1 cm path length were used throughout.  
 
Extinction coefficients were calculated (Equation 6.1.) with respect to the absorbance and concentration 
of the sample. 
𝜀 =  
𝐴
𝑐𝑙
 
Equation 6.1.  
ε, extinction coefficient; c, concentration; A, absorbance; l, path length. 
The SPR wavelength of AuNPs were worked out as according to a FWHM of the curve at the point 
where it resembles a parabola (Figure 6.1. and Equation 6.2.). 
 
 
Figure 6.1. and Equation 6.2. 
FWHM determination of AuNP SPR peak wavelength 
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Emission spectroscopy  
Emission and excitation data was obtained on an Edinburgh Instruments FLSP920 steady state, 
fluorescence and phosphorescence lifetime spectrometer using a 450 W xenon arc lamp as the excitation 
source and Hamamatsu R928 PMT as the detection source. Appropriate cut off filters were used 
throughout and all data was corrected with respect to the appropriate correction file of the Hamamatsu 
R928 PMT and F900 software was used to record the data.  
 
Emission quantum yield data was obtained on the spectrometer as described above with use of an 
integrating sphere. Quartz cuvettes with four clear faces of 1 cm2 were used and the data processed with 
the F900 software.  
 
Ln excited state lifetime measurements were carried out with the detection source as described above, 
using a microsecond flashlamp as the excitation source. F900 software was used to record the data and 
the data was analysed using the F900 software using the tail fit option and fitted to a monoexponential 
decay curve unless otherwise stated. All data was plotted to a χ2 value of between 0.9 and 1.3.  
 
NP characterisation  
DLS and Zeta potential data were collected on a Malvern Zetasizer NanoZS and the data processed 
using the Malvern Zetasizer software.  
 
TEM samples were imaged using Jeol 1200EX TEM and Gatan multiscan camera. Samples were air-
dried onto 200 mesh formvar coated copper and images were acquired using DigitalMicrograph 1.8.  
 
ICPMS measurments were performed on a 7500cx ICPMS at the university of Warwick. In all cases 
the metal concentration was determined with PlasmaCal calibration standards and the colloidal sample 
was dissolved in ultrapure Aqua Regia. 
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Synthesis of Cit@Au 
 
       
           HAuCl4.3H2O  
 
 
 
All glassware was cleaned with aqua regia (HCl : HNO3, (3 : 1)), washed with copious amounts of 
deionised water and oven dried at 120 oC  prior to use. 
 
A solution of trisodium citrate dihydrate (60.6 mg, 289 μmol), citric acid monohydrate (13.3 mg, 66.5 
µmol) and tetrasodium ethylenediaminetetraacetic acid monohydrate (1.0 mg, 2.25 μmol) were 
dissolved in deinised water (100 mL) and bought to reflux at 150 oC with rapid stirring in a round 
bottomed flask to create a vortex. A separate solution of chloroauric acid trihydate (8.0 mg, 20.3 μmol) 
in deionised water (25 mL) was prepared and heated in an oven to ca. 80 oC, before being added quickly 
to the round bottomed flask. The resulting solution was then refluxed for a further ten minutes to bring 
out a characteristic deep red solution and then was allowed to cool to room temperature over a period 
of one hour yielding Cit@Au at 1.6 nM. 
 
λmax SPR / nm Number distribution / 
nm 
Intensity distribution / 
nm 
PDI 
516  12 ± 3  18 ± 3 0.1 
 
 
 
 
trisodium citrate 
citric acid 
ethylenediaminetetraacetic acid 
100 oC, 10 minutes 
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6.2 Chapter 2 
Synthesis of tert-butyl (8-hydroxyquinolin-5-yl)carbamate (2) 
 
 
 
 
 
 
To a stirring solution of 1 (2.00 g, 8.58 mmol, 1.00 eq.) in water (40 mL), KHCO3 (1.20 g, 12 mmol, 
1.40 eq.) was added to raise the pH of the solution to 8. THF (50 mL) and water (10 mL) were added 
and the resulting solution left to stir under N2 at RT for 1 hour. After this time a solution of di-tertiary 
butyl bicarbonate (1.96 g, 8.99 mmol, 1.05 eq.) in THF : water (1 : 1 by volume, 10 mL) was added 
dropwise over 30 minutes under an N2 atmosphere. The resulting solution was then left stirring under 
N2 at 0 oC which was allowed to warm to RT over 17 hours. The THF was then removed in vacuo and 
the organic material extracted with DCM (1 x 400 mL). The organic layer was then dried over 
anhydrous Na2SO4 (ca. 10 g), filtered, and the solvent removed in vacuo to give 2 as a brown solid (1.71 
g, 6.58 mmol, 77%). 1H NMR (300 MHz, CDCl3) δH ppm: 8.79 (1H, dd, J = 4.2, 1.4, Ha), 8.26 (1H, dd, 
J = 8.6, 1.4, Hc), 7.52 (1H, br, Hd), 7.49 (1H, dd, J = 8.6, 4.2, Hb), 7.14 (1H, d, J = 8.2, He), 6.44 (1H, 
br, NH), 1.52 (9H, s, Hf). 13C{1H} PENDANT NMR (101 MHz, CDCl3) δC ppm: 154.6 (NHCOC), 
150.6 (ArC), 148.0 (ArCH), 138.3 (ArC), 131.5 (ArCH), 124.2 (ArCH), 124.0 (ArC), 121.9 (ArCH), 
109.4 (ArCH), 80.8 (OC(Me)3), 28.5 (OC(CH3)3). MS (ES-TOF)+ m/z: 261.1 [M + H]+. Characterisation 
data were in agreement with the literature.1 
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Synthesis of S-(6-bromohexyl) ethanethioate (4) 
 
 
 
 
 
To a stirring solution of 3 (2.00 g, 12.35 mmol, 1.00 eq.) in dry toluene (15 mL), thioacetic acid (1.86 
g, 24.47 mmol, 1.98 eq.) was added followed by a catalytic amount of ABCN (ca. 0.025 g) and the 
solution left to reflux at 125 oC under N2 for 3 hours. After this time, the mixture was cooled to RT and 
a solution of NaHCO3 (1 M, 60 mL) was added and the organic material was extracted with EtOAc 
(120 mL) and washed with NaHCO3 (1 M, 60 mL). The organic material was then dried with anhydrous 
Na2SO4 (ca. 10 g), filtered, and the solvent removed in vacuo to yield 4 as a yellow oil (2.70 g, 11.34 
mmol, 92%). 1H NMR (300 MHz, CDCl3) δH ppm: 3.40 (2H, t, J = 6.8, Ha), 2.86 (2H, t, J = 7.5, Hf), 
2.32 (3H, s, Hg), 1.85 (2H, p, J = 6.8, Hb) 1.59 (2H, p, J = 7.5, He), 1.42 (4H, m, Hc, Hd). 13C{1H} NMR 
(101 MHz, CDCl3) δC ppm: 196.0 (SCOMe), 33.8 (BrCH2CH2), 32.7 (BrCH2CH2), 30.7 (COCH3), 29.4 
(CH2CH2S), 29.0 (CH2CH2CH2), 28.0 (CH2CH2CH2), 27.7 (CH2CH2CH2). MS (ES-TOF)+ m/z: 239.1 
[M (79Br)]+. 241.1 [M (81Br)]+. Characterisation data were in agreement with the literature.2,3 
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Synthesis of S-(6-((5-((tert-butoxycarbonyl)amino)quinolin-8-yl)oxy)hexyl) ethanethioate (5) 
 
 
 
 
 
 
 
Compound 2 (1.00 g, 3.85 mmol, 1.00 eq.) was dissolved in acetone (45 mL), K2CO3 (1.53 g, 11.09 
mmol, 2.88 eq.) and a catalytic amount of tetraoctylammonium bromide (ca. 0.025 g) were added. The 
solution was stirred under N2 at 55 oC for 30 minutes after which time a solution of 4 (1.1 g, 4.62 mmol, 
1.20 eq.) in acetone (15 mL) was added and the solution was stirred at 60 oC for 72 hours under N2. The 
reaction mixture was then cooled to RT and the solvent removed in vacuo whereupon DCM (100 mL) 
and water (50 mL) were added. The organic material was extracted and washed with water (20 mL) and 
brine (20 mL), dried over anhydrous Na2SO4 (ca. 10 g), filtered and the solvent removed in vacuo to 
give a brown oil which was purified via column chromatography on silica (EtOAc : Hexane; 60 : 40) 
to yield 5 as a yellow oil (0.56 g, 1.34 mmol, 35%). 1H NMR (300 MHz, CDCl3) δH ppm: 8.93 (1H, dd, 
J = 4.2, 1.5, Hh), 8.22 (1H, dd, J = 8.5, 1.5, Hj), 7.54 (1H, br, Hk), 7.42 (1H, dd, J = 8.5, 4.2, Hi), 6.97 
(1H, d, J = 8.5, Hl), 6.67 (1H, br, NH), 4.17 (2H, t, J = 7.0, Hg), 2.85 (2H, t, J = 7.2, Hb), 2.29 (3H, s, 
Ha), 1.95 (2H, p, J = 7.6, Hf), 1.65 – 1.35 (15H, m, Hc, Hd, He, Hm). 13C{1H} NMR (101 MHz, CDCl3) 
δC ppm: 196.0 (SCOMe), 154.5 (NHCOO), 153.0 (ArC), 149.2 (ArCH), 140.3 (ArC), 130.8 (ArCH), 
125.2 (ArC), 122.7 (ArCH), 121.5 (ArCH), 121.5 (ArC), 108.3 (ArCH), 80.7(OC(Me)3), 69.0 
(OCH2CH2), 30.7 (COCH3), 29.5 (CH2CH2CH2), 29.1 (CH2CH2CH2), 28.9 (CH2CH2S), 28.7 
(CH2CH2CH2), 28.4 (C(CH3)3), 25.7 (CH2CH2CH2). MS (ES-TOF)+ m/z: 419.2 [M + H]+. 
Characterisation data were in agreement with the literature.4 
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Synthesis of S-(6-((5-aminoquinolin-8-yl)oxy)hexyl) ethanethioate (6) 
 
 
 
 
 
 
Compound 5 (0.56 g, 1.34 mmol, 1.00 eq.) was dissolved in dry DCM (23 mL) and stirred under N2 at 
RT. TFA (3.40 g, 29.82 mmol, 22.25 eq.) was added over 5 minutes and the solution left to stir at RT 
under N2 for 3 hours. After this time, the solvent was removed in vacuo whereupon DCM (100 mL) and 
NaHCO3 (1 M, 10 mL) were added. The organic material was extracted and the aqueous material was 
washed with DCM (2 x 10 mL). The organic extracts were combined and dried over anhydrous Na2SO4 
(ca. 10 g), filtered and the solvent removed in vacuo to give 6 as a red oil (0.41 g, 1.29 mmol, 97%). 1H 
NMR (300 MHz, CDCl3) δH ppm: 8.93 (1H, d, J = 3.8, Hh), 8.20 (1H, d, J = 8.4, Hj), 7.39 (1H, dd, J =  
8.4, 3.8, Hi), 6.90 (1H, d, J = 8.2, Hl), 6.75 (1H, d, J = 8.2, Hk), 4.13 (2H, t, J = 6.9, Hg), 3.90 – 3.50 
(2H, br, NH2), 2.86 (2H, t, J = 7.2, Hb), 2.30 (3H, s, Ha), 1.95 (2H, p, J = 7.4, Hf), 1.65 – 1.35 (6H, m, 
Hc, Hd, He). 13C NMR (101 MHz, CDCl3) δC ppm: 196.1 (SCOMe), 149.1 (ArC), 148.4 (ArC), 140.6 
(ArC), 135.1 (ArC), 130.3 (ArC), 120.7 (ArC), 120.3 (ArC), 110.6 (ArC), 110.2 (ArC), 69.3 
(OCH2CH2), 30.7 (COCH3), 29.5 (CH2CH2CH2), 29.2 (CH2CH2CH2), 29.1 (CH2CH2S), 28.7 
(CH2CH2CH2), 25.8 (CH2CH2CH2). MS (ES-TOF)+ m/z: 319.2 [M + H]+. Characterisation data were in 
agreement with the literature.4 
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Synthesis of 2,2'-((((carboxymethyl)azanediyl)bis(ethane-2,1-diyl))bis((2-((8-((6-
(acetylthio)hexyl)oxy)quinolin-5-yl)amino)-2-oxoethyl)azanediyl))diacetic acid (H3QuinSAc) 
 
To a stirring solution of 6 (0.40 g, 1.25 mmol, 2.19 eq.) in anhydrous pyridine (25 mL), DTPA-
bisanhydride (0.19 g, 0.57 mmol, 1.00 eq.) was added and the solution left to stir under N2 for 72 hours 
at RT. After this time, the solvent was removed in vacuo and water (20 mL) was added whereupon a 
tarry precipitate was observed. The water was decanted off and the precipitate triturated in MeCN (20 
mL) for 3 hours, filtered and washed with MeCN (10 mL) and Et2O (10 mL) to give H3QuinSAc as a 
light brown powder (0.30 g, 0.30 mmol, 53%). 1H NMR (300 MHz, d6-DMSO) δH ppm: 10.19 (2H, br, 
NH), 8.82 (2H, d, J = 3.8, Hh), 8.34 (2H, d, J = 8.4, Hj), 7.57 (2H, d, J = 8.2, Hl) 7.49 (2H, dd, J =  8.4, 
3.8, Hi), 7.06 (2H, d, J = 8.2, Hk), 4.08 (4H, t, J = 6.6, Hg), 3.48 (8H, s, Hm, Hp), 3.41 (2H, s, Hq), 3.03 
(4H, br, Ho), 2.92 (4H, br, Hn), 2.85 (4H, t, J = 7.1, Hb), 2.32 (6H, s, Ha), 1.81 (4H, t, J = 6.6, Hf), 1.60 
– 1.35 (12H, m, Hc, Hd, He). 13C{1H} PENDANT NMR (101 MHz, d6-DMSO) δC ppm: 195.7 (SCOMe), 
173.3 (CH2COOH), 170.5 (NHCOCH2), 152.3 (ArC), 149.0 (ArCH), 139.9 (ArC), 131.6 (ArCH), 125.8 
(ArC), 124.5 (ArC), 122.6 (ArCH), 121.6 (ArCH), 108.9 (ArCH), 68.5 (PhOCH2), 58.5 (NCH2CONH), 
55.9 (NCH2COOH), 55.5 (NCH2COOH), 52.5 (NCH2CH2N), 51.9 (NCH2CH2N), 30.8 (COCH3), 29.4 
(CH2CH2CH2), 28.8 (CH2CH2CH2), 28.6 (SCH2CH2), 28.2 (CH2CH2CH2), 25.4 (CH2CH2CH2).  MS 
(ES-TOF)+ m/z: 994.9 [M + H]+, 498.0 [M + H]2+. λmax 244 nm (ε = 67000 M-1 cm -1) and 321 nm (ε = 
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9000 M-1 cm-1), mp 196 – 198 OC, νmax / cm-1 1688 (C=O), 2936 (C-H), 3230 (O-H). Characterisation 
data were in agreement with the literature.4 
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Synthesis of EuQuinSAc 
 
 
 
 
 
 
 
 
H3QuinSAc (0.21 g, 0.21 mmol, 1.00 eq) was dissolved in THF : water (1 : 1 by volume) (20 mL) and 
the pH was adjusted to 6 with addition of TBAOH (40% in water). A solution of EuCl3.6H2O (0.08 g, 
0.21 mmol, 1.00 eq.) in water (4 mL) was prepared and added to the H3QuinSAc solution. The vessel 
holding the EuCl3.6H2O solution was washed out with water (2 x 1 mL) and this was also added to the 
H3QuinSAc solution. The solution was left to stir for 15 minutes at RT, whereupon the THF was 
removed in vacuo and the pH was adjusted to 6 with addition of TBAOH (40% in water), which yielded 
a tarry precipitate. The water was decanted out and the precipitate triturated in acetone for 1 hour, 
filtered and further triturated with MeCN for 1 hour and filtered to give EuQuinSAc as a brown powder 
(0.17 g, 0.15 mmol, 71%). MS (ES-TOF)+ m/z: 1144.4 [M + H (152Eu)]+. λmax 243 nm (ε = 66000 M-1 
cm-1) and 321 nm (ε = 9000 M-1 cm-1), mp > 300 oC, νmax / cm-1 1596 (C=O), 2933 (C-H), 3200 (N-H). 
Characterisation data were in agreement with the literature. 
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Synthesis of N-(2-((carboxymethyl)(2-((4-mercaptophenyl)amino)-2-oxoethyl)amino)ethyl)-N-(2-
((carboxymethyl)(2-oxo-2-(quinolin-6-ylamino)ethyl)amino)ethyl)glycine (H3QSH) 
 
To a stirring solution of DTPA-bisanhydride (1.00 g, 3.00 mmol, 1.08 eq.) in dry pyridine (40 mL) was 
added 6-aminoquinoline (0.40 g, 2.78 mmol, 1.00 eq.) and the resulting solution stirred under N2 at RT 
for 45 minutes. After this time 4-aminothiophenol (0.35 g, 2.80 mmol, 1.01 eq.) was added and the 
solution stirred at RT under an N2 atmosphere for 2 hours. After this time, the solvent was removed in 
vacuo and the resulting yellow solid was triturated in MeCN (60 mL) for 18 hours to reveal a yellow 
precipitate which was collected by suction filtration and washed with Et2O (25 mL) to leave a yellow 
solid (1.67 g) containing H3QSH as well as the two symmetrical species H3Quin and H3SH. 
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H3QSH was separated from H3Quin and H3SH via a preparative HPLC method. Prior to injection onto 
a solution of the sample was dissolved in a solution of THF : water (1 : 1 by volume) to make a 50 mg 
/ mL solution, to which an excess of tris(2-carboxyethyl)phosphine hydrochloride (24 mg) was added 
to reduce any disulphide bonds within the sample. The separation was achieved using a Luna C18 reverse 
phase column with an injection size of 1 mL of the solution previously described running a water / 
acetone gradient method (0 – 75% over 30 minutes) whereby solvents contained 0.05% by volume TFA, 
were of HPLC grade and were degassed with He gas prior to use. Between each injection, the column 
was washed with acetone and water (10 minutes for each). Monitoring the absorbance at 210 nm and 
336 nm allowed the detection of the three species whereby H3Quin was eluted after 14 minutes (MS 
(ES-TOF)+ m/z: 646.3 [M + H]+, 668.3 [M + Na]+), H3QSH after 20 minutes (MS (ES-TOF)+ m/z: 627.3 
[M + H]+, 649.3 [M + Na]+), and H3SH after 28 minutes (MS (ES-TOF)+ m/z: 630.4 [M + Na]+). 
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The solvent was removed from the solution containing H3QSH to reveal a yellow solid which was dried 
under high vacuum. 1H NMR (400 MHz, d6-DMSO) δH ppm: 10.31 (1H, br, NHs), 10.09 (1H, br, NHr), 
8.77 (1H, dd, J = 4.2, 1.5, Hc), 8.33 (1H, d, J = 2.2, Hf), 8.11 (1H, d, J = 7.9, He), 7.93 (1H, d, J = 9.1, 
Hh), 7.82 (1H, dd, J = 9.1, 2.2, Hg), 7.59 (2H, d, J = 8.5, Hb), 7.45 (1H, dd, J = 7.9, 4.2, Hd), 7.32 (2H, 
d, J = 8.5, Ha), 4.22 (2H, br, Hi), 3.66 (2H, br, Hq), 3.57 (6H, m, Hj, Hm, Hp), 3.38 (4H, br, Hn, Hl), 3.14 
(4H, br, Hk, Ho). 13C NMR (101 MHz, d6-DMSO) δ13 ppm: 172.9 (CH2COOH), 172.8 (CH2COOH), 
170.1 (CH2COOH), 169.8 (NHCOCH2), 168.5 (NHCOCH2), 149.0 (ArCH), 144.6 (ArC), 138.7 (ArC), 
136.5 (ArC), 135.6 (ArCH), 129.9 (ArC), 129.8 (ArCH), 129.3 (ArCH), 128.3 (ArC), 123.6 (ArCH), 
121.8 (ArCH), 120.1 (ArCH), 115.3 (ArCH), 57.4 (NCH2CONH), 54.7 (NCH2COOH), 54.0 
(NCH2COOH), 52.5 (NCH2CH2N), 49.4 (NCH2CH2N). MS (ES-TOF)+ m/z: 627.3 [M + H]+, 649.3 [M 
+ Na]+. λmax 247 nm (ε = 39000 M-1 cm -1) and 320 nm (ε = 3000 M-1 cm -1), mp = 214 - 216 oC, νmax / 
cm-1 1671 (C=O), 3000 (C-H), 3288 (O-H). Characterisation data were in agreement with the literature.5 
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Synthesis of EuQSH 
 
 
H3QSH (0.060 g, 0.096 mmol, 1.00 eq) was dissolved in THF : water (1 : 1 by volume) (12 mL) and 
the pH was adjusted to 6 with addition of TBAOH (40% in water). A solution of EuCl3.6H2O (0.044 g, 
1.25 mmol, 1.25 eq.) in water (1 mL) was prepared and added to the H3QSH solution. The vessel 
holding the EuCl3.6H2O solution was washed out with water (1 mL) and this also added to the H3QSH 
solution. The solution was left to stir for 15 minutes at RT, whereupon the THF was removed in vacuo 
and the pH was adjusted to 6 with addition of TBAOH (40% in water). The solution was reduced to 1 
mL in vacuo and MeCN (30 mL) was added to yield a precipitate and the solution was triturated for 1 
hour. After this time, the solution was filtered to give a brown solid which was washed with MeCN (10 
mL) and Et2O (10 mL) to give EuQSH (0.046 g, 50%). MS (ES-TOF)+ m/z: 797.1 [M + Na (152Eu)]+. 
λmax 246 nm (ε = 35000 M-1 cm-1) and 320 nm (ε = 3000 M-1 cm-1), mp > 300 oC, νmax / cm-1 1586 (C=O), 
3200 (N-H). Characterisation data were in agreement with the literature. 
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EuL@Au (L = QSH or EuQuinSAc) 
To a stirring solution of Cit@Au (3.2 nM, 2 mL) was added EuL (L = QuinSAc or QSH) (50 µL, 0.2 
mM in MeOH) and stirred for 15 minutes at RT. The coated NPs were purified via G15 sephadex size 
exclusion chromatography, whereby the red band was collected and checked for no aggregation via UV 
Vis. 
 
Sample λmax SPR / 
nm 
Number 
distribution / nm 
Intensity 
distribution / nm 
PDI 
EuQS@Au 521 12 ± 4 23 ± 10 0.3 
EuQuinSAc@Au 520 12 ± 3 24 ± 11 0.5 
 
 
xLC@Au (x = κ or λ) 
To a stirring solution of Cit@Au (3.2 nM, 2 mL) was added xLC (x = κ or λ) (5 µL, 0.5 mg per mL in 
0.001 M PBS) and stirred for 60 minutes at RT. The coated nanoparticles were purified via G100 
sephadex size exclusion chromatography, whereby the red band was collected and checked for no 
aggregation via UV Vis. 
 
Sample λmax SPR / 
nm 
Number 
distribution / nm 
Intensity 
distribution / nm 
PDI 
κstandard@Au 
 
520 15 ± 4 56 ± 54 0.2 
λstandard@Au 
 
522 17 ± 4 47 ± 26 0.3 
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xLC.EuL@Au (x = κ or λ) (L = QuinSAc or QSH) 
To a stirring solution of Cit@Au (3.2 nM, 2 mL) was added EuL (L = QuinSAc or QSH) (10 µL, 0.2 
mM in MeOH) and stirred for 15 minutes at RT. To the stirring solution was then added xLC (x = κ or 
λ) (5 µL, 0.5 mg per mL in PBS) and stirred for 60 minutes at RT. The coated nanoparticles were 
purified via G100 sephadex size exclusion chromatography, whereby the red band was collected and 
checked for no aggregation via UV Vis. 
 
Sample λmax SPR / 
nm 
Number 
distribution / 
nm 
Intensity 
distribution / nm 
PDI 
κstandard.EuQS@Au 
 
519 14 ± 4 56 ± 54 0.4 
κnew.EuQS@Au 
 
519 14 ± 4 30 ± 13 0.3 
κfur.EuQS@Au 
 
519 16 ± 5 36 ± 17 0.3 
 
 
BUCIS04-AF647 
The conjugation of BUCIS04 to AF647 was performed using BUCIS04 as according to instructions 
from the Fluoraprobe 647 kit as supplied by Life Technologies as was the lateral flow assay. 
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ELISA assay 
To an ELISA 96 well plate was added κnew light chain antibody (100 μL, 1 μg / mL in PBS to each 
well) and washed with PBS (0.01 M) and Tween 20 (0.05%). Each well was then treated with BSA 
(100 μL, 1% in PBS to each well) and was incubated for 1 hour and then was thoroughly washed with 
PBS and Tween 20. To the wells was added either BUCIS04 or BUCIS04-AF647 (100 μL, 
concentration varied between 2 μg / mL and 0.1 ng / mL with a dilution factor of 0.5 each time in PBS) 
and the sample incubated for 1 hour and then was thoroughly washed with PBS and Tween 20. After 
this time, a solution of goat anti mouse IgG HRP conjugate was diluted in PBS by a factor of 4000, and 
this was added to the wells (100 μL in PBS per well) and left for 10 minutes. During this time a solution 
of TMP (1 mg) in a mixture of citric acid (5 mL, 0.1 M) and sodium phosphate buffer (5 mL, 0.2 M) to 
give a final pH of 5,  was prepared which was then treated with H2O2 (50 μL). The TMP and H2O2 
solution was then added to the wells (100 μL per well) and incubated for 5 minutes after which time 
H2SO4 (100 μL, 0.2 M per well) was added and the absorption of each well at 450 nm was measured on 
a 96 well plate reader. 
 
FRET assay 
To a solution of κLC.EuL@Au (2.7 nM, 200 μL) (in tris buffer if reported) was added BUCIS04-
AF647 (1.0 mg / mL in PBS, 4 μL) and incubated for 10 minutes after which time the FRET signal was 
recorded via time resolved spectroscopy with a λexc = 320 nm and λem = 614 nm.  
 
Lifetime data from the PHERAstar® multimode plate reader was obtained with use of a TRF optic 
module. Whereby κLC.EuL@Au (2.7 nM, 100 μL per well) was added to the wells and BUCIS04-
AF647 (100 μg / mL in PBS, 20 μL) was added and incubated for 30 minutes. After this time, the 
lifetime signal was obtained with a TRF optic module with a with a λexc = 337 nm and λem = 615 nm, 
over a range of 2500 μs with 5 μs intervals between data points with the top optic being used. Data was 
processed on KaleidaGraph software whereby data was plotted to a bi-exponential decay curve. 
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6.3 Chapter 3 
Modification of functionalised AuNPs with blocking agent 
To a stirring solution of AuNPs (Either κnew.EuQS@Au or EuQS@Au) (2.7 nM, 2 ml) was added 
the appropriate blocking agent FCS (20 µL), BSA (100 µL of 20% solution), Tween 20 (1 µL) or Zonyl® 
FSA (1 µL) and the sample left to incubate for 30 minutes.  
 
Addition of BUCIS04-AF647 to functionalised AuNPs 
To a solution of AuNPs (Either κnew.EuQS@Au or EuQS@Au) at (2.7 nM, 200 μL) (in tris buffer if 
reported and with appropriate blocking agent modification) was added BUCIS04-AF647 (1.0 mg / ml 
in PBS, 4 μL) and incubated for 10 minutes after which time the FRET signal was recorded via time 
resolved spectroscopy with a λexc = 320 nm and λem = 614 nm. 
 
FRET assay for detection of κnew 
To a solution of BUCIS04-AF647 (1.0 mg / ml in PBS, 4 μL) was added κnew (4.9 mg / ml in PBS 5 
μL) and 10 μL PBS and the solution left to incubate for 10 minutes. After this time, the solution was 
transferred into a solution of κnew.EuQS@Au (2.7 nM, 200 μL) (in tris buffer and with blocking agent 
present if reported) and left to incubate for 10 minutes after which time the FRET signal was recorded 
via time resolved spectroscopy with a λexc = 320 nm and λem = 614 nm.  
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6.4 Chapter 4 
Synthesis of tert-butyl (3-acetylphenyl)carbamate (8) 
 
To a stirring solution of 3-aminoacetonpheone (2.50 g, 18.5 mmol 1.54 eq) in THF (50 mL) was added 
di-tertiary butyl bicarbonate (2M in THF, 6 mL, 12.00 mmol 1.00 eq) and TEA (4.2 mL) and the 
resulting solution was stirred at RT for 18 hours. After this time, water (100 mL) was added to the 
reaction mixture and the organic material was extracted with EtOAc (2 x 100 mL) which was then dried 
over anhydrous Na2SO4 (ca. 10 g), filtered, and the solvent removed in vacuo to give a yellow solid 
which was purified via column chromatography on silica (EtOAc : Hexane; 30 : 70) to yield 8 as a 
white solid (2.10 g, 8.94 mmol, 75%). 1H NMR (400 MHz, CDCl3) δH: 7.94 (1H, appt, J = 1.9, Hf), 7.65 
(1H, d, J = 7.8, He), 7.60 (1H, dt, J = 7.8, 1.9, Hc), 7.38 (1H, t, J = 7.8, Hd), 6.83 (1H, br, Hb), 2.59 (3H, 
s, Hg), 1.52 (9H, s, Ha). 13C{1H} PENDANT NMR (101 MHz, CDCl3) δC: 198.2 (MeCOPh), 152.8 
(NHCOO), 139.1 (ArC), 137.9 (ArC), 129.4 (ArCH), 123.1 (ArCH), 123.0 (ArCH), 118.2 (ArCH), 81.0 
(OC(Me)3), 28.4 (OC(CH3)3), 26.8 (COCH3). MS (ES-TOF)+ m/z: 258.1 [M + Na]+, 180 [M - tBu]+. 
Characterisation data were in agreement with the literature.6,7 
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Synthesis of (Z)-1-(3-aminophenyl)-3-hydroxy-3-phenylprop-2-en-1-one (9) 
 
 
NaH (60% dispersion in mineral oil) (1.00 g, 25.0 mmol, 5.88 eq) was washed with hexane (2 x 20 mL) 
prior to use. To the washed NaH under N2, was added dry THF (30 mL) and a solution of 8 (1.00 g, 
4.25 mmol, 1.00 eq.) in dry THF (10 mL) and the solution stirred at RT under N2 for 1 hour. After this 
time, a yellow solution was observed and a solution of ethyl benzoate (1.00 g, 6.66 mol, 1.57 eq.) in 
dry THF (10 mL) was added and the resulting solution was left to stir at RT for 18 hours. The remaining 
NaH was quenched with addition of water (5 mL) and the mixture was acidified with addition of HCl 
(2M, 25 mL) which afforded a yellow colour at pH 2. To this solution water (100 mL) was added and 
the organic material was extracted with EtOAc (2 x 100 mL) which was dried over anhydrous Na2SO4 
(ca. 10 g), filtered and the was solvent removed in vacuo to reveal an orange oil. The resulting oil was 
washed with hexane (3 x 100 mL) with sonication and the resulting oil dried under high vacuum. The 
oil was then placed under N2 and TFA (5 mL, 65.4 mmol) was added and the solution was stirred for 1 
hour under N2 at RT. After this time a saturated solution of NaHCO3 (100 mL) was added slowly and 
stirred until the observed effervescence had ended and EtOAc (3 x 100 mL) was added and the organic 
material was extracted and dried over Na2SO4 (ca. 10 g), the solution filtered, and the solvent removed 
in vacuo to give an orange oil that was purified via column chromatography on silica (EtOAc : Hexane; 
30 : 70) to yield 9 as a yellow oil (0.38 g, 1.59 mmol, 37%). 1H NMR (400 MHz, CDCl3) δH: 8.00 (2H, 
d, J = 7.1, Hf), 7.40 – 7.55 (3H, m, Hg, Hh), 7.38 (1H, dt, J = 7.8, 1.1, Hc), 7.33 (1H, appt, J = 2.2, Hd), 
7.28 (1H, t, J = 7.8, Hb), 6.88 (1H, ddd, J = 7.8, 2.2, 1.1, Ha), 6.84 (1H, s, He), 3.60 – 4.00 (2H, br, NH2). 
13C NMR (101 MHz, d6 – CDCl3) δC: 186.3 (PhCOCH), 185.6 (PhCOCH), 147.0 (H2NC), 136.9 (ArC), 
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135.6 (ArC), 132.5 (ArCH), 129.7 (ArCH), 128.0 (ArCH), 127.3 (ArCH), 119.2 (ArCH), 117.6 (ArCH), 
113.4 (ArCH), 93.2 (COCHCO). m/z: 240.1 [M + H]+, 262.1 [M + Na]+. 
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Synthesis of (Z)-5-(1,2-dithiolan-3-yl)-N-(3-(3-hydroxy-3-phenylacryloyl)phenyl)pentanamide 
(DBMSS) 
 
 
A solution of 9 (0.38 g, 1.59 mmol, 1.28 eq.), thioctic acid (0.26 g, 1.26 mmol, 1.02 eq.), EDC (0.24 g, 
1.55 mmol, 1.25 eq.) and HoBT.H2O (0.19 g, 1.24 mmol, 1.00 eq.) were dissolved in a solution of dry 
DMF (5 mL) and stirred at RT under N2 for 18 hours. After this time, water (100 mL) was added and 
the organic material was extracted with EtOAc (3 x 100 mL). The organic extracts were combined and 
dried over anhydrous Na2SO4 (ca. 10 g), filtered and the solvent removed in vacuo to give an orange 
oil. The resulting oil was triturated in hexane (250 mL) for 18 hours after which time a yellow powder 
was revealed and the hexane removed via filtration. The yellow solid was then dissolved in the 
minimum amount of acetone (10 mL) and the product was precipitated with addition of hexane (100 
mL) to yield DBMSS as a yellow solid (0.12 g, 0.28 mmol, 22%). 1H NMR (400 MHz, d6 – DMSO) 
δH: 10.13 (1H, s, NH), 8.28 (1H, appt, J = 1.8, Hk), 8.15 (2H, d, J = 7.3, Hm), 7.89 (2H, m, Hh, Hj), 7.67 
(1H, t, J = 7.3, Ho), 7.58 (2H, t, J = 7.3, Hn), 7.49 (1H, t, J = 8.0, Hi), 7.25 (1H, s, Hl), 3.64 (1H, dt, J = 
12.2, 6.2, Hc), 3.1 – 3.2 (2H, m, Ha), 2.42 (1H, dt, J = 6.2, 18.8, Hb), 2.35 (2H, t, J = 7.4, Hg), 1.88 (1H, 
m, Hb), 1.5 – 1.8 (4H, m, Hd, Hf), 1.42 (2H, p, J = 8.0, He). 13C{1H} PENDANT NMR (101 MHz, d6 – 
DMSO) δC: 185.3 (PhCO), 185.2 (PhCO), 171.4 (NHCOCH2), 139.9 (ArC), 135.1 (ArC), 134.6 (ArC), 
133.0 (ArCH), 129.2 (ArCH), 128.9 (ArCH), 127.3 (ArCH), 123.4 (ArCH), 122.3 (ArCH), 117.5 
(ArCH), 93.3 (COCHCO), 56.1 (CH2CHS), 39.5 (CHCH2CH2), 38.1 (CH2CH2S), 36.2 (COCH2), 34.2 
(CH2CH2CH2), 28.3 (CH2CH2CH2), 24.8 (CH2CH2CH2). MS (ES-TOF)+ m/z: 450.1 [M + Na]+. λmax 
(MeOH) 350 nm (ε = 19900 M-1 cm-1) and 240 nm (ε = 23200 M-1 cm-1), mp 108 - 110 OC, νmax / cm-1 
1652 (C=O), 2933 (C-H), 3290 (O-H). 
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Preparation of Eu.DBMSS.Z@Au 
               
 
To a stirring solution of Cit@Au (3.2 nM, 2 mL) was added a solution of Zonyl® FSA (diluted 1 in 10 
by volume in deionised water) (1 µL) and stirred for 5 minutes. Excess Zonyl® FSA was removed via 
centrifugation at 11800 RPM for 30 minutes and the supernatant was removed and the NPs were 
redispersed in deionised water to produce Z.Au. To a stirring solution of Z.Au (3.2 nM, 2 mL) was 
added DBMSS (0.2 mM, 120 µL in MeOH) and stirred for 15 minutes at RT. The coated NPs were 
purified via G15 Sephadex size exclusion chromatography, whereby the red band was collected and 
checked for no aggregation via UV Vis spectroscopy. To the resulting solution (2 mL), was added TEA 
(1 μL) and stirred with EuCl3.6H2O (80 μM, 60 μL in water) for 20 minutes.  
 
Sample λmax SPR / 
nm 
Number 
distribution / nm 
Intensity 
distribution / nm 
 
PDI 
Cit@Au 
 
516  12 ± 3  18 ± 3 0.1 
Z@Au 
 
517 15 ± 3 25 ± 3 0.1 
DBMSS.Z@Au 
 
524  15 ± 4 24 ± 4 0.2 
Eu.DBMSS.Z@Au 524 15 ± 3 18 ± 3 0.3 
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Appendices 
Chapter 2 appendix 
List of appendices 
1. 1H NMR of 2 in CDCl3  
2. 13C NMR of 2 in CDCl3 
3. MS (ES-TOF)+ of 2  
4. 1H NMR of 4 in CDCl3  
5. 13C NMR of 4 in CDCl3 
6. MS (ES-TOF)+ of 4  
7. 1H NMR of 5 in CDCl3  
8. 13C NMR of 5 in CDCl3 
9. MS (ES-TOF)+ of 5  
10. 1H NMR of 6 in CDCl3  
11. 13C NMR of 6 in CDCl3 
12. MS (ES-TOF)+ of 6  
13. 1H NMR of H3QuinSAc in d6 DMSO  
14. MS (ES-TOF)+ of H3QuinSAc  
15. COSY NMR of H3QuinSAc in d6 DMSO 
16. COSY NMR of aromatic region of H3QuinSAc in d6 DMSO 
17. COSY NMR of aliphatic region of H3QuinSAc in d6 DMSO 
18. HSQC NMR of aromatic region of H3QuinSAc in d6 DMSO 
19. HSQC NMR of aliphatic region of H3QuinSAc in d6 DMSO 
20. MS (ES-TOF)+ of H3Quin 
21. MS (ES-TOF)+ of H3SH 
22. MS (ES-TOF)+ of H3QSH  
23. 1H NMR of H3QSH in d6 DMSO 
24. 13C NMR of H3QSH in d6 DMSO  
25. COSY NMR of aromatic region of H3QSH in d6 DMSO 
26. COSY NMR of alipahtic region of H3QSH in d6 DMSO 
27. HMBC NMR of H3QSH in d6 DMSO 
28. HSQC NMR of H3QSH in d6 DMSO 
29. MS (ES-TOF)+ of EuQuinSAc  
30. MS (ES-TOF)+ of EuQSH  
31. Lifetime of EuQSH in H2O, λexc = 320 nm and λem = 614 nm  
181 
 
32. Lifetime of EuQSH in D2O, λexc = 320 nm and λem = 614 nm  
33. Lifetime of EuQSH in MeOH, λexc = 320 nm and λem = 614 nm  
34. Lifetime of EuQuinSAc in H2O , λexc = 320 nm and λem = 614 nm  
35. Lifetime of EuQuinSAc in D2O , λexc = 320 nm and λem = 614 nm  
36. Lifetime of EuQuinSAc in MeOH , λexc = 320 nm and λem = 614 nm  
37. Lifetime of EuQS@Au in H2O, λexc = 320 nm and λem = 614 nm  
38. IRF of Au@Cit, λexc = 320 nm and λem = 614 nm 
39. Lifetime of standard.EuQSHc@Au in H2O, λexc = 320 nm and λem = 614 nm 
40. Emission spectrum of LC.EuQuinSAc@Au λexc = 320 nm, corrected for PMT response 
41. Emission spectrum of λLC.EuQS@Au λexc = 320 nm, corrected for PMT response 
42. Emission spectrum of λLC.EuQuinSAc@Au λexc = 320 nm, corrected for PMT response 
43. Preparation of new.EuQS@Au as monitored via UV Vis 
44. Emission spectrum of new.EuQS@Au λexc = 320 nm, corrected for PMT response 
45. Preparation of fur.EuQS@Au as monitored via UV Vis 
46. Emission spectrum of fur.EuQS@Au λexc = 320 nm, corrected for PMT response 
47. ELISA assay of BUCIS04 against new 
48. ELISA assay control with BUCIS04 – AF647 and no assay reagents 
49. UV Vis of LC.EuQS@Au in Tris HCl and PBS buffers 
50. Emission spectrum of BUCIS04-AF647, λexc = 320 nm, corrected for PMT response 
51. Lifetime of standard.EuQS@Au, λexc = 320 nm and λem = 614 nm  
52. Lifetime of standard.EuQS@Au in tris HCl buffer, λexc = 320 nm and λem = 614 nm 
53. Lifetime of standard.EuQS@Au and 100 nm BUCIS04-AF647, λexc = 320 nm and λem = 614 
nm  
54. Lifetime of standard.EuQS@Au and 100 nm BUCIS04-AF647 in tris HCl buffer, λexc = 320 
nm and λem = 614 nm  
55. Lifetime of new.EuQS@Au , λexc = 320 nm and λem = 614 nm  
56. Lifetime of new.EuQS@Au in tris HCl buffer, λexc = 320 nm and λem = 614 nm  
57. Lifetime of new.EuQS@Au and 100 nm BUCIS04-AF647, λexc = 320 nm and λem = 614  
58. Lifetime of new.EuQS@Au and 100 nm BUCIS04-AF647 in tris HCl buffer, λexc = 320 nm 
and λem = 614 nm  
59. Lifetime of fur.EuQS@Au , λexc = 320 nm and λem = 614 nm  
60. Lifetime of fur.EuQS@Au in tris HCl buffer, λexc = 320 nm and λem = 614 nm  
61. Lifetime of fur.EuQS@Au and 100 nm BUCIS04-AF647, λexc = 320 nm and λem = 614   
62. Lifetime of fur.EuQS@Au and 100 nm BUCIS04-AF647 in tris HCl buffer, λexc = 320 nm 
and λem = 614 nm  
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1H NMR of 2 in CDCl3  
 
* = residual solvent resonance 
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13C{1H} NMR of 2 in CDCl3  
 
* = residual solvent resonance 
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MS (ES-TOF)+ of 2  
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1H NMR of 4 in CDCl3  
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13C{1H} NMR of 4 in CDCl3  
 
* = residual solvent resonance 
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MS (ES-TOF)+ of 4 
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1H NMR of 5 in CDCl3  
 
* = residual solvent resonance, # = Excess solvent resonance 
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13C{1H} NMR of 5 in CDCl3  
 
* = residual solvent resonance 
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MS (ES-TOF)+ of 5 
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1H NMR of 6 in CDCl3  
 
* = residual solvent resonance 
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13C{1H} NMR of 6 in CDCl3  
 
* = residual solvent resonance 
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MS (ES-TOF)+ of 6 
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1H NMR of H3QuinSAc in d6 DMSO  
 
* = residual solvent resonance 
* 
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13C{1H} PENDANT NMR of H3QuinSAc in d6 DMSO  
 
* = residual solvent resonance 
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MS (ES-TOF)+ of H3QuinSAc 
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COSY NMR of aromatic region of H3QuinSAc in d6 DMSO 
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COSY NMR of aliphatic region of H3QuinSAc in d6 DMSO 
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HSQC NMR of aromatic region of H3QuinSAc in d6 DMSO 
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HSQC NMR of aliphatic region of H3QuinSAc in d6 DMSO 
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MS(ES-TOF)+ of H3Quin 
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MS(ES-TOF)+ of H3SH 
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MS(ES-TOF)+ of H3QSH 
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1H NMR of H3QSH in d6 DMSO  
 
* = residual solvent resonance, # = water 
* # 
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13C{1H} PENDANT NMR of H3QSH in d6 DMSO  
 
* = residual solvent resonance 
 
* 
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COSY NMR of aromatic region of H3QSH in d6 DMSO 
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COSY NMR of aliphatic region of H3QSH in d6 DMSO 
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MS (ES-TOF)+ of EuQuinSAc 
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MS (ES-TOF)+ of EuQSH 
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Lifetime of EuQSH in H2O, λexc = 320 nm and λem = 614 nm 
  
 
      
 
 Lifetime of EuQSH in D2O, λexc = 320 nm and λem = 614 nm  
 
 
 
     
 
Lifetime of EuQSH in MeOH, λexc = 320 nm and λem = 614 nm  
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Lifetime of EuQuinSAc in H2O, λexc = 320 nm and λem = 614 nm         
                                              
 
            
 
Lifetime of EuQuinSAc in D2O, λexc = 320 nm and λem = 614 nm 
 
 
 
 
Lifetime of EuQuinSAc in MeOH, λexc = 320 nm and λem = 614 nm       
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Lifetime of EuQS@Au in H2O, λexc = 320 nm and λem = 614 nm             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lifetime of IRF Cit@Au in H2O, λexc = 320 nm and λem = 614 nm        
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Emission spectrum of standard.EuQuinSAc@Au. λexc = 320 nm, corrected for PMT response 
 
 
Emission spectrum of standard.EuQS@Au, λexc = 320 nm, corrected for PMT response 
 
 
Emission spectrum of standard.EuQuinSAc@Au, λexc = 320 nm, corrected for PMT response 
214 
 
 
 
Preparation of new.EuQS@Au as monitored via UV Vis 
Change in SPR of Cit@Au (3.2 nM in water) as a methanolic solution of EuQSH is added in to a final 
concentration of 1 μM, followed by the addition of a solution of new in 0.001 M PBS to a final 
concentration of 60 nM. The yellow curve is post gel filtration to show that no aggregation occurs from 
the purification method 
 
 
 
 
 
 
Emission spectrum of κnew.EuQS@Au, λexc = 320 nm, corrected for PMT response 
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Preparation of fur.EuQS@Au as monitored via UV Vis 
Change in SPR of Cit@Au (3.2 nM in water) as a methanolic solution of EuQSH is added in to a final 
concentration of 1 μM, followed by the addition of a solution of fur in 0.001 M PBS to a final 
concentration of 60 nM. The yellow curve is post gel filtration to show that no aggregation occurs from 
the purification method 
 
    
 
 
 
 
 
Emission spectrum of κfur.EuQS@Au, λexc = 320 nm, corrected for PMT response 
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ELISA assay of BUCIS04 against surface immobilised κnew as measured via the absorbance signal 
obtained with TMP and HRP 
 
 
 
 
 
 
 
 
Blank ELISA assay of BUCIS04 – AF647 showing the absorption signal with increasing concentrations 
of BUCIS04 – AF647 
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Absorption spectrum of κstandard.EuQS@Au in Tris HCl (50 mM) (blue) and PBS (0.01 M) (black)  
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Emission spectrum of BUCIS04-AF647, λexc = 320 nm, corrected for PMT response 
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Lifetime of standard.EuQS@Au with BUCIS04-
AF647, λexc = 320 nm and λem = 614 nm 
 
Lifetime of standard.EuQS@Au with BUCIS04-
AF647 in tris HCl buffer, λexc = 320 nm and λem = 614 
nm 
 
Lifetime of standard.EuQS@Au in water, λexc = 
320 nm and λem = 614 nm 
 
Lifetime of standard.EuQS@Au in tris HCl 
buffer, λexc = 320 nm and λem = 614 nm 
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Lifetime of new.EuQS@Au, λexc = 320 nm and λem 
= 614 nm 
 
Lifetime of  new.EuQS@Au in tris HCl buffer, λexc 
= 320 nm and λem = 614 nm 
 
Lifetime of new.EuQS@Au with BUCIS04-
AF647, λexc = 320 nm and λem = 614 nm  
 
Lifetime of new.EuQS@Au with BUCIS04-
AF647, in tris HCl buffer λexc = 320 nm and λem = 
614 nm 
 
220 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lifetime of fur.EuQS@Au, λexc = 320 nm and λem 
= 614 nm 
 
Lifetime of fur.EuQS@Au in tris HCl buffer, λexc 
= 320 nm and λem = 614 nm 
 
Lifetime of fur.EuQS@Au with BUCIS04-AF647, 
λexc = 320 nm and λem = 614 nm 
 
Lifetime of fur.EuQS@Au with BUCIS04-AF647, 
in tris HCl buffer λexc = 320 nm and λem = 614 nm 
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Chapter 3 appendix 
List of appendices 
All Lifetime data was gathered with, λexc = 320 nm and λem = 614 nm. 
1. Lifetime of EuQS@Au in water 
2. Lifetime of EuQS@Au in tris HCl 
3. Lifetime of EuQS@Au in water incubated with BUCIS04-AF647 
4. Lifetime of EuQS@Au in tris HCl incubated with BUCIS04-AF647 
5. Lifetime of EuQS@Au in 1% BSA  
6. Lifetime of EuQS@Au in 1% BSA in tris HCl 
7. Lifetime of EuQS@Au in 1% BSA incubated with BUCIS04-AF647 
8. Lifetime of EuQS@Au in 1% BSA in tris HCl incubated with BUCIS04-AF647 
9. Lifetime of EuQS@Au in 1% FCS  
10. Lifetime of EuQS@Au in 1% FCS in tris HCl 
11. Lifetime of EuQS@Au in 1% FCS incubated with BUCIS04-AF647 
12. Lifetime of EuQS@Au in 1% FCS in tris HCl incubated with BUCIS04-AF647 
13. Lifetime of EuQS@Au in with 0.05% Tween 20 
14. Lifetime of EuQS@Au in with 0.05% Tween 20 in tris HCl 
15. Lifetime of EuQS@Au in with 0.05% Tween 20 incubated with BUCIS04-AF647 
16. Lifetime of EuQS@Au in with 0.05% Tween 20 in tris HCl incubated with BUCIS04-AF647 
17. Lifetime of EuQS@Au in 0.05% Zonyl FSA   
18. Lifetime of EuQS@Au in 0.05% Zonyl FSA in tris HCl 
19. Lifetime of EuQS@Au in 0.05% Zonyl FSA incubated with BUCIS04-AF647 
20. Lifetime of EuQS@Au in 0.05% Zonyl FSA in tris HCl incubated with BUCIS04-AF647 
21. Lifetime of κnew.EuQS@Au in 1% BSA  
22. Lifetime of κnew.EuQS@Au in 1% BSA in tris HCl 
23. Lifetime of κnew.EuQS@Au in 1% BSA incubated with BUCIS04-AF647 
24. Lifetime of κnew.EuQS@Au in 1% BSA in tris HCl incubated with BUCIS04-AF647 
25. Lifetime of κnew.EuQS@Au in 1% FCS  
26. Lifetime of κnew.EuQS@Au in 1% FCS in tris HCl 
27. Lifetime of κnew.EuQS@Au in 1% FCS incubated with BUCIS04-AF647 
28. Lifetime of κnew.EuQS@Au in 1% FCS in tris HCl incubated with BUCIS04-AF647 
29. Lifetime of κnew.EuQS@Au incubated with premixed κnew and BUCIS04-AF647 
30. Lifetime of κnew.EuQS@Au incubated with premixed κnew and BUCIS04-AF647 in tris HCl 
31. Lifetime of κnew.EuQS@Au incubated with premixed κnew and BUCIS04-AF647 in 1% BSA 
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32. Lifetime of κnew.EuQS@Au incubated with premixed κnew and BUCIS04-AF647 in 1% BSA in 
tris HCl 
33. Lifetime of κnew.EuQS@Au incubated with premixed κnew and BUCIS04-AF647 in 1% FCS  
34. Lifetime of κnew.EuQS@Au incubated with premixed κnew and BUCIS04-AF64 in 1% FCS in 
tris HCl 
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Lifetime of EuQS@Au in water Lifetime of EuQS@Au in tris HCl 
 
Lifetime of EuQS@Au and 
BUCIS04-AF647 
Lifetime of EuQS@Au and 
BUCIS04-AF647 in tris HCl buffer 
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Lifetime of of EuQS@Au in 1% BSA 
 
Lifetime of of EuQS@Au in 1% BSA 
in Tris HCl 
 
Lifetime of of EuQS@Au in 1% FCS 
 
Lifetime of EuQS@Au in 1% FCS in 
Tris HCl 
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Lifetime of EuQS@Au in 1% BSA 
incubated with BUCIS04-AF647 
Lifetime of EuQS@Au in 1% BSA in 
Tris HCl incubated with BUCIS04-
AF647 
 
Lifetime of EuQS@Au in 1% FCS 
incubated with BUCIS04-AF647 
Lifetime of EuQS@Au in 1% FCS in 
Tris HCl incubated with BUCIS04-
AF647 
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Lifetime of EuQS@Au in 0.05 % 
Zonyl FSA 
Lifetime of EuQS@Au in 0.05 % 
Zonyl FSA in Tris HCl 
 
Lifetime of EuQS@Au in 0.05% 
Tween 20 
 
Lifetime of EuQS@Au in 0.05% 
Tween 20 in Tris HCl 
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Lifetime of EuQS@Au in 0.05 % Zonyl 
FSA incubated with BUCIS04-AF647 
 
Lifetime of EuQS@Au in 0.05 % Zonyl FSA 
in Tris HCl incubated with BUCIS04-AF647 
 
Lifetime of EuQS@Au in 0.05% Tween 20 
incubated with BUCIS04-AF647 
Lifetime of EuQS@Au in 0.05% Tween 20 in 
Tris HCl incubated with BUCIS04-AF647 
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Lifetime of κnew.EuQS@Au in 1% 
BSA 
Lifetime of κnew.EuQS@Au in 1% 
BSA in Tris HCl 
 
Lifetime of κnew.EuQS@Au in 1% 
FCS 
Lifetime of κnew.EuQS@Au in 1% 
FCS in Tris HCl 
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Lifetime of κnew.EuQS@Au in 1% 
BSA incubated with BUCIS04-
AF647 
 
Lifetime of κnew.EuQS@Au in 1% BSA in 
Tris HCl incubated with BUCIS04-AF647 
 
Lifetime of κnew.EuQS@Au in 1% 
FCS incubated with BUCIS04-
AF647 
 
Lifetime of κnew.EuQS@Au in 1% FCS 
in Tris HCl incubated with BUCIS04-
AF647 
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Lifetime of κnew.EuQS@Au with premixed 
κnew and BUCIS04-AF647 
Lifetime of κnew.EuQS@Au with premixed κnew 
and BUCIS04-AF647 in tris HCl 
 
Lifetime of κnew.EuQS@Au in 1% BSA with 
premixed κnew and BUCIS04-AF647 
Lifetime of κnew.EuQS@Au in 1% BSA with 
premixed κnew and BUCIS04-AF647 in tris HCl 
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Lifetime of κnew.EuQS@Au in 1% FCS with 
premixed κnew and BUCIS04-AF647 
 
Lifetime of κnew.EuQS@Au in 1% FCS with 
premixed κnew and BUCIS04-AF647 in tris HCl 
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Chapter 4 appendix 
List of appendices 
1. 1H NMR of 8 in CDCl3  
2. 13C NMR of 8 in CDCl3  
3. MS (ES-TOF)+ of 8  
4. 1H NMR of 9 in CDCl3  
5. 13C NMR of 9 in CDCl3  
6. MS (ES-TOF)+ of 9 
7. 1H NMR spectrum of DBMSS in d6-DMSO. 
8. 13C NMR spectrum of DBMSS in d6-DMSO. 
9. MS (ES-TOF)+ of DBMSS 
10. HSQC of aromatic region of DBMSS in d6 DMSO 
11. HSQC of aliphatic region of DBMSS in d6 DMSO 
12. HMBC of DBMSS in d6 DMSO 
13. HMBC of aromatic region of DBMSS in d6 DMSO 
14. HMBC of aliphatic region of DBMSS in d6 DMSO 
15. Lifetime of Eu(DBMSS)3 in MeOH, λexc = 350 nm and λem = 614 nm. 
16.  Lifetime of Eu(DBMSS)3 in MeOD, λexc = 350 nm and λem = 614 nm. 
17. Lifetime of Eu.DBMSS.Z@Au H2O, λexc = 350 nm and λem = 614 nm. 
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1H NMR of 8 in CDCl3  
 
* = residual solvent resonance 
 
 
 
 
 
 
 
 
* 
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13C{1H} PENDANT NMR of 8 in CDCl3  
 
* = residual solvent resonance 
 
* 
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MS (ES-TOF)+ of 8  
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1H NMR of 9 in CDCl3  
 
* = residual solvent resonance 
 
 
 
* 
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13C{1H} PENDANT NMR of 9 in CDCl3  
 
* = residual solvent resonance 
 
 
 
 
 
 
 
 
 
 
* 
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MS (ES-TOF)+ of 9 
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1H NMR spectrum of DBMSS in d6-DMSO. 
 
*= residual solvent resonance; • = water. 
 
 
* • 
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13C NMR spectrum of DBMSS in d6-DMSO. 
 
*= residual solvent resonance. 
 
 
* 
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MS (ES-TOF)+ of DBMSS 
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HSQC of aromatic region of DBMSS in d6 DMSO 
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HSQC of aliphatic region of DBMSS in d6 DMSO 
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HMBC of DBMSS in d6 DMSO 
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HMBC of aromatic region of DBMSS in d6 DMSO 
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HMBC of aliphatic region of DBMSS in d6 DMSO 
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Lifetime of Eu(DBMSS)3 in MeOH, λexc = 350 nm, λexc = 614 nm. 
 
 
Lifetime of Eu(DBMSS)3 in MeOD, λexc = 350 nm, λexc = 614 nm. 
 
Lifetime of Eu.DBMSS.Z@Au in H2O, λexc = 350 nm, λexc = 614 nm. 
